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deaths	 from	asthma	has	decreased	with	 the	use	of	modern	 therapy	 forms,	 the	overall	
prevalence	even	appears	 to	be	 increasing.	 [2]	Asthma	symptoms	can	manifest	 in	very	
heterogeneous	 ways	 with	 different	 degrees	 of	 severity;	 however,	 the	 disease	 is	
generally	 characterized	 by	 chronic	 inflammation	 of	 the	 airways,	 bronchoconstriction,	
enhanced	 mucus	 secretion	 and	 airway	 hyperresponsiveness.	 Ultimately,	 these	
pathologic	 abnormalities	may	 even	 result	 in	 structural	 and	 functional	 changes	within	
the	 diseased	 lung.	 [3]	 The	 immune-system	 of	 asthmatic	 patients	 inappropriately	
recognizes	common	environmental	stimuli	such	as	pollen	or	dust	as	antigens,	inducing	
inflammatory	 responses	 [4]	 leading	 to	 the	 typical	 asthma	 symptoms	 including	 chest	
tightness,	shortness	of	breath,	coughing	and	wheezing.		
Just	 as	 the	 symptoms	 and	 severity	 of	 different	 asthma	 cases	 vary,	 its	 pathogenesis	 is	
equally	 complex	 and	 differs	 between	 clinical	 endotypes,	 stemming	 from	 a	 diverse	
interplay	of	genetic,	epigenetic,	and	environmental	 factors.	 [5]	 It	 is	currently	assumed	
that	 the	disease	 is	approximately	60-75	%	heritable,	 [6]	with	several	 candidate	genes	
identified	in	genome-wide	association	studies.	Moreover,	exposure	to	particle	matters,	
smoking	and	obesity	have	been	found	to	increase	asthma	prevalence.	[7]	
Although	 standard	 therapies	 applying	 corticosteroids	 as	 controller	 and	 beta-2-
sympathomimetics	 as	 reliever	 treatments,	 as	 outlined	 in	 Figure	 1,	 can	 sufficiently	
control	 symptoms	 in	 most	 asthma	 patients	 today,	 a	 substantial	 share	 of	 diseased	
individuals	still	experience	unsatisfactorily	controlled	disease	patterns.	[8]	These	5-10	
%	 of	 the	 whole	 asthma	 population	 with	 severe	 or	 difficult	 to	 treat	 asthma	 suffer	
tremendously	 and	 have	 the	 highest	 levels	 of	 morbidity.	 [9]	 It	 is	 therefore	 crucial	 to	




on	halt	disease	causing	patterns	rather	 than	 just	 intervening	at	 the	end	of	 the	disease	
cascades	in	order	to	palliate	symptoms.		
The	 allergic	 form	of	 asthma	 comprises	 all	 levels	 of	 severity	 and	plays	 a	major	 role	 in	
disease	development	in	50-80	%	of	all	patients	suffering	from	severe	asthma	forms.	[10]	
A	 considerable	 share	 of	 severe	 cases	 exhibit	 early	 onset	 allergic	 disease	 with	 a	
noticeable	T	helper	2	(Th2)	cell	component,	resulting	in	high	levels	of	eosinophils,	mast	

















of	eukaryotic	cells	 to	control	gene	expression,	 [13]	 it	 is	extensively	being	studied	as	a	
method	to	specifically	and	therapeutically	downregulate	the	activity	of	disease-related	
genes.	 Offering	 the	 potential	 to	 theoretically	 silence	 any	 chosen	 gene	 with	 a	 known	




machinery	 subsequently	 targets	 sequence-complementary	 messenger	 RNA	 (mRNA)	
which	 is	 consequently	 degraded	 or	 inactivated.	 [16]	After	 loading	 of	 double-stranded	
siRNA	 into	 RISC,	 so-called	 Argonaute	 (Ago)	 slicing	 proteins	 cleave	 and	 release	 the	
passenger	RNA	strand,	leaving	the	now	single-stranded	guide	RNA	to	activate	and	direct	
the	 target	recognition	with	 the	respective	mRNA	via	 intramolecular	base	pairing.	 [17]	
To	 exploit	 this	 cellular	machinery	 therapeutically,	 siRNA	 has	 to	 be	 delivered	 into	 the	
cytosol	of	appropriate	target	cells,	where	the	endogenous	RISC	is	located.		
The	key	advantages	of	all	nucleic-acid	based	antisense	strategies	for	sequence-specific	
inhibition	 of	 gene	 expression	 are	 the	 precision	 of	 target	 discrimination	 controlled	 by	
Watson-Crick	base	pair	interactions	as	well	as	the	before-mentioned	unrestricted	target	
repertoire.	 [15]	 In	 contrast	 to	 other	 typical	 antisense	 strategies	 such	 as	 DNA	
oligonucleotides	or	ribozymes,	siRNA,	however,	utilizes	an	existing	cellular	machinery,	
resulting	in	much	more	potent	gene	silencing	effects.	[18]	This	in	turn	enables	the	use	of	
distinctly	 lower	 concentrations	 which	 is	 very	 relevant	 for	 therapeutic	 applications.	
Despite	 all	 its	 promising	 attributes,	 siRNA	 therapy	 still	 faces	 some	 challenges,	
eventuating	in	only	one	siRNA	therapeutic	currently	approved	for	the	market.	[19]	One	
of	the	biggest	hurdles	to	overcome	on	the	way	from	bench	to	bedside	is	successful	and	
sufficient	 delivery	 of	 the	 RNA	 molecules.	 Unfortunately,	 siRNA	 features	 some	
unfavorable	 physiological	 properties,	 such	 as	 instability	 towards	 serum	 nucleases	 as	
well	 as	 its	 negative	 charge	 impeding	 efficient	 cellular	 uptake.	 [20]	 Besides	 cellular	






to	 employ	 a	 suitable	 carrier	 system.	 In	 short,	 the	 ideal	 delivery	 system	 should	 be	
biocompatible	 and	 -degradable,	 effectively	 protect	 the	 sensitive	 RNA	 payload	 from	
















processes	 in	 asthma,	 and	 are	 therefore	 targeted	 in	 several	 preclinical	 studies.	 [23]	
Within	 the	 inflammatory	 cascade,	 antigen	 presenting	 cells	 (APCs)	 process	 antigenic	
molecules,	such	as	allergens,	and	present	them	to	naïve	T	helper	(Th0)	cells.	Subsequent	
activation	of	allergen-specific	Th2	cells	results	in	secretion	of	interleukins	(IL)	IL-4,	IL-5,	
and	 IL-13,	which	 in	 turn	 initiate	 and	enforce	 further	pathways	via	 recruiting	of	other	
immune	cells.	[24]		
As	 illustrated	 in	 Figure	 3,	 IL-4	 enhances	 Th2	 cell	 activation	 and	 thereby	 cytokine	
secretion,	and	leads	to	the	activation	of	B	cells,	which	then	produce	IgE	that	is	presented	
on	the	surface	of	mast	cells	and	can	interact	with	the	antigen	directly.	IL-5	recruits	and	
activates	 eosinophils,	 while	 IL-13	 stimulates	 goblet	 cells	 to	 enhance	 their	 mucus	
production.	Consequently,	eosinophils	and	mast	cells	secrete	second	messengers,	such	
as	cytokines,	leukotrienes,	and	histamine.	These	trigger	smooth	muscle	cell	constriction	
as	well	 as	 epithelial	 cell	 damage,	 resulting	 in	 inflammation,	 hyperresponsiveness	 and	
ultimately	remodeling	of	the	airways.	[4,	24]	
Although	 attempts	 have	 been	 made	 to	 prevent	 these	 processes	 by	 silencing	
inflammatory	cytokines	such	as	IL-5	[25]	or	IL-13	[26]	with	siRNA,	interference	with	a	
single	interleukin	modulates	only	certain	parts	of	the	process,	while	the	other	pathways	
still	 proceed.	 A	 more	 promising	 way	 to	 adjust	 the	 entire	 Th2	 driven	 inflammatory	
cascade	 is	 to	 downregulate	 GATA3,	 the	 central	 transcription	 factor	 regulating	 the	
expression	 of	 all	 these	 Th2	 cytokines,	 [27]	 thereby	 silencing	 the	 expression	 of	 all	 of	
them	 simultaneously.	 In	 this	 way,	 the	 underlying	 inflammation	 process	 in	 asthmatic	
lungs	 could	 be	 prevented	 early-on	 in	 contrast	 to	 most	 current	 therapies	 that	 only	
palliate	symptoms.	GATA3	silencing	was	already	proven	successful	in	a	murine	asthma	
model	[27]	and	even	in	a	human	phase	IIa	clinical	trial	using	a	GATA3	DNAzyme.	[28]	
Studies	 concerning	 siRNA,	 however,	 either	 applied	 naked	nucleic	 acids	which	 are	 not	
expected	 to	 be	 taken	 up	 to	 the	 cytoplasm	 efficiently,	 holding	 the	 full	 knockdown	
potential	 back,	 or	 viral	 vectors	 were	 used	 which	 are	 associated	 with	 a	 high	 risk	 of	









A	promising	 approach	 to	 facilitate	 delivery	 to	 target	 cells	 in	 the	 lung	 and	 circumvent	
problems	of	systemic	delivery	is	to	use	local	administration	routes	for	the	application	of	
siRNA	as	asthma	therapy.	Although	siRNA	is	prone	to	be	degraded	by	nuclease	digestion	
and	 rapidly	 excreted	 via	 the	 kidneys	 after	 intravenous	 (i.v.)	 injection,	 [30]	 a	 large	
number	 of	 studies	 still	 focuses	 on	 systemic	 application	 routes.	 Local	 administration	
such	as	pulmonary	delivery,	however,	not	only	avoids	first	pass	metabolism	of	applied	
drugs,	 but	 also	 enables	 significant	 reduction	 of	 doses,	 subsequently	 decreasing	
respective	 side	 effects.	 In	 case	 of	 lung	 diseases,	 the	 therapeutic	 molecules	 are,	
moreover,	directly	available	in	the	airways	and	can	bring	about	their	effect	at	the	site	of	
disease	within	 a	 prolonged	 lung	 retention	 period.	 [31]	 Despite	 the	 absence	 of	 serum	
proteins	and	comparably	 low	nuclease	activity	 [32],	 the	 lung	also	offers	 several	other	
beneficial	 characteristics	 as	 a	 target	 organ.	 With	 its	 large	 and	 highly	 vascularized	
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alveolar	 surface	 area	 and	 thin	 epithelium,	 it	 provides	 ideal	 conditions	 for	 exhaustive	
drug	absorption	if	systemic	effects	are	desired.	[33]		
However,	 certain	 requirements	 have	 to	 be	 fulfilled	 for	 successful	 drug	 application.	
Besides	 the	status	of	 the	patient’s	pulmonary	 function	and	 the	 influence	of	cough	and	





high	 momentum.	 [34]	 The	 ideal	 particle	 size	 for	 sufficient	 deposition	 at	 the	 lower	
respiratory	tract	is	therefore	assumed	to	be	between	1-5	µm	in	aerodynamic	diameter.	
It	has,	however,	to	be	noted,	that	the	particles	should	also	have	the	correct	size	not	to	be	







oftentimes	 missing	 correlation	 between	 in	 vitro	 and	 in	 vivo	 studies	 and	 the	 distinct	
differences	in	respiratory	tract	anatomy	between	animals	and	humans.	With	all	points	
taken	into	consideration	and	reasonable	formulation	adjustments,	the	pulmonary	route,	
however,	 displays	 a	 very	promising	way	of	delivering	 therapeutic	 siRNA	 to	 asthmatic	












which	 are	 the	 underlying	 cause	 of	 diseases	 such	 as	 asthma	 and	 therefore	 display	 a	
favorable	target	for	respective	nucleic	acid	based	therapies.	However,	transfection	of	T	
cells	was	 found	 to	be	an	especially	challenging	quest,	as	 they	 typically	do	not	express	
the	protein	caveolin	 [37]	which	 is	essential	 for	 the	 formation	of	 caveolae,	 the	 favored	
entry	 port	 of	 many	 conventional	 non-viral	 vector	 based	 transfection	 procedures.	





differentiating	 cell	 types,	 such	 as	 activated	 T	 cells,	 overexpress	 their	 transferrin	
receptor	 (TfR)	 in	 order	 to	 meet	 their	 high	 iron	 requirements.	 [38]	 Naïve	 T	 cells,	 in	
contrast,	only	show	negligible	TfR	expression,	enabling	specific	targeting	of	the	disease-
related	cells	by	utilizing	transferrin	as	a	targeting	ligand.	In	this	way,	healthy	cells	are	
left	 untreated	 and	 a	 general	 immune	 suppression	 can	 be	 avoided,	 resulting	 in	 a	 very	
specific	therapy.		
Once	 iron-bound	 transferrin	 (holo-Tf)	 binds	 to	 its	 receptor	 on	 the	 cell	 surface,	 the	
transferrin-TfR	complex	 is	 internalized	via	receptor	mediated	endocytosis,	as	outlined	
in	Figure	5.	Iron	is	released	into	the	cell	and	the	whole	complex	is	recycled	back	to	the	
surface,	where	 iron-free	 transferrin	 (apo-Tf)	 is	 released	and	 the	 receptor	 can	 take	up	

















via	 endocytosis	 [46]	 and	 are	 subsequently	 often	 trapped	 in	 the	 endosomes.	 For	





polymer	 for	 gene	 delivery,	 are	 said	 to	 exhibit	 the	 so-called	 proton-sponge	 effect,	
meaning	 that	 they	 capture	 many	 of	 the	 protons	 during	 acidification	 of	 the	
endo/lysosome	 with	 their	 free	 amine	 groups.	 [48]	 This	 in	 turn	 leads	 to	 an	 influx	 of	
counter	 ions	 and	 water,	 resulting	 in	 endosomal	 swelling	 and	 ultimately	 rupture,	
releasing	 the	 trapped	 particles	 into	 the	 cytoplasm,	 as	 Figure	 6	 illustrates.	 Recent	




human	 T	 cells	 compared	 to	 other	 cell	 types,	 further	 querying	 the	 usefulness	 of	 this	
mechanism	for	sufficient	release	in	this	context.	[50]	
Endosomal	 escape	 was	 in	 fact	 determined	 to	 be	 the	 rate-determining	 step	 in	 the	
delivery	 of	 therapeutics,	 preventing	 entrapment	 and	 breakdown	 in	 lysosomal	
compartments.	[51]	It	is	therefore	advisable	to	apply	additional	release	mechanisms	to	
ensure	successful	delivery	of	siRNA	molecules	to	the	cytosol	as	the	site	of	action	in	an	
adequate	 quantity.	 Ways	 to	 improve	 vesicular	 escape	 comprise	 modulation	 of	 the	
carrier	 system	 with	 specific	 functional	 groups	 including	 positively	 charged	 or	 pH	
sensitive	 moieties,	 [52]	 utilizing	 viral	 or	 liposomal	 systems	 enabling	 fusion	 with	 the	
endosomal	 membrane,	 [53]	 and	 other	 mechanisms	 based	 on	 enhancing	 osmotic	
pressure,	 particle	 swelling,	 or	 membrane	 destabilization.	 [49]	 Endosomolytic	 agents,	















the	 basis	 of	 polycationic	 polymer	 polyethylenimine	 (PEI)	 and	 targeting	 ligand	
transferrin	 (Tf),	 resulting	 in	 the	 so-called	 Tf-PEI,	 was	 chosen	 and	 fully	 characterized	








in	 successful	 gene	 knockdown.	 For	 GATA3	 silencing,	 a	 suitable	 siRNA	 sequence	
combination	 was	 found	 and	 applied	 within	 the	 Tf-Mel-PEI	 blend	 polyplexes	 to	
investigate	down-stream	effects	of	the	gene	knockdown	on	cytokine	levels.	These	were	
concludingly	 tested	 in	 an	 optimized	 model	 for	 activated	 T	 cells	 as	 a	 first	 step	 for	
evaluation	of	relevant	therapeutic	effects	in	an	inflammatory	environment.	
	
Chapter	 1	of	 this	 thesis	 provides	 a	 general	 introduction	 briefly	 covering	 all	 relevant	
topics	affecting	the	content	of	this	work.	
	
Chapter	 2	 introduces	 the	 concept	 of	 using	 pulmonary	 siRNA	 delivery	 as	 a	 novel	
treatment	strategy	for	lung	diseases	such	as	asthma.	Besides	relevant	characteristics	of	
the	lung	as	a	target	organ,	general	advantages	of	and	hurdles	for	pulmonary	delivery	of	
siRNA	are	discussed	 and	 current	 studies	 are	 summarized	 to	 conclude	perspectives	 of	
the	field.		
	
Chapter	 3	provides	 an	 overview	 of	 polymeric	 nanogels	 as	 a	 further	 form	 of	 delivery	
system	for	nucleic	acids.	In	this	chapter,	important	aspects	of	nanogel	formulation	and	
characterization	are	described	and	possible	modifications	as	well	as	stimuli-responsive	
behavior	 of	 these	 systems	 are	 exemplified	 rounded	 off	with	 information	 about	 active	
targeting,	 co-delivery	 and	 respective	 add-on	 treatments.	 Moreover,	 relevant	 in	 vivo	
studies	are	reviewed.		
	
Chapter	 4	 evolves	 around	 the	 disease	 asthma,	 approaching	 its	 biology	 and	
pathogenesis	as	well	as	current	treatment	forms.	In	this	context,	epidemiology,	etiology,	
pathophysiology	 and	 diagnosis	 of	 asthma	 are	 described	 in	 detail.	 Current	 disease	





Chapter	 5	 attempts	 to	 answer	 the	 question	 of	 how	 to	 effectively	 translate	
nanomedicines	for	asthma	from	basic	research	to	standard	clinical	routine	and	thereby	
close	 the	 gap	 between	 bench	 and	 bedside.	 Therefore,	 the	 different	 groups	 of	 drugs	
available	 for	 asthma	 treatment	 are	 described	with	 a	 special	 focus	 on	 nanomedicines.	
Subsequently,	 adequate	 study	 planning	 as	 well	 as	 factors	 having	 to	 be	 considered	




to	 treat	 cancerous	 and	 inflammatory	 diseases.	 Conjugate	 synthesis	 and	 polyplex	
preparation	 as	 well	 as	 characterization	 are	 described	 in	 detail	 to	 offer	 a	 way	 to	









chapters	 with	 Mel-PEI	 yielding	 the	 Tf-Mel-PEI	 blend	 and	 characterization	 as	 well	 as	






Chapter	 9	 addresses	 the	 specific	 knockdown	 of	 GATA3	 using	 the	 Tf-Mel-PEI	 blend	
polyplexes	including	evaluation	of	respective	treatment	impact.	For	this	purpose,	T	cell	
activation	processes	are	optimized	in	continuous	as	well	as	primary	T	cells	to	generate	a	
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The	 lung	 offers	 various	 beneficial	 characteristics	 as	 a	 target	 organ	 for	 therapeutic	
approaches.	 Besides	 the	 large	 (hundreds	 square	 meters)	 and	 very	 well	 perfused	 (5	
L/min)	surface	area,	extremely	thin	epithelium	(0.1-0.2	µm)	and	high	blood	volume	in	
pulmonary	capillaries	(0.25	L),	 it	also	captivates	with	a	relatively	 low	enzyme	activity	
and	 slow	 surface	 clearance.	 [58]	 Owing	 to	 its	 location	 and	 function,	 the	 pulmonary	
region	 is	 susceptible	 to	 a	 number	 of	 specific	 diseases,	 being	 directly	 accessible	 to	
harmful	 substances.	 Lung-related	 disorders	 therefore	 contribute	 substantially	 to	 the	
global	 disease	 burden	 in	 regards	 to	 public	 health	 and	 economic	 resources.	 For	 a	
considerable	 number	 of	 those	 pathologies	 including	 asthma,	 idiopathic	 pulmonary	
fibrosis	 (IPF),	 respiratory	 syncytial	 virus	 (RSV)	 and,	 moreover,	 lung	 cancer	 as	 the	
leading	cause	of	cancer	death	worldwide,	the	underlying	cause	is	elevated	transcription	
of	 certain	 genes.	 [59,	 60]	 Therefore,	 the	 interference	 with	 gene	 expression	 via	 RNA	













being	 retained	 by	 glomerular	 filtration.	 [62]	 Local	 delivery,	 however,	 enables	 direct	
transport	 to	the	target	site	while	circumventing	the	first	pass	effect	resulting	 in	 lower	
doses	and	respective	side	effects.		
The	primary	barrier	for	pulmonary	siRNA	delivery	is	the	extensively	branched	structure	
of	 the	 airways	with	 variable	 lengths	 and	diameters,	 followed	by	 the	 presence	 of	 lung	
fluids,	such	as	mucus	and	surfactant	[63],	as	well	as	mucociliary	clearance	mechanisms	




of	 these	 natural	 defense	 mechanisms	 is	 necessary	 when	 formulating	 pulmonary	
therapeutics.	 [64]	 To	 improve	 siRNA	 stability	 and	 efficacy	 without	 using	 delivery	
systems,	it	can	be	chemically	modified	or	conjugated	to	appropriate	biomolecules.	[65]	
Besides	this,	carrier	vectors	can	of	course	help	to	overcome	delivery	challenges	of	naked	
nucleic	 acids.	 Due	 to	 improved	 toxicity	 profiles	 concerning	 immunogenicity	 and	
tumorigenicity	as	well	as	ease	and	reproducibility	of	manufacturing,	non-viral	vectors	
are	mostly	preferred	over	virus-based	systems.	[31]	A	great	range	of	different	materials	
is	 available,	 including	 polymers,	 lipids,	 peptides	 and	 inorganic	 material,	 which	 can	
furthermore	 be	 tailored	 with	 diverse	 surface	 modifications	 [66],	 such	 as	 targeting	
ligands	or	membrane-active	substances.		
Administration	of	siRNA	to	the	lungs	is	usually	performed	via	inhalation	or	intranasally,	
as	 both	 ways	 present	 easy	 and	 non-invasive	 options.	 For	 inhalation,	 siRNA	 can	 be	
formulated	into	liquid	aerosols	produced	by	inhalers	or	nebulizers	or	as	a	dry	powder	
aerosol.	 [65]	 Currently	 available	 inhalation	devices	 comprise	pressurized	dry	powder	
inhalers	 (DPIs),	 nebulizers,	 soft	 mist	 inhalers	 (SMIs),	 and	 the	 most	 commonly	 used	
metered	 dose	 inhalers	 (pMDIs).	 For	 successful	 pulmonary	 application,	 particle	
deposition	 near	 the	 targeted	 lung	 cells	 is	 fundamental,	 arrangeable	 with	 optimal	
particle	size,	shape	and	density.	The	ideal	aerodynamic	diameter	of	droplets	or	powder	
particles	would	be	between	1-5	µm,	as	smaller	particles	are	very	 likely	 to	be	exhaled,	
while	 larger	 ones	might	 easily	 deposit	 in	 the	 throat	 and	 upper	 airway	walls.	 [63]	 By	
precisely	controlling	these	particle	characteristics	and	thereby	deposition	mechanics	of	
drug	 formulations,	 specific	 regions	 in	 the	 pulmonary	 tract	 can	 be	 reached.	 [67]	 Even	
more	 distinct	 delivery	 is	 possible	 by	 targeting	 of	 certain	 cell	 types	 in	 the	 lung,	 for	
example	by	coupling	 ligands	 that	bind	 to	receptors	expressed	on	 the	surface	of	 target	
cells.	 The	 native	 glycoprotein	 transferrin,	 for	 instance,	 was	 shown	 to	 be	 an	 effective	
mediator	 to	 reach	 activated	 T	 cells	 as	 disease	 mediators	 in	 asthmatic	 lungs	 [68]	 or	
malignant	 lung	 cancer	 cells	 [69].	 After	 successfully	 reaching	 the	 target	 cells,	 siRNA	
particles	have	to	be	efficiently	 taken	up	which	 is	mostly	achieved	by	endocytosis.	 It	 is	
then	 crucial	 for	 the	 nucleic	 acid	 to	 escape	 the	 endosomes	 to	 avoid	 degradation	 upon	
acidification	and	to	achieve	cytoplasmic	delivery	to	the	RNA-induced	silencing	complex	
(RISC),	 the	 target	 location	 of	 siRNA.	 In	 fact,	 recent	 studies	 identified	 escape	 of	 the	
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endosomal	pathway	as	 the	 rate-determining	step	 in	delivery	of	 therapeutic	molecules	
[51],	 justifying	 the	 various	 approaches	 to	 improve	 endosomal	 release.	 Among	 others,	
membrane	fusion	or	disruption,	pore	formation,	and	osmotic	lysis	via	buffering	effects	
are	currently	investigated	options.	[70]	
Almost	 all	 recent	 studies	 investigating	 the	 pulmonary	 delivery	 of	 therapeutic	 siRNA	




pulmonary	 siRNA	 delivery	 from	 bench	 to	 bedside	 is	 to	 develop	 and	 characterize	
inhalable	 drug	 products.	 Appropriate	 ways	 to	 analyze	 aerosolized	 siRNA	 delivery	
vectors	 in	 vitro	 comprise	 dissolution	 tests,	 inertial	 cascade	 impaction,	 delivered	 dose	
uniformity	assay,	laser	diffraction,	and	laser	Doppler	velocimetry,	as	well	as	the	isolated	
lung	 perfusion	 model	 as	 a	 useful	 ex	 vivo	 option.	 Subsequently,	 formulations	 can	 be	
examined	 in	 vivo	 using	 methods	 such	 as	 gamma	 scintigraphy,	 3D	 SPECT	 or	 MRI	
fluorescence	imaging.	[64]	
The	majority	 of	 in	 vivo	 studies	 are	 still	 carried	 out	 in	mice,	 as	 they	 are	 small,	 rather	
economical	 in	 terms	of	husbandry	and	offer	 fast	 and	efficient	 reproduction.	However,	
rodent	airways	distinctly	differ	from	those	of	humans	in	regards	to	anatomy,	histology	
and	 physiology.	 [71]	 As	 different	 pharmacokinetic	 properties	 such	 as	 particle	
deposition	 and	 mucociliary	 clearance	 strongly	 affect	 the	 eventual	 active	 dose,	 it	 is	
essential	 to	consider	 this	 fact	before	extrapolating	 these	results	 to	human	application.	
Furthermore,	animal	models	should	 ideally	mimic	the	clinical	conditions	as	accurately	
as	 possible	 to	 examine	 potential	 medications	 in	 a	 realistic	 disease	 environment	 and	
integrating	 the	 fact	 that	 respiratory	 function	 is	 compromised	 in	 patients	 with	 lung	
diseases.	 Due	 to	 the	 ease	 of	 experimental	 setup	 and	 control,	 the	 application	 route	 of	
choice	 is	 usually	 intratracheal	 or	 intranasal.	 Although	 intranasal	 delivery	 is	 very	
straightforward,	 since	 the	 formulation	 just	 has	 to	 be	 instilled	 in	 the	 nasal	 cavity	 and	
breathed	in,	humans	are	not	obligate	nose	breathers	and	their	nasal	cavity	filters	out	the	
vast	 amount	 of	 particles,	 resulting	 in	 a	 low	 lung	 deposition.	 [72]	 Intratracheal	




deposition,	 eventuating	 in	 a	 lower	 total	 drug	 loss.	 [64]	Moreover,	 this	method	 is	 not	
suitable	 for	 human	 clinical	 studies	 or	 even	 usage	 in	 the	 clinical	 routine	 due	 to	 its	
invasiveness,	 as	 inserting	 a	 tube	 within	 surgical	 incision	 is	 highly	 impracticable	 and	
uncomfortable	for	the	patient.	[34]	Accordingly,	focusing	more	on	the	testing	of	actual	







being	 approved	 in	 the	US	 and	 EU	 as	 the	 very-first	 siRNA	medication,	 [19]	 significant	
progress	in	the	development	of	RNAi	based	therapeutics	has	been	made,	paving	the	way	
for	more	products	to	follow.	As	a	large	share	of	airway	related	diseases	evolve	around	
inflammatory	 processes	 for	 which	 long-term	 therapies	 are	 needed,	 it	 is	 inevitable	 to	




further	 focused	 on	 the	 development	 of	 biodegradable	 delivery	 vectors	 in	 order	 to	
achieve	 safe	 and	 compatible	 formulations.	With	 all	 points	 considered,	 the	 pulmonary	






























































With	 its	 nearly	 unrestricted	 possibilities,	 gene	 therapy	 attracts	 more	 and	 more	
significance	in	modern-day	research.	The	only	issue	still	seeming	to	hold	back	its	clinical	
success	 is	 the	actual	effective	delivery	of	genetic	material.	Nucleic	acids	are	 in	general	
challenging	 to	 administer	 to	 their	 intracellular	 targets	 due	 to	 their	 unfavorable	
pharmaceutical	 characteristics.	 Polymeric	 nanogels	 present	 a	 promising	 delivery	
platform	 for	 oligonucleotide-based	 therapies,	 as	 the	 growing	 number	 of	 reports	
deliberated	in	this	review	represents.	Within	the	scope	of	this	article,	recent	progress	in	
the	 employment	 of	 nanogels	 as	 gene	 delivery	 vectors	 is	 summarized	 and	 different	
examples	 of	 modified,	 stimuli-responsive,	 targeted	 and	 co-delivering	 nanogels	 are	
discussed	 in	 detail.	 Furthermore,	 major	 aspects	 of	 successful	 gene	 delivery	 are	




Gene	 therapy	 describes	 the	 process	 of	 introducing	 foreign	 genomic	 material	 into	
specific	 host	 cells	 in	 order	 to	 gain	 a	 therapeutic	 benefit	 by	 correcting	 existing	
disfunctions	 or	 sustaining	 respective	 cells	 with	 new	 functions.	 [73]	 While	 at	 early	
stages,	gene	therapy	mainly	focused	on	rare	genetic	disorders,	the	concept	of	delivering	
nucleic	 acids,	 including	 plasmid	 DNAs,	 short	 interfering	 RNAs	 (siRNAs),	 as	 well	 as	






any	 chosen	 gene.	 Despite	 all	 progress,	 however,	 there	 are	 still	 several	 hurdles	 yet	 to	
overcome	 on	 the	 way	 to	 a	 successful	 translation	 of	 these	 findings	 into	 the	 clinical	




The	most	 challenging	 step	 towards	 effective	 gene	 delivery,	 in	 fact,	 appears	 to	 be	 the	
search	 for	 a	 suitable	 carrier	 system.	 As	 for	 most	 biotherapeutics,	 the	 transport	 of	
genetic	 material	 to	 their	 intracellular	 targets	 is	 demanding,	 due	 to	 their	 unfavorable	
biopharmaceutical	 properties.	 [78]	 Nucleic	 acids	 are	 not	 only	 heavily	 susceptible	 to	
enzymatic	 and	 chemical	 degradation	 and	 rapidly	 cleared	upon	 systemic	 injection,	 but	
also	generally	hindered	from	crossing	cellular	membranes.	It	 is	therefore	inevitable	to	
package	 therapeutic	 DNA	 or	 RNA	 in	 appropriate	 delivery	 systems	 that	 protect	 their	
payload,	 facilitate	 cell	 internalization	 and	 guide	 its	 way	 towards	 the	 required	
intracellular	 target	 compartment:	 nucleus	 for	 DNA,	 or	 cytosol	 for	 siRNA	 and	 mRNA.	
Although	 viral	 vectors	 show	 high	 gene	 transfection	 efficiencies,	 their	 clinical	 utility	
remains	very	limited	due	to	their	potential		immunogenicity	and	severe	side	effects.	[79]	
Modern	 gene	delivery	 approaches,	 therefore,	mainly	 focus	 on	nonviral	 vectors	with	 a	
particular	 emphasis	 on	 polymeric	 carrier	 systems.	 	 Polymers	 can	 purposefully	 be	
designed	 for	 specific	 application	 needs	 regarding	 characteristics	 such	 as	 different	








over	 drug	 release	 rates	 than	 macro-sized	 vehicles.	 As	 opposed	 to	 bulky	 delivery	
systems,	vehicles	in	the	nano-scale	can	enter	target	cells	with	greater	ease	and	are	able	
to	 specifically	 attack	 diseases	 at	 their	 site	 of	 action	 as	 they	 can	 circulate	 in	 the	 body	
after	injection.	[81]	
Polymeric	 nanogels	 are	 a	 special	 representative	 of	 nano-sized	 systems,	 consisting	 of	
nanoparticles	composed	of	hydrogels	which	are	 in	 turn	made	of	cross-linked	polymer	
networks.	Combining	beneficial	functions	of	dendritic	systems	with	those	of	hydrogels	
such	 as	 large	 encapsulation	 cavities	 and	 the	 capability	 of	 swelling	 as	 well	 as	
responsiveness,	 these	 novel	 structures	 not	 only	 fill	 the	 size	 gap,	 but	 also	 present	 a	
functional	 link	 between	 common	 dendrimer	 or	 polymer	 scaffolds	 and	 macroscopic	
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hydrogels.	 [82]	 As	 opposed	 to	 larger	 hydrogel	 particles,	 nanogels	 can	 easily	 be	
administered	 intravenously	 and	 deliver	 their	 payload	 to	 various	 target	 regions	 and	
cells.	Further	advantages	of	 these	promising	drug	delivery	platforms	comprise	 simple	
and	efficient	drug	loading,	physical	stability	of	both	carrier	and	incorporated	drug,	and	a	
versatile	design.	As	 they	 form	complexes	with	biomacromolecules	 such	as	proteins	 in	
suitable	size	dimensions,	they	not	only	ease	the	way	for	their	delivery,	but	also	help	to	
maintain	their	biological	activity	by	keeping	them	in	the	correct	confirmation,	arousing	
special	 interest	 for	biomedical	applications.	 [81]	Due	to	their	characteristic	properties	
such	as	softness	and	swelling	behaviour,	nanogels	are	predestined	to	achieve	controlled	
as	well	as	responsive	release	at	the	target	location	[83].	The	possibility	to	trigger	these	
soft	 delivery	 systems	 to	 alter	 their	 structure	 upon	 changes	 in	 parameters	 such	 as	
temperature,	pH,	or	ionic	environment	facilitates	both	storage	and	administration	of	the	
therapeutic	 formulation	compared	to	hard	nanomedicines.	Nanogels	can	therefore	e.g.	
be	 applied	 in	 a	 low	 viscous	 form	 that	 transitions	 into	 a	 dense	 film	 or	 a	 high	 viscous	
depot	form	after	administration.	[84]	The	versatile	architecture	of	nanogels	enables	the	






generation	 of	 heat	 and	 ionic	 changes.	 [82]	 Nevertheless,	 nanogels	 are	 nowadays	
intensely	investigated	throughout	a	great	variety	of	application	fields,	having	the	great	
benefit	 of	 being	 customizable	 for	 respective	 needs	 not	 just	 in	 terms	 of	 size	 and	
crosslinking	 density,	 but	 also	 surface	 modifications	 such	 as	 with	 specific	 targeting	
ligands.	[78]	Drug	delivery	representing	the	area	with	the	greatest	impact	of	nanogels,	
they	 have	 also	 emerged	 to	 be	 vastly	 applicable	 in	 other	 sections,	 particularly	 in	 the	
biomedical	 field,	 comprising	 imaging	 and	 diagnostic	 purposes	 [85],	 sensing	 [86],	
bioengineering	 [87]	 and	 the	 exploitation	 of	 responsive	 nanomaterials	 [82].	 A	 tabular	
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in	 Figure	 1:	 the	 use	 of	 polymer	 precursors	 or	 the	 heterogeneous	 polymerization	 of	
monomers.	 As	 amphiphilic	 copolymers	 are	 prone	 to	 self-assemble	 into	 nanoscaled	
structures	in	an	aqueous	environment,	the	former	can	be	stabilized	by	utilizing	different	
cross-linking	methods,	based	on	amines	or	disulfides,	click	chemistry,	or	are	photo-	or	
physically	 induced.	 The	 fabrication	 of	 nanogel	 networks	 by	 polymerization	 of	
monomers	can	proceed	in	an	emulsion	or	inverse	emulsion	process,	depending	on	the	
continuous	 phase.	 By	 incorporation	 of	 bifunctional	 monomers	 and	 initiation	 of	





[82]	 Due	 to	 the	 mostly	 rather	 harsh	 conditions	 and	 the	 oftentimes	 required	 use	 of	
catalysts	 during	 the	 synthesis	 of	 nanogels	 [93],	 it	 is	 usually	 preferred	 to	 add	 the	
sensitive	nucleic	acid	payload	 in	 the	aftermath.	 In	order	 to	use	polymeric	nanogels	as	
effective	 gene	 delivery	 vectors,	 it	 is	 generally	 necessary	 for	 them	 to	 possess	 or	 get	
incorporated	 site-specific	 cationic	 entities	 [110].	 In	 most	 cases,	 the	 siRNA,	 pDNA,	 or	
mRNA	 is	 then	 just	 added	 to	 the	 readily	 prepared	 nanogel	 at	 the	 desired	 N/P	 ratio	
(residual	molar	ratio	of	the	amine	groups	of	the	nanogel	to	the	phosphate	groups	of	the	
nucleic	 acid)	 and	 mixed	 thoroughly.	 During	 a	 short	 incubation	 period,	 a	 polyion	




synthesized	 using	 amphiphilic	 reactive	 ester	 block	 copolymers	 of	 pentafluorophenyl	




revealed	 to	 especially	 avoid	 acidic	 compartments	 and	 hence	 endolysosomal	 uptake	
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study	 aiming	 for	 gene	 knock-down	 in	 primary	 mouse	 osteoblasts,	 weight	 to	 weight	




a	 surfactant-free	 inverse	 nanoprecipitation	 method	 resulting	 in	 disulfide	 crosslinked	




polyglycerol	 moieties	 in	 the	 nanogel	 structures,	 they	 were	 able	 to	 vary	 and	 thereby	
investigate	the	interactions	between	the	nanogels	and	the	miRNA	in	more	detail.	In	this	
way,	they	synthesized	and	characterized	six	potential	nanocarriers,	depicted	in	Figure	
2,	 	 giving	new	 insights	 into	some	 important	 features	 for	 the	design	of	oligonucleotide	
delivery	 systems	 by	 comprehensive	 comparison	 of	 the	 varying	 nanogels.	 Nanogels	 3	
and	 4	 (NG3	 and	 NG4)	 showed	 particularly	 high	 efficiencies	 to	 complex	 miR-34a,	 a	
miRNA	that	targets	genes	playing	a	key	role	in	the	regulation	of	apoptosis	and	cell	cycle	
arrest	as	well	as	inducing	the	inhibition	of	cell	proliferation	and	migration.	Both	cationic	
nanogels	 were	 able	 to	 neutralize	 the	 negatively	 charged	 miRNA	 in	 a	 dose-related	
manner	 and	 showed	 higher	 cellular	 uptake	 than	 the	 less	 positively	 charged	 NG2,	
confirming	the	widely	accepted	hypothesis	that	cationic	surface	charge	of	nanoparticles	
aids	 their	 internalization	 process.	 Complexes	 of	 miR-34a	 with	 NG3	 and	 NG4	 were	
successfully	 taken	up	by	U-87	MG	cells	 and	 significantly	 increased	 the	miR-34a	 levels	
after	 transfection.	 NG3	 complexes,	 however,	 showed	 superior	 knockdown	 abilities	 in	
vitro	 as	well	 as	 in	 vivo,	 inhibiting	 the	 proliferation	 of	 U-87	MG	 cells	 and	 significantly	
arresting	the	tumor	growth	in	mice	bearing	human	U-87	MG	glioblastoma	multiforme,	


















polyethylenimine	 (PEI)	 as	 a	 gene	 carrier	 system,	 including	 its	 relatively	 high	
cytotoxicity	and	induction	of	aggregation	of	erythrocytes	and	hemolysis,	the	former	was	
coupled	 to	 the	 natural	 polysaccharide	 heparin	 to	 form	 novel	 biodegradable	 cationic	
hydrogels.	[111]	
The	transfection	efficiency	of	heparin-PEI	(HPEI)	was	found	to	be	comparable	to	that	of	
25k	 PEI,	 while	 demonstrating	 improved	 blood	 and	 biocompatibility	 and	 decreased	
toxicity.	 While	 being	 stable	 in	 vitro,	 the	 nanogels	 were	 easily	 degradable	 through	





proliferation,	 tumorigenesis	 and	 angiogenesis,	 which	 is	 down-regulated	 in	 most	
examined	 tumor	 types,	was	 successfully	 transfected	 and	 expressed	 in	 SKOV3	 ovarian	
cancer	 cells	 by	 HPEI	 nanogels.	 [112]	 The	 observed	 reduction	 in	 tumor	 weight,	
angiogenesis	and	cell	proliferation	as	well	as	the	induction	of	tumor	cell	apoptosis	could	
even	be	 extended	 in	 a	 pursuant	 combination	of	 the	HSulf-1	HPEI	 complexes	with	 the	
anticancer	drug	cisplatin.	[113]	
Moreover,	 heparin-Pluronic	 supramolecular	 nanogels	 were	 synthesized	 by	 coupling	
aminated	Pluronic	to	heparin	through	amide	linkages.	This	conjugate	was	loaded	with	
basic	 fibroblast	 growth	 factor	 (bFGF),	 an	 inducer	 of	 neovascularization,	 by	 a	 direct	
dissolution	 method.	 The	 highly	 negatively	 charged	 heparin	 was	 shown	 to	 stabilize	
genetic	material	 and	growth	 factors	 such	as	bFGF	by	 forming	high-affinity	 complexes.	
After	 coating	 these	with	PEI,	polyplexes	were	prepared	with	pDNA	encoding	vascular	
endothelial	growth	factor	VEGF165		and	delivered	to	endothelial	progenitor	cells	(EPCs),	









Although	 RNAi	 has	 great	 potential	 for	 application	 in	 the	 treatment	 of	 pulmonary	
diseases,	 the	 lack	of	stable,	biocompatible	carriers	 to	overcome	the	various	 intra-	and	
extracellular	barriers	still	impedes	clinical	translation.	To	enhance	the	colloidal	stability	
of	 siRNA-encapsulating	 nanogels	 and	 to	 prevent	 siRNA	 release	 in	 the	 presence	 of	
competing	 polyanions	 abundantly	 present	 in	 respiratory	 biofluids,	 such	 as	 lung	
surfactant	 and	mucus,	 novel	 bioinspired	 hybrid	 nanogels	were	manufactured.	 siRNA-
loaded	dextran	nanogels	were	combined	with	a	pulmonary	surfactant	coating	to	build	
up	a	core-shell	nanoarchitecture.	Despite	the	fact	that	the	surfactant	shell	considerably	





To	 stimulate	 receptor-mediated	 endocytosis	 of	 the	 particles,	 folate	was	 attached	 as	 a	
targeting	ligand.	Indeed,	both	uptake	and	gene	knockdown	were	enhanced,	eventuating	
in	efficient	silencing	at	nanomolar	siRNA	concentrations.	[103]	
Subsequently,	 surfactant-coated	 as	 well	 as	 uncoated	 nanogels	 were	 delivered	 to	
resident	 alveolar	 macrophages	 (rAM),	 critical	 contributors	 in	 lung	 inflammatory	
responses,	via	pharyngeal	aspiration	in	BALB/c	mice.	While	both	achieved	high	levels	of	
siRNA	uptake	in	rAM,	only	the	coated	formulation	significantly	reduced	gene	expression	






An	 enhancement	 in	 stability	 and	 functionality	 of	 PEG-block-polycation/siRNA	
complexes	was	achieved	by	wrapping	them	with	hydrated	silica	via	polycondensation	of	
soluble	 silicates	 onto	 their	 surface	 comprising	 a	 disulfide	 cross-linked	 core.	 This	
nanogelling	process	efficiently	protected	the	polyplexes	from	counter	polyanions	under	
non-reducing	 conditions,	 while	 maintaining	 the	 environment-responsive	 disulfide	
cleavage	leading	to	the	release	of	the	siRNA.	Assumedly,	a	lower	endosomal	entrapment	
or	lysosomal	degradation	of	the	siRNA	resulted	in	an	increased	gene	silencing	effect	in	















delivery	 systems,	 especially	 in	 the	 research	 for	 tumor	 therapy	 and	 inflammatory	
diseases,	 since	 they	 are	 able	 to	 accumulate	 and	 release	 their	 payload	 at	 the	 desired	
target	site	via	structural	changes	evoked	by	temperature	changes.	[117]	
Cao	 et	 al.	 integrated	 the	 thermo-sensitive	 polymer	 Poly(N-isopropylacrylamide)	
(PNIPAM)	 in	 the	 side	 chain	 of	 low	molecular	weight	 PEI	 via	 the	 conventional	 radical	
graft	 copolymerization	 to	 form	 an	 amphiphilic	 graft	 copolymer	 at	 a	 reaction	
temperature	of	80	°C	and	encapsulated	TRP53	gene,	a	tumor	suppressor	gene	playing	a	
central	 role	 in	cell	 cycle	regulation	and	programmed	cell	death.	The	resulting	cationic	








°C,	 releasing	 93%	 of	 the	 protein	 without	 any	 alterations	 in	 its	 structure	 or	 activity.	
Efficient	 intraepidermal	 protein	 delivery,	 especially	 in	 barrier	 deficient	 skin,	 was	
detected	 and	 transglutaminase	 1	 was	 successfully	 transported	 to	 respective	 knock-
down	models	of	human	skin,	restoring	skin	barrier	function.	[118]	
Further	 thermo-sensitive	 hydrogels	 were	 constructed	 by	 PNIPAM-co-acrylic	 acid	
(PNIPAM-co-AAc)	 to	 generate	 self-assembled	 particles	 with	 a	 nanogel	 character.	
Binding	of	the	carboxyl	group	on	the	outside	of	PNIPAM-co-AAc	with	the	amine	group	of	
amine	 functional	 magnetic	 iron	 oxide	 nanoparticles	 was	 mediated	 by	 hydrophobic	
interactions.	 Fluorescent	 dye	 containing	 nanogels	were	 then	 coated	with	 cationic	 PEI	
and	complexed	with	certain	genes	by	the	electrostatic	formation	of	polyplexes.	Efficient	










Based	 on	 two	 linear	 polymer	 precursors,	 disulfide-containing	 tetralysine	 (TetK)	 and	
oligoethylenimine	 (OEI),	 pH-dependent	 nanogel	 particles	were	 formed	 by	 covalent	 in	
situ	 cross-linking	 with	 homobifunctional	 cross-linkers.	 The	 resulting	 nanogels	 were	
proven	 to	 increase	 in	 size	 as	well	 as	 zeta-potential	when	 encountering	 a	 decrease	 in	
environmental	 pH.	Besides	 that,	 they	were	degraded	 in	presence	of	 glutathione	 at	 10	
mM,	a	concentration	similar	to	the	intracellular	space.	[116]	
In	another	approach	to	generate	both	pH-	and	temperature-responsive	delivery	systems	
for	 the	 co-delivery	 of	 plasmid	 DNA	 and	 proteins,	 carbohydrate-based	 nanogels	 were	
synthesized	 via	 reversible	 addition-fragmentation	 chain	 transfer	 (RAFT)	
polymerization	 technique	 containing	2-lactobionamidoethyl	methacrylamide	 (LAEMA)	
and	methyl	ethyl	methacrylate	(PEGMA).	DNA-nanogel	complexes	were	formed	by	the	
interaction	 of	 carbohydrate	 tails	 with	 DNA	 and	 stabilized	 with	 a	 linear	 cationic	
glycopolymer	which	further	improved	cellular	uptake	and	gene	expression	in	vitro.	The	
acid-degradable	 profile	 of	 the	 nanogels	 enables	 a	 burst	 release	 of	 the	 encapsulated	
biomaterials	in	cell	endosomes.	[120]	
Dimde	 et	 al.	 developed	 an	 elegant	 pH-sensitive	 nanogel	 on	 the	 basis	 of	 two	
macromolecular	 precursors,	 pH-reactive	 dendritic	 polyglycerol	 (dPG)	 and	 low	
molecular	 weight	 PEI-acrylamide,	 that	 were	 combined	 via	 thiol-Michael	
nanoprecipitation	 method.	 Owing	 to	 these	 mild	 conditions,	 lacking	 the	 need	 of	 any	
catalyst,	the	sensitive	siRNA	cargo	could	be	encapsulated	directly	during	the	synthesis	
process	 minimizing	 siRNA	 loss	 or	 degradation.	 Resulting	 nanogels	 with	 pH-sensitive	











external	 stimuli	 to	 a	 great	 extent.	Nanogels	with	 unique	 photodegradation	 properties	
were	 developed	 using	 ethylene	 glycol	 diglycidyl	 ether	 (EGDE)	 as	 cross-linker,	 in	
conjugation	with	 the	polyamines	 spermine,	protamine	 sulfate	 and	PEI.	These	 systems	
were	 then	 employed	 to	 condense	 different	 plasmids	 as	well	 as	 anticancer	 drugs	 into	
nano-range	 particles	 encouraging	 their	 controlled	 release.	 Degradation	 of	 these	
nanogels	upon	UV	light	exposure	occurs	via	the	photo-oxidation	of	EGDE,	leading	to	the	
removal	 of	 cross-links	 allowing	 the	 subsequent	 release	 of	 the	 constituent	 network	
polymer,	 resulting	 in	 changes	 in	 gel	 weight,	 mechanical	 properties,	 mesh	 size	 and	






Under	 certain	pathological	 circumstances,	 such	as	 inflammation	or	hypoxia	which	are	
for	example	characteristic	for	tumors	or	infarcts,	a	phenomenon	called	‘EPR’,	enhanced	
permeability	 and	 retention,	 is	 hypothesized	 to	 take	 place	 at	 the	 disease	 area.	 The	
impairment	 of	 the	 protecting	 endothelial	 lining	 of	 the	 blood	 vessel	walls	 by	 secreted	
factors	such	as	kinin	and	vascular	permeability	factor	leads	to	leaky	vessels	with	larger	
cell	 gap	 sizes.	 This	 increased	 vascular	 permeability	 combined	with	 vitiated	 lymphatic	
drainage	can	be	exploited	 for	a	 form	of	passive	 targeting,	as	 it	 results	 in	an	 increased	
accumulation	 of	 drug	 payloads	 in	 the	 desired	 regions	 while	 circumventing	 off-target	
sites,	 thereby	minimizing	 side	 effects	 in	healthy	organs.	 [121]	 It	 is	 currently	 critically	
discussed	 if	 EPR	 has	 a	 viable	 impact	 on	 tumor	 targeting	 in	 patients,	 or	 if	 it	 is	 more	
relevant	 in	 artificially	 induced	 animal	 models	 of	 tumors.	 However,	 the	 pathological	
changes	that	cause	experimental	passive	targeting	are	well	described.	[122]	
As	opposed	to	this	passive	targeting,	it	 is	also	possible	to	attach	specific	ligands	to	the	




disease	 in	 order	 to	 enhance	 accumulation	 of	 the	 delivered	 agents	 in	 the	 tissues	 of	
interest.	Since	folic	acid	is	a	vital	nutrient	crucial	for	cells	to	biosynthesize	nucleotides	
and	maintain	important	cellular	pathways	[123],	many	human	malignancies,	especially	




nanogel	 was	 synthesized	 by	 chemically	 grafting	 hydrophobic	 chains	 onto	 a	
polysaccharide,	and	the	obtained	macromolecular	micelles	were	decorated	with	 folate	
using	a	PEG	linker.	An	extra	amount	of	PEG	was	added	to	overcome	the	slight	decrease	
of	 solubility	 caused	 by	 folate	 grafting	 and,	 additionally,	 to	 reduce	 the	 opsonin	
adsorption	and	subsequent	scavenging	by	the	mononuclear	phagocyte	system	in	order	
to	 lengthen	 the	 system’s	 lifespan	 in	 blood.	 After	 incubating	 HeLa	 cells	 with	 both	 the	
targeted	 folate-decorated	 and	 non-targeted	 nanogels,	 the	 latter	were	 detected	 on	 the	
cell	surface,	while	targeted	gels	were	localized	in	the	cytoplasm,	proving	the	support	of	
internalization	 by	 receptor-mediated	 endocytosis	 via	 folate.	 [124]	 In	 a	 subsequent	
study	 aimed	 to	 further	 characterize	 the	 uptake	 mechanisms	 and	 intracellular	 fate	 of	
folate-functionalized	nanogels,	specific	siRNA	sequences	were	used	to	selectively	inhibit	
uptake-mediating	 proteins	 such	 as	 clathrin	 or	 caveolin	 and	 thereby	 attenuate	 the	
respective	endocytic	pathways.	Nanogel	uptake	was	shown	to	occur	mainly	via	flotillin-
1	and	Cdc42-dependent	endocytosis	and	a	shown	impairment	by	free	folate	suggests	a	






Several	 of	 the	mentioned	 studies	 employed	 co-delivery	of	 different	 substances	 in	 one	
transport	system	in	order	to	strengthen	the	therapeutic	effect	of	the	delivered	genetic	
material.	 While	 a	 certain	 emphasis	 is	 put	 on	 the	 dual	 delivery	 of	 nucleic	 acids	 with	





Ding	 et	 al.	 recently	 published	 their	 findings	 on	 a	 self-assembling	 protamine-based	
nanogel	 co-delivering	 epigallocatechin-3-O-gallate	 (EGCG)	 with	 matching	 siRNA	 for	
sensitization	 to	 EGCG-involving	 chemotherapy	 in	 an	 approach	 to	 combine	 two	
promising	strategies,	co-delivery	and	selective	tumor	targeting.	Their	multicomponent	
carrier	system	was	able	to	increase	the	cytotoxicity	to	a	drug-resistant	cell	 line	by	15-
fold	 compared	 to	 EGCG	 chemotherapy	 alone	 and	 demonstrated	 enhanced	 selectivity	
and	tumor	growth	inhibition	in	respective	xenograft	tumor-bearing	mice.	[88]	
A	 special	 type	 of	 co-delivery	 was	 used	 in	 an	 attempt	 to	 cope	 with	 one	 of	 the	 most	
challenging	 hurdles	 for	 polymer-based	 gene	 delivery:	 the	 issue	 of	 overcoming	 the	
endosomal	 entrapment	 of	 polyplexes.	 Therefore,	 a	 polysaccharide-based	 cationic	
nanogel	 composed	 of	 hexadecyl	 group-bearing	 cycloamylose	 was	 generated	 and	
complexed	 with	 plasmid	 DNA	 (pDNA)	 as	 well	 as	 the	 membrane	 phospholipid	
hydrolyzing	 enzyme	 phospholipase	 A2	 (PLA2).	 Complexation	 with	 specific	
concentrations	of	PLA2	were	shown	to	enhance	pDNA	expression	levels	and	resulted	in	
similar	 hemolytic	 activity	 to	 that	 of	 native	 PLA2,	 implicating	 a	 membrane	 disruption	
ability	 of	 the	 nanogel/PLA2	 complex	 when	 delivered	 into	 cells,	 triggering	 the	
subsequent	release	of	pDNA	from	the	endosome	to	the	cytoplasm.	[127]	
Another	 approach	 to	 facilitate	 the	 cytosolic	 transport	 after	 delivery	 by	 nanogels	was	
pursued	by	Joris	et	al.	for	siRNA.	Here,	it	is	thought	to	be	of	particular	importance	that	
the	 sensitive	 cargo	 is	 released	 to	 the	 cytoplasm	 prior	 to	 fusion	 of	 endosomes	 with	
lysosomes	 to	prevent	degradation.	 In	an	effort	 to	circumvent	 this	 issue	and	even	 take	
advantage	 of	 the	 lysosomal	 accumulation,	 cells	 were	 treated	 with	 drugs	 provoking	
siRNA	 release	 from	 lysosomes	 to	 the	 cytosols,	 after	 having	 been	 transfected	 with	
nanogels.	 The	 group	 was	 able	 to	 show	 how	 a	 simple	 incubation	 of	 H1299	 eGFP-
expressing	cells	with	the	applied	FDA-approved	cationic	amphiphilic	drugs	(CADs)	after	










Figure	 3.	 CAD-mediated	 inhibition	 of	 Acid	 sphingomyelinase	 causes	 lysosomal	 lipid	





Several	 of	 the	 nanogels	 currently	 under	 investigation	 for	 their	 use	 as	 gene	 delivery	
systems	 were	 already	 examined	 in	 vivo	 in	 respective	 animal	 models,	 the	 majority	
thereof	were	considering	siRNA	or	other	types	of	therapeutic	RNA.		
A	recent	report	describes	cationic	nanogel	polymers	prepared	by	atom	transfer	radical	
polymerization	 (ATRP)	 in	 inverse	 miniemulsion	 and	 loaded	 with	 siRNA.	 The	 use	 of	
 
 41	
quaternized	 dimethylaminoethyl	 methacrylate	 (Q-DMAEMA)	 as	 hydrophilic	 cationic	
moiety	 enabled	 siRNA	 binding	 without	 facing	 the	 problem	 of	 polymer	 aggregation.	







Intra-tumor	 delivery	 of	 siRNA	 was	 aimed	 for	 with	 self-assembled	 nanogels	 of	
cholesterol-bearing	cycloamylose	with	a	spermine	group	to	deliver	vascular	endothelial	
growth	 factor	 (VEGF)-specific	 siRNA.	 The	 nanogel	 complexes	were	 taken	 up	 by	 renal	
cell	 carcinoma	 (RCC)	 cells	 through	 endocytosis	 resulting	 in	 efficient	 knockdown,	 and	
intra-tumor	 injections	 were	 able	 to	 significantly	 suppress	 neovascularization	 and	
growth	of	RCC	in	mice.	[108]	
Another	 study	 tested	 the	 delivery	 of	 self-amplifying	 replicon	 RNA	 (RepRNA)	 in	
biodegradable,	chitosan-based	nanogel-alginate	and	demonstrated	RepRNA	delivery	to	
dendritic	 cells.	 Accumulation	 in	 vesicular	 structures	with	 patterns	 typifying	 cytosolic	
release	 promoted	 RepRNA	 translation	 in	 vitro	 as	 well	 as	 in	 vivo	 after	 vaccination	 of	
Balb/c	mice	and	New	Zealand	white	rabbits.	[109]	
A	 further	 nanogel	 for	 siRNA	 delivery	 was	 manufactured	 on	 the	 base	 of	 fully	 water-
soluble	 DNA-grafted	 polycaprolactone	 brushes,	 that	were	 used	 to	 further	 assemble	 a	
crosslinked	nanogel	via	functional	nucleic	acid	hybridization.	After	being	intravenously	
administered	 to	 MDA-MB-231	 tumor-bearing	 mice,	 the	 delivery	 system	 exhibited	
favorable	physiological	stability	as	well	as	a	prolonged	blood	half-life	and	an	increased	
accumulation	 at	 the	 tumor	 site	 compared	 to	 lipofectamine	 as	positive	 control.	 	 siRNA	
specific	 for	 polo-like	 kinase	 1	 (PLK1),	 the	 chosen	 oncogenic	 target	 over-expressed	 in	







covalent	 bond	 crosslinked	 nanogel	 is	 susceptible	 to	 high	 cytosolic	 concentrations	 of	




rates	 in	 4T1-luc	 tumor	 cell	 bearing	 BALB/C	 mice.	 At	 the	 same	 time,	 the	 developed	
system	 showed	 lower	 cytotoxicity	 and	 negligibly	 low	 hemotoxicity	 in	 healthy	 mice,	
evading	recognition	and	clearance	by	the	reticuloendothalial	system.	Biodistribution	of	
the	nanogel	 comprising	Cy5-siRNA	was,	moreover,	 tested	 in	 tumor	bearing	mice	after	
injection	into	the	tail	vein.	The	highest	fluorescence	intensity	signal	was	obtained	at	the	
tumor	site	12	h	post-injection	and	the	preferred	accumulation	in	the	tumor	tissue	was	
confirmed	 by	 examination	 of	 harvested	 single	 organs,	 as	 shown	 in	 Figure	 4.	 The	













Albeit	 not	 explicitly	 falling	 into	 the	 scope	 of	 this	 review	 focusing	 on	 gene	 delivery,	
chimeric	antigen	receptor	(CAR)	T	cell	therapy	as	a	kind	of	gene	therapy	with	immense	
relevance	 is	worth	mentioning	 here	 as	 an	 example	 of	 the	 diverse	 application	 field	 of	
nanogels.	 In	 a	 recent	 approach,	 nanogels	 were	 used	 to	 selectively	 deliver	 large	
quantities	 of	 supporting	 protein	 drugs	 onto	 T	 cells	 and	 release	 their	 payload	 in	 a	
particular	 responsive	 way,	 namely	 upon	 T	 cell	 receptor	 (TCR)	 activation.	 Therefore,	






the	 cell	 surface	 in	 order	 to	 sustain	 stimulation.	 In	 vitro,	 T	 cells	 treated	 with	 TCR-
responsive	 nanogels	 expanded	 16-fold	 more	 in	 tumors	 than	 those	 supported	 with	
systemic	cytokine	 injections,	and	 in	vivo,	nanogels	backpacked	CAR	T	cells	eradicated	





Altogether,	 the	 ideal	 carrier	 system	 for	 successful	 gene	 delivery	 has	 to	 meet	 several	
specific	requirements.	First	of	all,	the	genetic	material	has	to	be	efficiently	encapsulated	
in	a	stable	complex	that	at	best	endures	circulation	in	the	body.	Nanogels	certainly	fulfill	
this	 demand,	 as	 their	 hydrophilicity	 contributes	 to	 high	 loading	 capacities	 for	
hydrophilic	biotherapeutics	and	their	tailorable	size	and	crosslinking	density	allow	for	
adjusting	 their	 pore	 sizes	 to	 various	 loaded	 molecules.	 Thus,	 nanogels	 can	 stably	
encapsulate	 their	 cargo	 during	 the	 synthesis.	 It	 is,	 however,	 essential	 to	 ensure	 that	
drug	molecules	are	not	chemically	modified	during	this	process.	[129]	Nucleic	acids,	as	





The	 next	 step	 would	 be	 to	 transport	 the	 therapeutic	 molecule	 to	 the	 desired	 target	
region	and,	 if	 applicable,	 to	 specific	 target	 cells.	As	discussed	before,	nanogel	 systems	
are	both	adjustable	to	benefit	from	passive	targeting	effects	and	to	be	customized	by	the	




drug	so	 that	 it	can	bring	about	 its	effect.	As	 important	as	a	stable	complex	of	delivery	






Most	 common	 nanogels	 release	 their	 payload	 by	 hydrolytic	 degradation	 of	 their	 gel	
network,	resulting	in	a	sustained	release	leading	to	relatively	 low	drug	concentrations	
in-	 and	 outside	 of	 cells.	 As	 nucleic	 acids	 need	 to	 reach	 their	 site	 of	 action	 in	 the	
intracellular	room,	respective	nanogel	carriers	should	be	taken	up	by	cells	and	degrade	
upon	the	altered	physiological	conditions	therein.	 	Several	bio-	and	stimuli-responsive	
nanogels	 have	 successfully	 been	 designed	 for	 the	 use	 as	 gene	 delivery	 systems	 as	
described	in	this	review.	Improvement	of	therapeutic	efficacy	as	reflected	in	parameters	
such	as	enhanced	transfection	efficiency	for	reduction-sensitive	nanogels	as	opposed	to	
non-reducible	representatives,	 implicates	 the	 intracellular	cleavage	of	disulfide	bonds.	
However,	 no	 direct	 evidence	 for	 this	 phenomenon	 has	 been	 found	 so	 far,	 leaving	 the	
exact	 intracellular	 fate	 of	 these	 nanogels	 uncertain.	 [78]	 The	 low	 pH	 of	 lysosomes	 is	
commonly	 used	 to	 reduce	 respective	 carrier	 systems	 releasing	 their	 payload	 in	 a	
controlled	way.	For	nucleic	acids,	however,	it	is	particularly	important	that	they	are	able	




A	 further	aspect	not	 to	be	underappreciated	 is	 the	biocompatibility	of	a	drug	delivery	
system,	 as	 this	 eventually	 determines	whether	 it	 can	 be	 applied	 as	 a	 therapeutic.	 To	
achieve	 non-toxic	 carriers,	 they	 can	 either	 be	 straightaway	manufactured	 from	well-
tolerated	materials,	or	they	have	to	be	built	upon	substances	that	are	transformed	into	
non-toxic	 products	 via	metabolization.	Most	modern	 nanogels	 currently	 designed	 for	
therapeutic	 purposes	 are	 already	 constructed	 from	 some	 of	 the	 many	 available	
biodegradable	 polymers.	 Even	 though	 sparsely	 relevant	 for	 the	 scientific	 level,	 but	
nonetheless	crucial	for	ultimate	drug	approval	and	industrial	production	is	the	ease	of	











important	 criteria	 for	 drug	 evaluation,	 one	 crucial	 factor	 for	 easing	 this	 translation	
especially	 in	 regards	 to	 nucleic	 acid	 delivery	 is	 a	 comprehensive	 investigation	 of	 the	
immune-compatibility	of	respective	systems.	Both	nanotechnology-based	formulations	
in	general	 and	biological	products	 such	as	 therapeutic	nucleic	acids	 in	detail	bear	 the	
risk	 of	 unintended	 immune-mediated	 adverse	 effects.	 [130]	 Although	 this	 area	 is	
substance	of	intensive	research	and	several	immunological	targets	such	as	cell	surface	





sequence	 itself	 has	 influence	 on	 possible	 immunostimulations.	 [131]	 Their	 results	
suggest	 that	 immunogenicity	of	 respective	 formulations	 is	 tunable	and	can	be	used	 to	
manufacture	delivery	systems	with	specifically	designed	immune	responses	as	needed	





The	molecular	 weight	 of	 copolymeric	 nanogels	 lying	 above	 the	 renal	 threshold	 (∼40	
KDa),	they	are	not	excretable	via	the	kidneys	and	might	tend	to	accumulation,	making	it	








liver	 and	 spleen	 and	 at	 the	 same	 time	 provide	 shielding	 of	 undesired	 charges,	 as	 a	
rather	 neutral	 surface	 charge	 has	 been	 shown	 to	 prolong	 the	 circulation	 time	 of	 gel	
particles.	 [83]	 This	 improvement,	 however,	 has	 to	 be	 carefully	 weighed	 with	
maintaining	 the	 stimuli-responsiveness	 of	 the	 nanogel,	 oftentimes	 being	 reliant	 on	
charged	groups.	Another	nanogel-related	drawback	 is	 the	 continuing	heterogeneity	of	
respective	 formulations.	 Despite	 advances	 in	 nanoscale	 fabrication	 allowing	 for	 finer	
particle	size	distribution	control,	exact	reproducibility	of	particle	size	and	stoichiometry	
of	nanogels	remains	difficult	to	achieve.	[83]		
Furthermore,	 some	 questions	 not	 satisfyingly	 acknowledged	 yet,	 such	 as	 the	 exact	
intracellular	fate	of	both	carrier	material	and	nucleic	acid	cargo	or	the	accurate	balance	
between	stability	and	release	behavior	of	built	 complexes,	 still	 leave	room	 for	 further	
improvements.	More	detailed	investigations	of	the	pharmacodynamics	and	-kinetics	of	
nanogels	 as	 well	 as	 their	 interactions	 with	 their	 encapsulated	 payload	 would	 be	 an	
important	step	towards	application	in	the	clinical	routine.	Rationally	designed	nanogels	
taking	all	mentioned	aspects	into	account	then	offer	an	auspicious	base	for	a	variety	of	
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inflammatory	 state	 of	 the	 lungs	 and	 lower	 respiratory	 tract	 characterized	 by	 acute,	
intermittent	 episodes	 of	 increased	 inflammation	 and	 airflow	 obstruction.	 [134]	Acute	
obstruction	 is	 usually	 reversible	 and	 therefore	 manageable,	 but	 the	 chronic	
inflammatory	state	results	in	physiologic	changes	within	the	lungs	that	can	lead	to	more	
severe	 and	 in	 some	 instances	 life-threatening	 exacerbations,	 permanently	 decreased	
lung	function,	and	poor	quality	of	life.	The	high	social	and	economic	burden	associated	






highest	 prevalence	 in	 Australia,	 Northern	 and	 Western	 Europe,	 and	 Brazil.	 [136]	 In	
childhood,	 the	 disease	 is	 more	 common	 in	males,	 but	 as	 the	 disease	 progresses	 into	
adulthood,	slightly	more	women	are	affected.	Though	asthma	can	be	diagnosed	at	any	
age,	 symptoms	 manifest	 in	 early	 childhood	 with	 80%	 of	 asthmatics	 diagnosed	 by	 6	
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years	of	age.	 [137]	Many	children	with	asthma	 improve	while	 some	achieve	complete	
remission	in	adolescence,	however	some	have	persistent	asthma	and	some	demonstrate	
recurrence	 after	 apparent	 remission.	 Children	 who	 experience	 multiple	 wheezing	
episodes	before	3	years	of	 age	and	who	 continue	 to	wheeze	after	 age	6,	 experience	a	
decline	in	their	lung	function	and	often	have	persistent	symptoms	through	adolescence	
and	into	adulthood.	[138-140]	Other	factors	associated	with	persistence	of	asthma	into	
adulthood	 are	 parental	 asthma,	 low	 birth	weight	 or	 prematurity,	male	 gender,	 atopic	
dermatitis	(eczema),	allergic	rhinitis,	and	food	allergies.	[141]		





fairly	 uncommon	 in	 the	 developed	 world	 (1.1	 per	 100,000	 population	 in	 the	 United	
States).	 Independent	 risk	 factors	 for	 asthma	 related	 mortality	 include	 older	 age,	
presence	of	severe	and	persistent	symptoms,	and	those	living	in	the	developing	world.	
[144]	
The	 economic	 and	 social	 burden	 of	 asthma	 is	 significant.	 It	 is	 a	 disease	 that	
disproportionately	affects	those	of	 lower	income	and	education,	and	those	of	minority	
status.	In	the	Global	Asthma	Report	on	the	burden	of	asthma	on	society,	as	measured	by	
years	 of	 life	 lost	 due	 to	 premature	 death	 and	 years	 of	 life	 living	 with	 disability,	 is	
greatest	 in	 the	 young	 and	 the	 elderly	 and	 leads	 among	 chronic	 diseases	 in	 these	
categories.	 [145]	 In	 the	United	States,	more	 than	50%	of	 asthmatics	 report	having	an	
exacerbation	 each	 year,	 accounting	 for	more	 than	14	million	doctor’s	 visits,	 2	million	
emergency	 room	 trips,	 and	 close	 to	 half	 a	 million	 hospital	 admissions.	 [146]	 The	




















exposure	 to	 domestic	 animals	 suggests	 the	 role	 of	 epigenetics,	 or	 environmental	
influence.	[149,	150]	This	is	also	supported	by	the	increasing	prevalence	of	the	disease	
in	 developing	 countries	 with	 the	 spread	 of	 urbanization.	 Additionally,	 recurrent	
episodes	of	wheezing	in	infants	from	acute	viral	respiratory	infections	due	to	influenza	
virus,	 respiratory	 syncytial	 virus,	 and	 human	 metapneumovirus,	 among	 others,	 have	
been	shown	 to	be	directly	 related	 to	 later	development	of	airway	hyperreactivity	and	
asthma.	 [151,	 152]	 All	 of	 these	 highlight	 the	 significant	 role	 that	 environmental	
exposures	 in	 combination	 with	 genetic	 predilections	 have	 in	 the	 development	 and	














inflammatory	 cells,	 structural	 cells,	 and	 inflammatory	 mediators	 in	 a	 complex	
interaction.	 [155-157]	 Generally,	 the	 underlying	 cause	 of	 airflow	 obstruction	 and	 the	
patient’s	 distress	 is	 two-fold;	 smooth-muscle	 surrounding	 the	 airways	 contracts	with	











Bronchospasm	of	 the	 airways	 is	 a	 reflex	 response	designed	 to	protect	 the	 lungs	 from	
harm.	In	healthy	individuals,	this	is	commonly	seen	as	a	response	to	extreme	cold,	heat,	
and	environmental	pollution	(smoke,	dust,	heavy	fog).	In	asthmatics,	the	lungs	become	
hyperresponsive	 to	 triggers,	 and	 therefore	 the	 response	 is	 exaggerated	 and	 often	
persistent	causing	a	significant	narrowing	of	the	airways	and	decreased	airflow.	[157]	
Multiple	factors	play	a	role	in	this	mechanism	and	will	be	discussed	here.	
Physical	 disruption	 of	 the	 epithelium	 from	 trauma,	 invading	 pathogens,	 extremes	 in	






Multiple	 inflammatory	 mediators	 (histamine,	 prostaglandin	 D2,	 and	 cysteinyl-
leukotriene)	 released	 by	 mast	 cells,	 act	 directly	 on	 smooth-muscle	 to	 induce	
bronchospasm.	 Histamine	 acts	 directly	 on	 peripheral	 nerves	 innervating	 smooth	
muscle,	specifically	causing	bronchial	smooth	muscle	to	contract	via	H1	receptors.	Mast	
cells	are	found	lining	the	epithelium	as	well	as	airway	smooth	muscle	layer.	While	mast	





itself	 across	 two	matching	 IgE	molecules	 (cross-linking),	 the	 high-affinity	 receptor	 is	
activated	beginning	a	tyrosine-dependent	cascade	resulting	in	activation	of	the	mast	cell	
and	 release	 of	 its	 granule	 stores.	 Crosslinking	 by	 certain	 antigens,	 rather	 than	 full	
activation,	 causes	 the	mast	 cell	 to	become	sensitized	 to	environmental	 changes	 in	 the	













major	 antigen	 presenting	 cells	 that	 activate	 the	 cell-mediated	 immune	 response.	 In	
healthy	 lungs,	T-helper	1	 cells	predominate.	However,	 for	 less	understood	 reasons,	 in	
asthmatic	 lungs,	 the	 dendritic	 cells	 are	mostly	 immature	 and	 promote	 differentiation	
and	response	of	T-helper	2	 (TH2)	cells	 instead.	This	 is	partially	accomplished	 through	





Figure	 2.	 	 Cell-mediated	 and	 molecular	 pathogenesis	 of	 bronchospasm	 and	 airway	
inflammation	during	an	acute	asthma	exacerbation.	
	
TH2	 cells	 are	 critical	 to	 the	 coordination	 of	 the	 inflammatory	 response	 through	 the	
release	 of	 IL-4,	 IL-5,	 and	 IL-13.	 Release	 of	 these	 cytokines	 result	 in	 recruitment	 of	
eosinophils	 (IL-5),	 the	 maintenance	 and	 survival	 of	 both	 eosinophils	 and	 mast	 cells	
within	 the	 airways,	 and	 increased	 IgE	 formation	 (IL-4	 and	 IL-13).	 IL-13	 also	 induces	
hypersecretion	 of	 mucus	 from	 goblet	 cells	 lining	 the	 airways.	 Eosinophils	 increase	
airway	hyperreactivity	by	releasing	major	basic	protein	and	free	radicals,	which	cause	
injury	to	the	mucosa.	They	also	release	a	small	amount	of	histamine,	though	much	less	
than	 mast	 cells.	 Overall,	 the	 importance	 of	 eosinophils	 in	 asthma	 is	 unclear	 as	 they	
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appear	 to	 play	 dual	 roles	 in	 both	 a	 dysregulated	 allergic	 response	 as	 well	 as	 tissue	
homeostasis	 and	 repair.	 [160]	 In	 some	 patients,	 particularly	 those	 with	 adult-onset	
asthma,	neutrophils	are	attracted	into	the	airways	in	larger	numbers	than	eosinophils,	
but	their	role	and	how	they	affect	the	course	of	the	disease	is	largely	unknown.	[161]		
The	 disruption	 of	 the	 epithelium,	 already	mentioned,	 also	 releases	 several	 additional	
inflammatory	mediators,	 including	vascular	endothelial	growth	factor	which	promotes	
angiogenesis	 in	 the	 lungs.	 The	 significant	 increase	 in	 vasculature	 surrounding	 the	
airways	results	 in	more	edema	during	periods	of	high	inflammation,	due	to	 leakage	of	




mucosa	 of	 the	 lower	 airways	 is	 characterized	 by	 infiltration	 of	 a	 larger	 number	 of	
eosinophils,	 T-lymphocytes,	 and	 mast	 cells	 as	 compared	 to	 healthy	 lungs.	 There	 is	 a	
greater	susceptibility	for	viral	and	bacterial	infections	and	an	exaggerated	inflammatory	
response	 to	 such	 infections.	 [152]	 The	 basement	 membrane	 is	 thickened	 due	 to	
subepithelial	 collagen	deposition	 from	 fibrogenic	mediators	 released	by	 the	 increased	
numbers	 of	 eosinophils.	 [160]	 And	 the	 smooth	 muscle	 surrounding	 the	 airways	
becomes	hypertrophic,	 in	part	due	 to	 the	 increased	vascularity,	 but	 also	 from	growth	
factor	stimulation	and	frequent	episodes	of	bronchospasm.	[156]		







Chronic	 symptoms	 of	 asthma	 include	 frequent	 non-productive	 cough,	 often	 worse	 at	





tightness	 and	 pain.	 There	 is	 increased	mucus	 production	 that	 is	 difficult	 to	 clear	 and	
contributes	 to	 air	 trapping	 (difficulty	 exhaling)	 and	 dyspnea.	 [163]	 If	 suffering	 from	
severe	 exacerbations,	 patients	 present	 with	 significant	 increase	 in	 their	 work	 of	
breathing	with	increased	respiratory	rate,	accessory	respiratory	muscle	use,	and	nasal	
flaring.	Though	many	will	have	audible	wheezing,	auscultation	of	 the	 lungs	reveals	an	
expiratory	 wheeze	 (sometimes	 also	 inspiratory	 wheezing	 in	 severe	 attacks)	 and	 a	
prolongation	of	the	expiratory	phase	due	to	air	trapping.	There	will	often	be	asymmetry	
of	 breath	 sounds	 due	 to	 segmental	 atelectasis	 from	 mucus	 plugging.	 This	 mucus	
production	 and	 inflammatory	 exudate	 can	 also	 cause	 crackles	 to	 be	 heard.	 In	 severe	
exacerbations,	 airflow	 may	 be	 so	 limited	 that	 no	 wheezing	 may	 be	 heard	 and	 is	 an	
ominous	finding.	[134]	
Diagnosis	of	asthma	is	based	primarily	on	symptoms	and	response	to	therapy.	Testing	
of	 lung	 function	 can	 confirm	 the	 diagnosis,	 but	 is	 difficult	 to	 perform	 on	 very	 young	
patients,	and	 therefore	has	 limited	utility	 in	 the	 initial	diagnosis	of	patients	under	 the	
age	of	6	years.	While	full	pulmonary	function	testing	can	confirm	the	diagnosis,	simple	
spirometry	 and	 a	 flow-volume	 loop	 is	 sufficient.	 A	 reduction	 in	 forced	 expiratory	
volume	 in	 1	 second	 (FEV1),	 but	 no	 reduction	 in	 forced	 vital	 capacity	 (FVC)	 (reduced	
FEV1/FVC	ratio	<	70%	of	predicted)	 is	suggestive	of	 the	disease.	 [134]	This	combined	
with	a	reduction	in	peak	expiratory	flow	(PEF)	as	seen	by	a	convex	shape	on	the	flow-
volume	loop	is	diagnostic	of	asthma.	The	measurements	obtained	by	lung	function	tests	
are	depicted	 in	Figure	4,	which	also	demonstrates	 the	 characteristic	 convex	 shape	of	





and	 careful	 examination	 and	 review	 of	 the	 history	 may	 indicate	 a	 different	 etiology.	
Table	1	lists	the	other	causes	of	wheezing	categorized	by	age	when	onset	of	symptoms	




effects.	 In	 the	 case	 of	 inhaled	 foreign	 bodies,	 delay	 in	 correct	 diagnosis	 and	 prompt	
removal	can	result	in	permanent,	sometimes	life-threatening,	injury	and	scarring.	[165]	
	
Infant	 Toddler	 School-age	 Adolescent	 Adult	











Cystic	Fibrosis	 Pulmonary	edema	 Pulmonary	edema	 Cardiomegaly	
Vascular	ring	 Bacterial	tracheitis	 Tumor	 Tumor	 Pulmonary	edema	
Tracheal	stenosis	 Cardiomegaly	   		 Tumor	
Laryngeal	web	 Pulmonary	edema	 		 		 		
Cystic	lesion/tumor	 Tumor	 		 		 		
Cardiomegaly	   		 		 		




management.	 Severity	 is	 based	 on	 patient	 symptoms,	 functional	 impairment,	 and	 the	
patient’s	 risk	 for	 future	 adverse	 events.	 Symptom	 severity	 can	 range	 from	 mild	
infrequent	 episodes	 of	 wheeze	 or	 cough	 without	 limitation	 to	 daily	 activities,	 to	
frequent	 episodes	 of	 severe	 exacerbation	 with	 daily	 symptoms	 causing	 considerable	
limitation	in	daily	activities.	
Asthma	 is	 classified	 as	 either	 intermittent	 or	persistent	based	on	 the	number	of	days	
with	 symptoms,	 frequency	 of	 nighttime	 symptoms,	 use	 of	 short	 acting	 rescue	
medications,	 interference	 with	 normal	 activities,	 objective	 measurements	 of	 lung	





provide	 equal	 consideration	 to	 both	 symptoms	 and	 objective	 data	 when	 classifying	
asthma.	This	 is	 especially	 true	 in	pediatric	patients,	 as	 they	may	demonstrate	normal	
lung	function	with	objective	testing	but	still	suffer	from	severe	or	frequent	symptoms.	







Assessing	 risk	 of	 future	 adverse	 events	 helps	 clinicians	 identify	 those	 patients	 that	
require	 more	 careful	 monitoring	 and	 also	 helps	 to	 influence	 more	 aggressive	
management	 strategies	 to	 prevent	 complications.	 Patients	 are	 categorized	 as	 low,	
medium	 and	 high	 risk.	 Those	 factors	 that	 are	 predictive	 of	 increased	 exacerbations,	
severe	exacerbations,	 or	death	 include:	Two	or	more	emergency	department	visits	or	
hospitalizations	 in	 the	 past	 year	 for	 asthma,	 previous	 intensive	 care	 unit	 admission,	
previous	endotracheal	 intubation	 from	asthma,	 tobacco	use	or	 second-hand	exposure,	






use	 of	 rescue	 medication,	 prevent	 chronic	 symptoms	 (cough,	 exercise	 intolerance,	
shortness	of	breath,	etc.),	maintain	normal	activity,	prevent	loss	in	pulmonary	function,	
and	 reduce	 the	 side	 effects	 of	 medication.	 Although	 pharmacologic	 treatment	 is	 the	
mainstay	in	asthma	management,	it	is	only	a	part	of	successful	treatment	of	the	disease.	
Once	 the	 severity	 of	 asthma	 has	 been	 classified,	 successful	management	 comes	 from	
identification	 and	 avoidance	 of	 triggers,	 identification	 and	 management	 of	 comorbid	
conditions	that	can	worsen	the	disease,	education	and	empowerment	of	the	patient	and	
family	 to	develop	skills	 in	self-management,	and	 frequent	assessment	and	monitoring.	
[134]	
Comorbidities	 that	 directly	 affect	 the	 ability	 to	 successfully	 manage	 asthma	 are	
important	to	identify	and	treat.	Foremost	are	other	allergic	or	inflammatory	conditions,	
such	as	sinusitis,	rhinitis,	eczema,	and	gastroesophageal	reflux	disease,	which	add	to	the	
severity	 of	 inflammation	 in	 the	 body	 and	 can	worsen	 asthma	 symptoms.	Obesity	 and	
obstructive	 sleep	 apnea	 alter	 pulmonary	 mechanics	 and	 add	 to	 airflow	 obstruction,	
particularly	at	night.	Additionally,	obesity	and	metabolic	syndrome	have	been	linked	to	
an	 increase	 in	 inflammatory	markers,	 which	would	 impact	 the	 chronic	 inflammatory	
state	 associated	 with	 asthma.	 [169]	 Finally,	 multiple	 psychosocial	 factors,	 including	
stress	 and	 depression	 have	 been	 shown	 to	 worsen	 asthma	 symptoms	 and	 outcome.	
While	 the	 exact	 cause	of	 this	 correlation	has	 yet	 to	be	 identified,	 there	 is	 evidence	 to	
suggest	 that	 increased	 stress	 is	 associated	 with	 more	 pro-inflammatory	 cytokines	
released	throughout	the	body.	[170]	
Patients	with	asthma	should	be	monitored	frequently	to	assess	whether	symptoms	are	
being	well-controlled.	 Clinicians	 are	 encouraged	 to	 use	 judgment	 in	 the	 frequency	 of	
clinical	 assessment,	 but	 according	 to	 the	 United	 States	 Department	 of	 Health	 and	
Human	Services	guidelines	for	management	of	asthma,	the	interval	should	not	exceed	6	
months	in	the	well-controlled	patient	and	should	be	much	more	frequent	in	the	poorly	
controlled	 or	 those	 in	 the	 high	 risk	 category.	 [134]	 Assessments	 should	 include	 both	
clinical	 assessment	 via	 history	 and	 focused	 physical	 exam	 as	 well	 as	 patient	 self-
assessment	 of	 their	 own	 symptoms	 and	 understanding	 of	 their	 disease	 control	 and	
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compliance.	 Objective	 measurements	 with	 spirometry	 should	 be	 obtained	 every	 1-2	
years.	
Pharmacologic	 management	 of	 asthma	 is	 divided	 into	 acute	 and	 chronic	 therapies.	
Chronic	management	 is	 aimed	 at	 reducing	 underlying	 lung	 inflammation	 and	 chronic	
symptoms	 while	 preventing	 exacerbations.	 Acute	 management	 consists	 of	 providing	
rapid	 relief	 of	 symptoms	 and	 airflow	 obstruction	 during	 exacerbation	 and	 returning	












rate.	When	 used	 alone,	 they	 have	 been	 shown	 to	 increase	 the	 risk	 of	 asthma-related	
death	 and	 therefore	 are	 only	 recommended	 for	 use	when	 combined	with	 an	 inhaled	
corticosteroid	and	when	a	patient’s	symptoms	are	difficult	to	control.	[172-174]		
Corticosteroids	 work	 via	 direct	 immune	 suppression	 of	 leukocytes	 and	 inhibition	 of	
inflammatory	products.	They	 inhibit	 the	genes	 that	encode	 for	a	host	of	 inflammatory	
cytokines	that	activate	and	direct	 the	 immune	response	of	 leukocytes.	Specifically,	 the	
suppression	of	IL-2	prevents	T	lymphocyte	activation	and	suppression	of	phospholipase	
A2	which	 is	a	 critical	 factor	 in	 lymphocyte	adhesion,	emigration,	 and	chemotaxis.	The	
inhibition	of	prostaglandins	and	leukotrienes	also	helps	to	reduce	mast	cell	activation,	
bronchial	 vasodilation,	 and	 smooth	 muscle	 contraction.	 [175]	 Inhaled	 formulations	
(budesonide,	mometasone,	and	fluticasone)	are	preferred	in	order	to	decrease	systemic	
side	 effects,	 but	 are	 ineffective	 in	 treating	 the	 increased	 inflammation	 during	 asthma	
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exacerbations.	 In	 these	 instances,	 the	 more	 potent	 systemic	 corticosteroids	
(prednisone,	methylprednisolone	and	dexamethasone)	are	preferred.	[176]		
Additional	agents	are	used	that	either	target	other	steps	in	the	inflammatory	pathway,	
or	 work	 to	 decrease	 bronchospasm	 and	 hyperreactivity.	 Montelukast	 and	 zafirlukast	
are	 leukotriene	 receptor	 antagonists	 and	 zileuton	 is	 a	 5-lipoxygenase	 inhibitor	which	
blocks	 the	 formation	 of	 the	 leukotrienes.	 [177]	 Several	 anticholinergics,	 ipratropium	




and	 acts	 to	 inhibit	 leukotriene	 production	 as	 well	 as	 relax	 bronchial	 smooth	muscle.	
Historically	it	was	the	agent	of	choice	in	management	of	acute	exacerbations,	but	due	to	
its	narrow	therapeutic	window	and	many	drug	interactions,	it	is	only	recommended	as	
adjunctive	 treatment	 in	 severe	 asthma.	 [134]	 Finally,	 several	 monoclonal	 antibodies	
have	been	developed	that	specifically	target	IgE	(omalizumab)	and	IL-5	(mepolizumab)	
and	have	been	shown	effective	in	reducing	asthma	symptoms	in	the	poorly	controlled.	
Although	 there	 both	 drugs	 have	 been	 shown	 effective	 in	 treatment	 younger	 children	
with	 severe	 asthma,	 neither	 drug	 is	 yet	 approved	 under	 age	 12	 in	 the	 United	 States.	
[179,	180]		
The	choice	of	which	medication	to	use	focuses	on	a	step-wise	approach,	which	escalates	
therapy	 (adding	 new	medication	 or	 increasing	 doses)	 based	 on	 a	 patient’s	 symptoms	
and	control,	and	deescalates	therapy	as	symptoms	improve	and	control	 is	maintained.	
The	main	goal	 is	 to	use	 the	 least	number	and	 lowest	doses	of	medications	 to	 achieve	
symptom	control	 and	 thereby	 avoid	unnecessary	 side	 effects.	Figure	3	 illustrates	 the	
step-wise	 approach	 to	pharmacologic	 treatment	 of	 asthma.	 Patients	with	 intermittent	
asthma	 are	 generally	 treated	with	 as	 needed	 use	 of	 a	 SABA.	 For	 those	with	 exercise-




adolescents	 or	 adults).	 If	 symptoms	 remain	uncontrolled,	 a	 LABA	 (in	 adolescents	 and	
adults)	or	LM	is	added	 if	 it	has	not	been	done	previously.	 If	 therapy	 is	escalated,	high	
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dose	 ICS	 is	 used	plus	 introduction	of	 a	monoclonal	 antibody	 in	 adolescents	 or	 adults.	
The	 final	 step	 in	 the	 worst	 controlled	 asthmatics	 is	 the	 addition	 of	 a	 low-dose	 oral	









The	 management	 of	 an	 acute	 asthma	 exacerbation	 should	 focus	 on	 relief	 of	 airflow	
obstruction,	 correction	 of	 hypoxemia	 if	 present,	 and	 reduction	 in	 acute	 inflammation.	
The	majority	of	 the	medications	used	 to	 control	 asthma	previously	mentioned	have	a	
longer	onset	of	action,	and	therefore	have	no	utility	in	the	acute	exacerbation.	[134]	For	
most	exacerbations,	multiple	doses	of	a	SABA	and	initiation	of	short	course	of	systemic	
corticosteroids	 is	 sufficient	 to	 achieve	 improvement	 of	 symptoms	 and	 return	 to	
baseline.	Many	 scoring	 systems	 have	 been	 developed	 and	 validated	 to	 determine	 the	
severity	 of	 an	 acute	 attack	 and	may	 be	 useful	 for	 clinicians	 to	 guide	management.	 In	
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general,	a	patient	should	be	assessed	 for	 their	work	of	breathing,	subjective	 feeling	of	
dyspnea,	degree	of	air	exchange,	and	presence	of	hypoxemia.	[134]		
Mild	 exacerbations	 are	 characterized	 by	 dyspnea	 with	 exertion,	 subjective	 feeling	 of	
tightness	in	the	chest	or	shortness	of	breath,	increased	cough	(particularly	at	night),	and	
occasional	 expiratory	 wheeze	 or	 prolonged	 expiratory	 phase	 on	 auscultation.	 These	
patients	 can	 be	 managed	 at	 home	 with	 intermittent	 use	 of	 a	 SABA,	 generally	 with	
prompt	 relief.	 If	 symptoms	 have	 persisted	 for	more	 than	 48	 hours	 or	 are	worsening,	
consideration	 can	 be	 given	 to	 start	 a	 short	 (3-5	 days)	 course	 of	 oral	 corticosteroids.	
[176]	Moderate	exacerbations	are	generally	characterized	by	dyspnea	interfering	with	
normal	 activity,	 persistent	 expiratory	 wheeze,	 slight	 decrease	 in	 air	 exchange,	 and	
increased	 cough.	 These	 patients	 have	 no	 increased	 work	 of	 breathing	 or	 accessory	
muscle	 use.	 Those	 in	 moderate	 exacerbation	 should	 be	 evaluated	 promptly	 by	 a	
healthcare	provider.	Several	doses	of	a	SABA,	either	repeated	every	20	minutes	or	given	
continuously	 via	 aerosolization	 should	 be	 administered	 and	 the	 patient	 started	 on	 a	
short	course	of	oral	corticosteroids.	Often	these	patients	will	require	scheduled	use	of	
their	 SABA	 (frequently	 every	 4-6	 hours)	 for	 the	 first	 24-48	 hours	 of	 treatment	 until	
peak	effect	of	the	steroids	has	been	obtained.	[134]		
Severe	 exacerbations	 present	 with	 dyspnea	 at	 rest,	 difficulty	 speaking	 and	 increased	
work	of	breathing	with	accessory	muscle	use.	Air	 exchange	 is	usually	diminished	and	
wheezing	may	occur	both	during	 inspiration	 and	 expiration.	Often,	 these	patients	 are	
hypoxemic	 and	 require	 urgent	 attention.	 They	 should	 be	 helped	 into	 a	 position	 of	
comfort	 and	 provided	 supplemental	 oxygen	 if	 needed.	 A	 SABA	 should	 be	 given	
continuously	 over	 the	 first	 hour	 of	 evaluation	 and	 systemic	 corticosteroids	 initiated.	
The	 addition	 of	 ipratropium	 in	 combination	 with	 a	 SABA	 early	 in	 the	 course	 of	
treatment	has	been	 shown	 to	 reduce	hospitalization	 and	 is	 recommended.	 [181,	 182]	
Patients	 should	 be	 reassessed	 frequently	 and	 care	 escalated	 quickly	 if	 little	 or	 no	






The	 use	 of	 epinephrine	 or	 terbutaline	 (both	 potent	 beta-2	 adrenergic	 agonists),	 given	
intramuscularly,	can	provide	temporary	bronchodilation	allowing	the	inhaled	particles	
of	the	SABA	to	penetrate	deeper	into	the	lungs,	and	should	be	considered	very	early	in	
those	presenting	with	severe	or	 life	 threatening	symptoms.	 Intravenous	access	should	
be	established	as	quickly	as	possible	and	isotonic	fluid	administration	begun	to	support	
cardiac	 function	 and	 correct	 dehydration	 if	 present.	 Magnesium	 sulfate,	 a	 potent	
bronchodilator,	 can	be	given	 intravenously	 in	 severe	exacerbations	not	 responding	 to	
SABAs,	and	can	improve	pulmonary	function	and	possibly	prevent	hospitalization.	[183,	
184]	Additional	 adjunctive	 therapies	 that	 have	 shown	 some	benefit	 in	 severe	 asthma	
attacks	 include	 heliox	 (a	 helium	 and	 oxygen	mixture),	 non-invasive	 positive	 pressure	
ventilation	(NIPPV),	intravenous	terbutaline,	and	ketamine	sedation.	
Heliox	 (with	 the	 oxygen	 component	 not	 exceeding	 40%)	 has	 been	 shown	 to	 increase	
laminar	flow	into	and	throughout	the	respiratory	tree.	It	is	felt	that	this	improved	flow	
allows	better	penetration	of	 inhaled	medications	and	improved	ventilation.	[185,	186]	
Intravenous	 beta-2	 agonists	 (terbutaline)	 can	 augment	 the	 action	 of	 inhaled	 SABAs	
when	air	exchange	 is	poor,	 though	care	must	be	taken	with	these	 formulations	due	to	
their	 more	 prominent	 cardiac	 side	 effects.	 [187]	 Ketamine,	 an	 N-methyl-D-aspartate	
receptor	antagonist	and	dissociative	anesthetic,	causes	bronchodilation	and	can	be	used	
in	 refractory	 cases.	 It	 can	 also	 be	 useful	 in	 decreasing	 agitation	 and	 anxiety	 in	 those	
suffering	 severe	 exacerbations	 and	 is	 a	 preferred	 induction	 agent	 if	 endotracheal	
intubation	 is	 required.	 [188,	 189]	 It	 is	 effective	 both	 in	 small	 titrated	 doses	 and	 as	 a	
continuous	drip.	
NIPPV	 can	 ease	 dyspnea,	 improve	 work	 of	 breathing,	 and	 in	 some	 cases	 prevent	
endotracheal	 intubation.	 Previously,	 the	 addition	 of	 positive	 pressure	 was	
contraindicated	in	asthmatics	out	of	concern	for	worsening	air	trapping	and	increasing	
the	 risk	 of	 barotrauma	 to	 the	 lungs.	 [190]	 However,	 research	 now	 suggests	 that	 the	
positive	 pressure	 can	 actually	 reduce	 air	 trapping	 by	 stenting	 open	 the	 airways	 and	
allowing	 better	 ventilation.	 This	 has	 been	 shown	 in	 several	 small	 studies	 in	 adult	




If	 necessary,	 endotracheal	 intubation	 of	 an	 asthmatic	 patient	 should	 not	 be	 delayed,	
however,	 extreme	 care	 should	 be	 taken	 to	 avoid	 complication.	 Manipulation	 of	 the	
airway	can	cause	severe	bronchospasm	due	to	airway	hyperreactivity	often	resulting	in	
rapid	 decline	 and	 progression	 to	 cardiac	 arrest	 from	 loss	 of	 the	 airway	 and	 no	
ventilation.	 In	 addition,	 there	 is	 a	 significant	 increase	 in	 the	 risk	 of	 barotrauma	 from	
increased	 hyperinflation,	 air	 trapping,	 and	 airway	 pressure,	 all	 of	 which	 are	 already	
elevated	 within	 the	 lungs	 during	 exacerbation.	 [191]	 Indications	 for	 endotracheal	
intubation	 include	 persistent	 hypoxemia	 despite	 optimal	 delivery	 of	 supplemental	
oxygen	or	NIPPV,	persistent	respiratory	distress	and	respiratory	muscle	fatigue,	altered	
mental	 status,	 and	 respiratory	 or	 cardiac	 arrest.	 Endotracheal	 intubation	 should	 be	
performed	by	the	most	experienced	provider	to	avoid	repeated	attempts.	[192]	
Once	intubated,	great	care	must	be	taken	in	choosing	correct	ventilator	settings	to	avoid	
barotrauma	 or	 cardiac	 compromise	 from	 hyperinflation.	 Generally,	 in	 intubated	
patients,	the	goal	of	ventilation	is	to	reduce	hypercarbia	but	this	is	not	always	possible	
or	 advisable	 in	 those	with	 asthma.	 Due	 to	 air	 trapping	 and	 inflammation,	 asthmatics	
often	 have	 prolonged	 expiration,	 which	 poses	 a	 significant	 problem	 with	 ventilator	
management.	 [191]	 If	 the	 expiratory	 time	 during	 the	 respiratory	 cycle	 is	 not	 long	
enough,	there	will	be	a	steady	increase	in	functional	residual	capacity	(known	as	breath-
stacking)	 which	 results	 in	 increasingly	 higher	 airway	 pressures	 which	 can	 lead	 to	
alveolar	 rupture,	 pneumothorax,	 and	 increased	 intrathoracic	 pressure	 that	 reduces	
pulmonary	blood	 flow	and	venous	return	to	 the	heart.	This	 leads	 to	both	reduction	 in	
preload	and	outflow	obstruction	and	results	in	eventual	cardiovascular	collapse.	[191]	
To	 avoid	 these	 complications,	 often	 respiratory	 rate	 and	 tidal	 volumes	 must	 be	
decreased,	 and	 inspiratory	 to	 expiratory	 ratios	 adjusted.	 In	most	 cases,	 this	 does	 not	
allow	 for	 adequate	 removal	 of	 carbon	 dioxide	 from	 the	 lungs	 and	 therefore	 a	 certain	
degree	 of	 hypercarbia	 must	 be	 allowed.	 Overall,	 patients	 who	 require	 endotracheal	
intubation	 generally	 suffer	 higher	morbidity	 and	mortality	 and	 longer	 hospital	 stays.	
[191,	192]	
In	 intubated	 patients,	 a	 previously	 unavailable	 therapeutic	 option	 can	 be	 considered.	
Inhalational	 anesthetics	 (halothane,	 isoflurane,	 sevoflurane)	 are	 all	 potent	
bronchodilators	and	can	be	administered	 to	 improve	airflow	obstruction.	 [193]	Other	
rescue	medications	 should	 continue	 to	be	used,	 either	 intravenously	or	 via	 inhalation	
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medication	 to	 reverse	 acute	 airway	 obstruction	 and	 buy	 time	 until	 steroids	 can	
decrease	 the	 flare	 in	 inflammation	 and	 subsequent	 edema.	 In	 the	most	 severe	 cases,	
steroids	are	 still	 the	mainstay	of	 treatment	and	 the	only	 thing	known	 to	decrease	 the	
acute	 inflammation	 and	 eventually	 end	 the	 acute	 exacerbation.	 All	 other	 treatments	
mentioned	here,	including	SABAs,	are	simply	short-term	rescue	measures	that	provide	
relief	from	the	symptoms	of	acute	airflow	obstruction	and	cannot	treat	the	underlying	
inflammation.	 This	 highlights	 the	 importance	 of	 optimizing	 the	 long-term	 chronic	









have	 “poorly	 controlled”	asthma.	Nevertheless,	97%	of	 the	questioned	patients	would	
describe	their	asthma	as	“adequately	controlled”	themselves.	[195]		
According	to	the	Global	Asthma	Report	(GAR)	2014	[196],	asthma	is	not	only	a	cause	of	
substantial	 burden	 to	 patients	 regarding	 their	 reduced	 quality	 of	 life	 due	 to	 physical,	
psychological	and	social	effects,	but	also	a	tremendously	high	global	economic	burden.	
Thus,	the	indirect	costs	of	the	disease,	with	its	negative	impact	on	productivity	leading	
the	 way,	 are	 at	 least	 as	 high	 as	 its	 direct	 costs,	 making	 it	 a	 problem	 of	 worldwide	
concern.	Given	 the	 fact	 that	 there	are	essential	asthma	medicines	with	proven	benefit	
available	for	most	patients,	a	major	global	 focus	should	be	put	on	the	improvement	of	
access	 to	 care	 and	adherence	 to	 these	 evidence-based	 treatments.	Both	 in	developing	
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and	 developed	 countries,	 this	 especially	 requires	 education	 of	 both	 health	 care	
providers	 and	 patients	 about	 the	 correct	 use	 and	 respective	 long-term	 benefits	 of	
medications.	Additional	barriers	to	effective	management	occur	in	developing	countries,	
including	 lack	 of	 affordability	 of	 quality-assured	 medicines	 and	 poor	 infrastructure,	
indicating	the	need	for	political	commitment	for	better	asthma	care.	The	key	intention	





4	 countries	 had	 national	 asthma	 strategies	 in	 place	 for	 children	 and/or	 adults.	
Therefore,	 the	 GAR’s	 key	 recommendation	 to	 health	 authorities	 in	 all	 countries	 is	 to	
ensure	 the	 availability	 of	 nationally	 appropriate	 asthma	 management	 guidelines	 and	
provide	access	for	everyone	to	the	quality-assured,	affordable	essential	medicines	these	
guidelines	 suggest.	 Although	 suchlike	 guidelines	 first	 created	 in	 the	 1980s	were	 in	 a	
great	 measure	 commercially	 sponsored	 consensus	 statements,	 today	 they	 are	 most	
commonly	 evidence-based	 and	 independent	 of	 support	 from	 the	 pharmaceutical	
industry.	They	play	a	crucial	role	in	both	standardizing	timely	and	correct	assessment	of	
asthma	 symptoms	 and	 severity	 and	 effective	 case	 management,	 hence	 lessening	 the	
overall	burden	of	the	disease.	The	World	Health	Organization	(WHO)	recently	published	
respective	 asthma	management	 guidelines	 in	 their	 report	 “Prevention	 and	 Control	 of	





detection	 and	 diagnosis	 of	 the	 disease.	 Since	 the	 before-described	 symptoms	 are	
manifold	 and	 can	 vary	 strongly	 between	 patients,	 it	 can	 be	 challenging	 to	 detect	 and	
treat	asthma	early	on	without	missing	other	possible	disorders.	Particular	emphasis	has	
to	be	put	on	a	distinct	and	thorough	differential	diagnosis,	as	most	symptoms	are	also	
observed	 in	 a	 number	 of	 other	 pulmonary	 and	 airway	 diseases	which	 can,	 therefore,	
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mimic	 asthma	 clinically.	Hence,	 it	 is	 necessary	 to	maintain	 a	 rather	broad	differential	
diagnosis	 in	order	not	 to	misdiagnose	other	 lung	diseases	with	airflow	obstruction	as	
asthma,	 especially	 for	 patients	 believed	 to	 have	 severe	 asthma	 that	 do	 not	 respond	
adequately	to	standard	asthma	therapy.		
Although	 a	 clear	 and	 precise	 official	 definition	 is	 important	 to	 distinguish	 similar	
diseases,	 the	guidelines	concerning	asthma	have	become	rather	ambiguous	and	vague	
over	the	last	years.	While	former	directives	still	highlighted	eosinophils	and	mast	cells	
as	 predominant	 cells	 in	 asthma	 development	 [198],	 the	 emphasis	 in	 the	 latest	
specifications	 by	 the	 Global	 Initiative	 for	 Asthma	 (GINA)	 is	 only	 put	 on	 variability	 in	
lung	function	and	airflow	limitation	[199].	These	symptoms,	however,	are	also	present	
in	 chronic	 obstructive	 pulmonary	 disease	 (COPD)	 and	 other	 related	 lung	 diseases.	
Particularly	in	atopic	patients	with	a	long	smoking	history,	the	differentiation	between	




from	 asthmatic	 origins.	 Since	 it	 became	 obvious	 that	 a	 considerable	 group	 of	 asthma	
patients	 also	 have	 a	 clinically	 relevant	 history	 of	 smoking	 and,	 therefore,	 respective	
severe	 airway	 symptoms	 due	 to	 the	 two	 different	 kinds	 of	 airway	 inflammation,	 this	
condition	 is	described	as	 so-called	Asthma-COPD-overlap-syndrome	 (ACOS).	Although	
recent	 studies	 suggest	 that	 subgroups	 of	 asthma	 and	 COPD	 patients	 do	 have	
overlapping	immune	responses	[201],	critics	question	the	benefit	of	this	new	affiliation	
of	two	diseases	with	different	underlying	pathological	processes.		
During	 viral	 infections	 caused	 e.g.	 by	 respiratory	 syncytial	 virus	 or	 adenoviruses,	
especially	 children	 can	 feature	 airflow	 obstruction,	 wheezing	 and	 other	 asthma-like	
symptoms	[202]	which	can	be	easily	misdiagnosed	as	childhood	asthma.	Furthermore,	
dysfunctional	breathing	disorders	like	the	vocal	cord	dysfunction	syndrome	(VCD)	can	
show	 clinical	 pictures	 very	 similar	 to	 asthma	 and	 often	 even	 coexist	 in	 patients	with	
actual	bronchial	asthma.	Although	in	many	cases	these	patients	receive	high-dose	anti-
asthmatic	 therapy,	 treatment	 of	 the	 underlying	 disorders	 such	 as	 gastroesophageal	
reflux	and	postnasal	drip	would	really	be	needed.	Pulmonary	sarcoidosis	can,	likewise,	





Because	 of	 the	 described	 circumstances	 it	 is	 strongly	 suspected	 that	 quite	 some	
diagnosis	of	asthma	has	been	made	overhasty	and	haphazardly	in	the	past.	In	order	to	
prevent	these	misjudgments,	the	first	measure	for	patients	with	alleged	asthma	should	
be	 a	 chest	 X-ray	 to	 preclude	 parenchymal	 disease,	 tumors,	 pneumothorax,	 and	 other	
thoracic	conditions.	A	particular	mistrust	of	asthma	diagnosis	 is	applicable	 in	patients	
without	eosinophilia	and	in	those	who	do	not	respond	to	adequate	anti-asthmatic,	anti-
inflammatory	 treatment	 with	 bronchodilators	 and	 inhaled	 corticosteroids	 with	 an	
expected	 normalization	 of	 lung	 function.	 Here,	 the	 differential	 diagnosis	 has	 to	 be	
broadened	 and	 the	 diagnostic	 accuracy	 has	 to	 be	 improved	 by	 considering	 ancillary	
examinations	such	as	high-resolution	CT,	bronchoalveolar	lavage	and	sputum	cytology	
or	even	open	lung	biopsy.	[200]	
Besides	 the	dissociation	 from	other	possible	diseases,	 in	modern	asthma	therapy,	 it	 is	




Another	major	hurdle	 in	 the	 effective	 treatment	of	 asthma,	 especially	 in	 smokers	 and	
patients	with	more	 severe	 forms	 of	 the	 disease,	 is	 the	 reduced	 responsiveness	 to	 the	
anti-inflammatory	 effects	 of	 corticosteroids.	 Although	 the	 regular	 application	 of	 low	
doses	 of	 inhaled	 corticosteroids	 (ICS)	 can	 control	 most	 patients’	 symptoms	
appropriately	nowadays,	approximately	10%	need	maximal	doses	and	in	1%	even	oral	
corticosteroids	are	required	in	order	to	maintain	optimal	control.	In	contrast	to	this	so-




to	 quantify	 clinical	 steroid	 responsiveness,	 it	 remains	 a	 difficult	 task	 to	measure	 the	




to	 identify	 complete	 resistance.	 [203]	 Resistant	 patients	 were	 observed	 to	 clinically	
differ	from	responsive	asthmatics	by	showing	a	longer	duration	of	symptoms,	a	greater	
degree	 of	 airway	hyperresponsiveness,	 and	 a	more	 frequent	 family	 history	 of	 asthma	
[204].	 	 The	 lower	 responsiveness	 in	 patients	 with	 severe	 asthma	 implies	 that	 the	
mechanisms	 of	 steroid	 resistance	 are	 possibly	 contributing	 to	 the	 grade	 of	 disease	
severity	[205].	In	contrast	to	general	familial	glucocorticoid	resistance,	steroid-resistant	
asthma	 patients	 are	 not	 cortisol	 deficient,	 nor	 do	 they	 have	 any	 abnormalities	 in	 sex	
hormones	[206].	Furthermore,	plasma	cortisol	and	adrenal	suppression	in	response	to	
exogenous	 corticosteroids	 are	 normal	 and	 usually	 the	 typical	 side	 effects	 of	 systemic	
corticosteroids	 can	be	observed.	Nevertheless,	bronchial	biopsies	of	 resistant	patients	
showed	increased	eosinophil	and	lymphocyte	counts	as	well	as	a	missing	suppression	of	
the	TH2	 cytokines	 IL-4	 and	 IL-5	 compared	 to	 sensitive	patients	despite	 the	 treatment	
with	high	doses	of	corticosteroids	[207].	
As	 circulating	 cells	 from	 patients	 with	 steroid-resistance	 asthma	 also	 show	 reduced	
responses	 in	 vitro,	 it	 is	 feasible	 to	 investigate	 the	 underlying	molecular	 mechanisms	




observed	 that	 IL-2	 and	 IFN-γ	 secretion	 are	 not	 inhibited	 [209]	 and	 secretion	 of	
cytokines	and	chemokines	of	peripheral	monocytes	and	alveolar	macrophages	are	less	
restricted	than	in	patients	with	corticosteroid-sensitive	asthma	[210,	211].	
Several	 mechanisms	 resulting	 in	 a	 reduced	 responsiveness	 to	 steroids	 have	 already	
been	 identified,	 indicating	 that	 individual	 therapeutic	 approaches	 may	 be	 needed	 to	
overcome	 this	 pitfall	 in	 asthma	 treatment.	 As	 this	 phenomenon	 is	 apparently	 more	
common	within	families,	it	can	be	expected	that	genetic	factors	play	a	crucial	role	in	its	
occurrence.	 Eleven	 genes	 have	 been	 found	 to	 differ	 between	 patients	 with	
corticosteroid-resistant	 and	 -sensitive	 asthma	 in	 microarray	 studies	 of	 PBMCs	 [212],	
giving	reason	 to	assume	that	 it	might	be	possible	 to	develop	a	genetic	 test	 for	steroid	
resistance.	 A	 large	 proportion	 of	 patients	 with	 steroid-insensitive	 asthma	 shows	 a	




[213].	 This	 can	 be	 the	 result	 of	 activation	 of	 several	 kinases,	 such	 as	 p38	 mitogen-
activated	 protein	 kinase	α	 or	 γ,	 which	 in	 turn	 might	 be	 due	 to	 reduced	 activity	 and	
expression	 of	 phosphatases	 [203].	 A	 further	 related	 mechanism	 is	 the	 increased	
expression	of	GR	β	which	 inhibits	activated	GR	α.	Besides	 that,	 increased	secretion	of	
macrophage	 migration	 inhibitory	 factor,	 competition	 with	 the	 transcription	 factor	
activator	 protein	 1,	 and	 reduced	 expression	 of	 histone	 deacetylase	 2	 (HDAC	 2)	were	




HDAC	 2	 expression	 by	 theophylline	 or	 other	 phosphoinositide	 3-kinase	 δ	 inhibitors.	
Respective	 long-term	 studies	 with	 low-dose	 theophylline	 combined	 with	 oral	
corticosteroids	 and	 ICSs	 are	 underway.	 [203]	 Besides	 that,	 common	 strategies	 to	
manage	 steroid-resistance	 include	 the	 use	 of	 alternative	 broad-spectrum	 anti-
inflammatory	 drugs,	 such	 as	 phosphodiesterase-4	 (PDE4)	 and	 p38MAPK	 inhibitors.	
Unfortunately,	when	given	systematically,	these	treatments	show	side	effects	that	limit	
the	 oral	 dose	 and	 efficacy,	 however,	 developing	 inhalable	 versions	was	 proven	 to	 be	
difficult.	 Therefore,	 the	well-tolerated	 ICSs	would	 be	 the	 preferred	 anti-inflammatory	
therapy	in	combination	with	other	drugs	for	 increased	responsiveness.	This	effect	can	





regularize	 the	vascular	remodeling	 in	affected	airways	as	a	 further	barrier	 in	efficient	
treatment	 [215].	 Numerous	 studies	 have	 shown	 the	 abnormal	 expansion	 and	
morphological	 dysregulation	 of	 the	 bronchial	 vascular	 network	 in	 asthmatic	 lungs	 by	
reporting	an	 increased	number,	 size	and	density	of	blood	vessels,	 vascular	 leakage	as	
well	 as	 plasma	 engorgement.	 A	 more	 intense	 blood	 flow	 to	 the	 airway	 tissue	 is	
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suggested	 to	 promote	 chronic	 influx	 of	 inflammatory	mediators	 and	 pathological	 cell	
proliferation.	[216]	
Nevertheless,	appropriate	treatment	attempts	and	respective	trials	are	scarce.	However,	
some	 novel	 findings	 give	 reason	 to	 further	 explore	 the	 potential	 of	 anti-angiogenic	
therapies	 as	 a	 new	 drug	 class	 for	 future	 asthma	 management.	 Re-purposing	 anti-
angiogenic	tumor	therapy	agents	for	asthma	as	a	genomically	and	phenotypically	more	
stable	target	is	claimed	to	be	relatively	straightforward	[215]	and	some	of	those	agents	
have	 indeed	 already	 been	 tested	 successfully	 in	 asthma	 mouse	 models.	 As	 vascular	
endothelial	 growth	 factor	 A	 (VEGF-A)	 is	 a	 key	 driver	 of	microvascular	 remodeling	 in	
asthma	 [217],	 several	 treatment	 approaches	 have	 tried	 to	 use	 it	 as	 a	 target.	 It	 was	
shown	that	the	multi-kinase	inhibitor	sunitinib	significantly	inhibits	eosinophilic	airway	
inflammation	 and	 remodeling	 in	 chronic	 experimental	 asthma	 in	 response	 to	 either	
Ovalbumin	 (OVA)	or	 toluene	diisocyanate.	 [218,	219]	Likewise,	 the	VEGF	neutralizing	
monoclonal	 antibody	 bevucizamab	 reduced	 epithelial,	 airway	 smooth	 muscle	 and	
basement	membrane	 thickness	 compared	 to	untreated	OVA-challenged	mice.	 [220]	 In	
another	 study,	 co-administration	 of	 the	 collagen	 XVIII	 fragment	 endostatin	with	 OVA	
challenge	 in	 mice	 inhibited	 airway	 hyperresponsiveness	 as	 well	 as	 pulmonary	
inflammation	and	sub-epithelial	angiogenesis	was	greatly	reduced.	[221]	Further	trials	
targeted	 circulating	 endothelial	 precursor	 cells,	 vasculogenesis	 or	 lymphangiogenesis.	
Nonetheless,	the	authors	concede	that	there	are	still	substantial	hurdles	to	therapeutic	








of	 this	 control	 should	 be	 part	 of	 patient	 monitoring	 once	 treatment	 is	 established.	
Therefore,	 asthma	 control	 is	 also	 increasingly	 being	 used	 as	 an	 outcome	measure	 in	
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respective	 research	 studies.	 Due	 to	 the	 complexity	 and	 individuality	 of	 the	 disease,	
precise	 determination	 of	 the	 control	 level	 is	 difficult	 and	 commonly	 used	 assessment	
methods	such	as	lung	function	tests	have	their	limitations.	As	patients	can	show	normal	
lung	function	between	exacerbations	but	may	still	not	have	adequate	control	over	their	
symptoms,	 the	 degree	 of	 control	 is	 often	 over-estimated	 by	 both	 clinicians	 and	 the	
patients	 themselves.	 In	order	 to	measure	 the	 level	of	asthma	control	 in	a	quantitative	
and	comparable	way,	several	composite	assessment	tools	have	been	developed.		
In	 a	 recent	work,	 studies	were	 identified	by	a	 comprehensive	 literature	 search	which	
are	attempting	to	develop	and/or	test	composite	score	instruments	for	asthma	control.	
[222]	 Seventeen	 score	 instruments	 with	 published	 validation	 information	 where	





work	 attendance,	 whereas	 only	 2	 (Asthma	 Control	 Questionnaire	 (ACQ)	 and	 Asthma	
Control	Scoring	System	(ACSS))	 include	pulmonary	 function	parameters	and	1	 (ACSS)	
assesses	sputum	eosinophilia.	While	more	than	half	of	the	evaluated	instruments	assess	
exacerbations,	 only	 the	 Test	 for	 Respiratory	 and	 Asthma	 Control	 in	 Kids	 (TRACK)	




The	most	widely	used	 tool	 in	patients	older	 than	12	years	 is	 the	Asthma	Control	Test	
(ACT)	 [223],	 that	 quantifies	 asthma	 control	 as	 a	 continuous	 variable	 and	 offers	 a	
numeric	value	to	differentiate	between	controlled	and	uncontrolled	asthma,	similar	to	








caregiver’s	perspectives.	Another	option	 is	 a	parent	 completed	version	of	 the	Asthma	
Therapy	 Assessment	 Questionnaire	 (ATAQ),	 designed	 to	 identify	 children	 and	
adolescents	of	5-17	years	with	current	problems	in	asthma	control	[226].	
To	 ensure	 that	 the	 selected	 instrument	 will	 really	 measure	 the	 wanted	 outcome,	
profound	knowledge	of	the	psychometric	properties	of	the	tool	is	needed.	Furthermore,	





patient	 survey	 to	 collect	 information	 based	 on	 control	 scores	 and	 contains	 a	
management	 algorithm	 to	 incorporate	 recommendations	 for	 education,	 therapy	
adherence,	 adequate	 inhaler	 techniques	 and	 follow-up	 visits.	 A	 study	 evaluating	 the	
benefits	of	implementing	the	Asthma	APGAR	in	practice	demonstrated	that	it	resulted	in	





Beyond	 the	 care	 in	 medical	 practices,	 pharmacists	 play	 an	 equally	 important	 role	 in	
achieving	 optimal	 therapy	 and	maximum	 improvement	 in	 the	 patient’s	 quality	 of	 life	
(QoL).	 Although	 the	 scope	 of	 pharmaceutical	 care	 is	 often	 primarily	 focused	 on	
pharmacotherapy	 and	 drug-related	 outcomes,	 it	 is	 encroaching	 upon	 other	 areas	 of	




choice	 for	 both	 diagnosing	 asthma	 and	 assessing	 asthma	 control	 in	 response	 to	
treatment.	 This	 method	 is	 easy	 and	 safe	 to	 perform,	 however,	 for	 the	 patient	 it	 is	
physically	 demanding	 as	 it	 requires	 maximal	 effort	 and	 may	 cause	 breathlessness,	
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syncope	 and	 cough	 and	 can	 even	 induce	bronchospasm	 in	 poorly	 controlled	patients.	
Two	 important	 values	 obtained	 from	 the	 spirometry	 measurement	 are	 the	 FEV1,	 a	




filled,	making	 the	 spirogram	a	 volume-time	 curve.	 Conventional	 volume-displacement	
spirometers	 provide	 a	 direct	 measurement	 of	 the	 respired	 volume	 from	 the	
displacement	 of	 a	water	 sealed	 bell,	 a	 rolling	 sealed	 piston	 or	 bellows.	New	 forms	 of	
advanced	 spirometers,	 however,	 utilize	 a	 sensor	detecting	 flow	as	 the	primary	 signal,	
for	example	from	the	pressure	drop	across	a	resistance	or	the	cooling	of	a	heated	wire.	
The	sensed	flow	is	then	converted	into	volume	by	electronic	or	numerical	integration	of	










A	 further	 pulmonary	 function	 test	 rather	 used	 to	 detect	 and	 measure	 a	 patient’s	
variability	of	lung	capacity	is	the	PEF	measurement.	It	assesses	the	maximum	expiratory	
flow	 occurring	 just	 after	 the	 start	 of	 a	 forced	 expiration	 from	 the	 point	 of	maximum	
inspiration.	In	contrast	to	a	spirometer,	the	peak	flow	meter	has	significant	limitations,	
as	 its	 measurements	 are	 effort	 dependent	 and	 results	 vary	 considerably	 between	
different	instruments.	Furthermore,	the	range	of	values	regarded	as	normal	and	healthy	
is	rather	wide.	Nevertheless,	PEF	monitoring	by	patients	can	be	useful	when	they	suffer	
from	 intermittent	 symptoms	 and	 find	 it	 difficult	 to	 gauge	 asthma	 severity	 based	 on	
those.	[231]	
Besides	 lung	 function	measurements,	 pharmacists	 are	 a	 crucial	 factor	 in	 the	 patients’	
education.	 As	 a	 successful	 treatment	 outcome	 in	 asthmatic	 patients	 depends	 on	
continuing	 compliance	with	 their	 therapy,	 even	 in	 times	 they	 do	 not	 suffer	 from	 any	
obvious	 symptoms,	 the	 importance	 of	 a	 regular	 intake	 of	 medication	 has	 to	 be	
emphasized.	 In	 addition	 to	 a	 personalized	 drug	 regimen,	 every	 patient	 should	 get	 an	
individually	 tailored	 care	plan	 in	 order	 to	 cope	with	 variations	 in	 asthma	 severity.	 In	
this	way,	asthmatics	are	able	to	slightly	adjust	their	therapy	themselves	without	having	
to	 consult	 their	 physician	 every	 time.	When	 they	 use	 PEF	measurements	 to	monitor	
their	disease,	as	with	inhaler	devices,	their	technique	should	regularly	be	inspected	and	
reinforced.	In	general,	patients	have	to	be	familiarized	with	clinical	symptoms	of	toxicity	
or	 undertreatment,	 such	 as	 shortness	 of	 breath,	 wheeze,	 tremor	 or	 change	 in	 O2	
saturation.	 Patients	 receiving	 corticosteroids	 in	 particular,	 should	 be	 educated	 and	
monitored	concerning	adverse	effects	of	 this	drug	class	and	respective	measures	 they	
can	 take	 to	 avoid	 or	 reduce	 them.	While	 local	 side	 effects	 of	 inhaled	 corticosteroids	
include	 oral	 thrush,	 hoarseness	 and	 dysphonia,	 patients	 on	 oral	 therapy	 should	 be	
monitored	 for	 hyperglycemia,	 gastrointestinal	 and	 neuropsychiatric	 effects,	 adrenal	
suppression,	osteoporosis	and	infections.	[232]	
Oftentimes,	medication	 adherence	 rates	decline	 for	 children	becoming	 teenagers.	 In	 a	
study	 assessing	 adolescent	 asthmatic	 needs	 and	 preferences	 regarding	 medication	
counseling	 and	 self-management,	 it	 was	 shown	 that	 effective	 adherence-enhancing	
interventions	 for	 this	 patient	 group	 are	 missing.	 Although	 lack	 of	 perceived	 need	 or	
beneficial	 effects	 were	 also	 mentioned	 as	 reasons	 for	 not	 taking	 the	 medication	 as	
prescribed,	 forgetting	 was	 identified	 being	 the	 major	 cause	 for	 non-adherence.	
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Participating	 adolescents	 revealed	 that	 their	 parents	 mainly	 still	 play	 a	 role	 in	
reminding	and	collecting	refills	and	suggested	smartphone	applications	with	a	reminder	
function	and	easy	access	 to	online	 information	as	 favorable	means	 for	 successful	 self-
management.	 [233]	 It	has	been	reported	that	 inhaler	reminders	also	offer	an	effective	
strategy	to	improve	adherence	in	adult	patients.	A	6-month	randomized	trial	compared	
3	 patient	 groups	 receiving	 asthma	 controller	 treatment:	 while	 one	 just	 obtained	 the	
usual	care,	personalized	adherence	discussions	were	performed	with	the	second	group.	
In	the	third	group	patients	received	twice-daily	SmartTrack	reminders	for	missed	doses	
and	 automated	 e-mails	 about	 their	 daily	 inhaler	 use	 were	 sent	 to	 their	 practitioner.	
Results	 demonstrated	 that	 the	 electronic	 inhaler	 reminders	 including	 adherence	
feedback	 were	 able	 to	 improve	 the	 compliance	 even	 more	 than	 the	 patient-specific	
behavioral	interventions.	[234]	
Besides	poor	adherence,	inadequate	inhaler	techniques	can	also	be	a	substantial	cause	
for	 persisting	 asthma	 symptoms.	 The	 correct	 use	 of	 devices	 is	 central	 to	 effectively	
deliver	the	contained	medication,	however,	especially	for	dry	powder	inhalers,	serious	
technique	errors	are	not	uncommon.	The	failure	to	exhale	before	inhalation,	insufficient	
breath-hold	 at	 the	 end	of	 the	 inhalation	process,	 and	 inhalation	not	 forceful	 from	 the	
start	are	among	the	most	frequent	mistakes	which	are	often	connected	to	not	only	poor	
asthma	control,	but	also	severe	consequences	such	as	asthma-related	hospitalizations.	
[235]	 This	 demonstrates	 the	 great	 need	 of	 comprehensive	 education	 and	 training	
measures,	whose	success	has	already	been	proven	in	numerous	studies.	Among	others,	
Plaza	et	al.	showed	the	effectiveness	of	repeated	educational	 interventions	including	a	




has	 to	 be	 drawn	 to	 a	 thorough	 training	 of	 correct	 inhalation	 techniques	 involving	
encompassing	education	of	the	parents.	
Although	asthma	was	and	 is	often	 regarded	as	being	mainly	 a	 childhood	disease,	 it	 is	
also	 a	 relevant	 origin	 of	 morbidity	 and	 mortality	 in	 the	 older	 generation	 leading	 to	




that	 asthma	 in	 the	 elderly	 phenotypically	 differs	 from	 that	 in	 younger	patients	 [238],	
showing	 the	 need	 for	 new	 diagnostic	 and	 therapeutic	 strategies	 in	 this	 population,	
especially	 considering	 the	 fact	 that	 life	 spans	 are	 rising	 and	 the	 proportion	 of	
individuals	aged	65	and	older	 is	evermore	increasing	worldwide.	The	high	occurrence	
of	 various	 comorbidities,	 aging-related	 lung	 and	 immune	 alterations	 as	 well	 as	
epigenetic	 factors	 can	 lead	 to	 complex	 interactions	and	a	diverse	pathophysiology.	As	
most	 former	 studies	 were	 based	 on	 allergic	 or	 TH2-mediated	 asthma,	 which	 is	 not	 a	
predominant	 characteristic	 of	 asthma	 in	 the	 elderly	 [239],	 and	 respective	 clinical	
studies	often	exclude	older	patients	[240],	the	knowledge	in	this	area	is	still	incomplete.	
Examinations	 have	 to	 consider	 numerous	 age-related	 changes,	 e.g.	 decreasing	
respiratory	 mechanical	 properties,	 a	 shift	 in	 immune	 cells	 from	 naïve	 to	 memory	
lymphocytes,	reduction	of	total	serum	immunoglobulin	E	(IgE),	loss	of	lung	volume	and	
decline	in	FEV1	to	name	only	a	few.	Regarding	pharmacotherapy,	special	attention	has	
to	 be	 paid	 to	 the	 higher	 sensitivity	 to	 side-effects	 of	medications	 [241],	 the	 frequent	
polypharmacy	and	 thereby	 increasing	 risk	of	drug	 interactions,	 as	well	 as	 factors	 like	
misunderstanding	of	the	disease	and	treatment	regimen,	poor	compliance	and	memory	
problems	[242,	243].		
Furthermore,	 as	 aging	 is	 often	 associated	 with	 a	 sedentary	 everyday	 life	 and	 weight	
gain,	 recommendations	 for	 regular	 exercise	 and	 promotion	 of	 a	 healthy	 lifestyle	 are	
particularly	 advisable	 [238],	 however,	 this	 is	 not	 less	 true	 for	 all	 other	 age	 groups.	 A	
recent	 study	evaluating	 the	association	of	 severity	and	control	of	 asthma	with	 factors	
like	body	mass	index,	insulin	resistance,	levels	of	adipokines	and	inflammatory	markers	
in	 asthmatic	 children	 and	 adolescents	 found	 that	 asthma	was	 associated	with	 insulin	
resistance	and	a	systemic	inflammatory	response	possibly	mediated	by	adipokines,	with	
leptin	levels	standing	out	among	the	subjects	with	excess	weight.	[244]	
Assessing	 the	 effect	 of	 exercise	 therapy	 on	 overweight	 women	 with	 chronic	
inflammatory	 diseases	 led	 to	 the	 observation	 that	 neutrophil	 counts	 can	 be	 reduced	
[245]	 and	 in	 asthma	 patients	 in	 particular,	 aerobic	 exercise	 training	 was	 proven	 to	
lower	the	number	of	eosinophils	in	induced	sputum	as	well	as	the	levels	of	the	fraction	
of	 exhaled	 nitric	 oxide	 (FeNO)	 [246].	 In	 children	 with	 persistent	 allergic	 asthma,	 a	





is	 able	 to	 reverse	 the	 OVA-induced	 reduction	 of	 glucocorticoid	 receptor	 and	
consequently	induce	an	increased	expression	of	the	anti-inflammatory	cytokines	IL-10	
and	 IL-1ra,	 while	 inflammatory	 mediators	 like	 NF-κB	 and	 TGF-β	 as	 well	 as	 airway	




Nevertheless,	 it	 has	 to	 be	 minded	 that	 vigorous	 activity	 can	 also	 provoke	 asthma	
symptoms	like	cough,	wheeze	or	dyspnoea.	While	sports	with	physical	efforts	of	rather	
short	 durations	 and	 low	 ventilary	 levels	 have	 a	 small	 risk	 for	 the	 development	 of	
asthma	 symptoms,	 team	 sports	 in	 general	 can	 be	 regarded	 as	 medium-risk	 sports.	
Participating	in	swimming,	endurance	and	winter	sports,	however,	entails	a	higher	risk	
for	triggering	exercise-induced	asthma	(EIA)	and	bronchoconstriction	(EIB)	due	to	the	
long	 duration	 of	 exertion	 and	 the	 low	 air	 temperature,	 respectively.	 Other	 factors	
influencing	how	beneficial	or	detrimental	different	sports	can	be	for	asthmatic	patients	
are	e.g.	the	humid	air	inhaled	during	swimming	vs.	chlorine-based	irritants	in	the	pool	






complex	 and	 therefore	 difficult	 to	 control.	 This	 may	 only	 apply	 to	 a	 relatively	 small	
group	of	 the	overall	 patient	population,	 however,	 they	 account	 for	more	 than	50%	of	
asthma-related	healthcare	utilization	[252]	and	are	at	increased	risk	of	asthma-caused	
death	[253],	reasons	enough	to	make	them	a	top	priority	in	respective	research.	
One	 approach	 to	 find	 new	 therapies	 is	 to	modulate	 and	 improve	 currently	 successful	











More	 than	 100	 genes	 are	 considered	 to	 conduce	 to	 asthma	manifestations,	 including	
primary	 disease	 conferring	 genes,	 asthma	 severity	 varying	 genes	 and	 treatment	
modifying	 genes.	 A	 well-investigated	 example	 that	 has	 been	 associated	 with	 a	 more	
severe	form	of	asthma	and	a	decreased	response	to	beta	agonists	is	the	substitution	of	
arginine	 with	 glycine	 at	 position	 16	 of	 the	 β2-adrenergic-receptor	 [254].	 Recent	
genome-wide	association	studies	combined	with	replication	in	additional	cohorts	and	in	
vitro	 cell-based	models	 identified	 novel	 pathway-related	 pharmacogenetic	 variations.	
As	 these	 have	 the	 potential	 to	 influence	 the	 efficacy	 of	 therapeutic	measures,	 a	more	
detailed	 understanding	 of	 the	 underlying	 genetic	 mechanisms	 may	 lead	 to	 the	




For	a	 long	 time,	asthma	has	been	viewed	as	a	 single	disease	characterized	by	chronic	
airway	 inflammation	 and	 remodeling	 with	 anti-inflammatory	 therapy	 as	 the	 major	
approach	 to	 treatment.	 But	 more	 recently,	 the	 disease	 is	 recognized	 to	 be	 a	
multidimensional	 syndrome	 involving	 clinical,	 physiologic,	 and	 pathologic	 domains,	
which	may	coexist,	 but	 are	not	necessarily	 related.	 [253]	As	 the	understanding	of	 the	
heterogeneity	 of	 asthma	 is	 increasing,	 more	 and	 more	 different	 phenotypes	 and	
endotypes	 are	 identified,	 incorporating	observable	 clinical	 characteristics	 and	 specific	
biologic	mechanisms	in	a	more	complex	way.	[254]	A	phenotype	can	be	“defined	as	the	
composite	observable	characteristics	or	traits	of	an	organism	that	result	from	genetic	as	
well	 as	 environmental	 influences”	 [256].	 These	 kinds	 of	 phenotypes	 including	
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dependence	 on	 high-dose	 corticosteroid	 treatment,	 severe	 airflow	 obstruction	 and	
recurrent	 exacerbations	 concomitant	 with	 an	 allergic	 background	 and	 late	 onset	 of	
disease	 have	 been	 revealed	 by	 analytical	 clustering	 methods,	 among	 others	 in	 the	
Severe	 Asthma	 Research	 Program	 (SARP)	 [257].	 This	 investigation	 identified	 five	
clusters	of	patients	differing	in	age,	sex,	age	of	onset,	presence	of	atopy	and/or	obesity,	
degree	of	lung	dysfunction,	and	reversibility	of	airflow	obstruction.	In	another	approach	
using	 sputum	 analysis,	 four	 phenotypes	 based	 on	 the	 predominant	 inflammatory	 cell	
type,	 such	 as	 eosinophilic	 or	 neutrophilic,	 were	 found	 [258].	 In	 these	 groupings,	 the	
most	evident	differentiation	was	between	patients	with	mild	 to	moderate,	early-onset	
asthma	 with	 eosinophilic	 or	 paucigranulocytic	 predominant	 sputum	 patterns	 and	
patients	 with	 more	 severe	 form	 of	 asthma	 and	 greater	 sputum	 neutrophilia.	
Furthermore,	to	comprise	not	only	the	clinical	picture,	but	also	find	subtypes	based	on	
the	 underlying	 biologic	 mechanisms,	 different	 endotypes	 were	 defined,	 including	
biomarkers,	 lung	 physiology,	 genetics,	 histopathology,	 epidemiology	 and	 respective	
treatment	response.	For	example,	the	aspirin-exacerbated	respiratory	disease	endotype	
features	 leukotriene-related	 genetic	 polymorphisms	 leading	 to	 an	 upregulated	
leukotriene	 synthesis.	 As	 5-lipoxygenase	 inhibitors	 block	 the	 synthesis	 pathway	
upstream,	 they	are	 recognized	as	 the	 superior	 treatment	 for	 this	patient	group.	 [259]	
The	 allergic	 bronchopulmonary	 mycosis	 endotype,	 in	 contrast,	 is	 associated	 with	
colonization	of	the	airways	by	mold	and	might	therefore	benefit	from	antifungal	agents.	




The	most	 common	 grouping	 of	 asthma	 patients	 divides	 into	 allergic	 and	 non-allergic	
forms.	While	allergic	asthma	is	present	in	all	groups	of	asthma	severity,	with	50-80%	it	
is	of	particular	importance	in	patients	with	severe	asthma	[260],	therefore	finding	new	
treatments	 for	 this	 population	 is	 an	 interesting	 area	 of	 research.	 Besides	 the	 well-
known	 function	 of	 IgE,	 it	 is	 also	 assumed	 that	 several	 different	 cytokines	 and	




of	 biological	 drugs	 such	 as	 monoclonal	 antibodies	 and	 small-molecule	 inhibitors,	
especially	 as	 reasonable	 add-on	 treatments	 for	 those	 patients	 whose	 severe	 asthma	
forms	do	not	 respond	 to	 conventional	 therapies	 in	 a	 satisfactory	way.	While	 the	anti-
inflammatory	 effect	 of	 corticosteroids	 interferes	 with	 several	 pathways	 that	 are	
involved	 in	 asthma	 pathogenesis,	 cytokine-based	 therapy	 usually	 only	 targets	 a	
restricted	 cascade.	 As	 experimental	 anti-cytokine	 therapies	 have	 also	 been	 shown	 to	
induce	variable	responses	in	individual	patients,	the	need	to	accurately	characterize	the	
patient’s	 phenotypic	 pattern	 becomes	 even	 more	 evident.	 A	 certain	 biological	 drug	
addressing	the	particular	molecular	targets	relevant	for	each	subgroup	has	to	be	found	
in	order	to	achieve	the	best-possible	outcome	for	individual	patients.	[24]	
As	 the	 first	 biologic	 in	 asthma	 treatment,	 omalizumab	 (Xolair®,	 Novartis)	 has	 been	
approved	 in	 the	 United	 States	 in	 2003.	 The	 murine	 monoclonal	 antibody	 (mAb)	 is	






showing	 a	 greater	 avidity	 for	 IgE,	 such	 as	 RG7449	 that	 targets	 B-lymphocytes	 before	
they	are	activated	to	produce	IgE.	[261]	
After	 more	 than	 a	 decade	 without	 any	 new	 appearances	 on	 the	 market,	 the	 anti-
interleukin	5	(IL-5)	humanized	mAb	mepolizumab	(Nucala®)	by	GlaxoSmithKline	was	
approved	 in	 the	end	of	2015	as	 an	add-on	 treatment	 for	patients	with	 severe	asthma	
and	 eosinophilic	 inflammation.	 IL-5	 was	 identified	 as	 a	 useful	 target	 as	 it	 promotes	
eosinophil	growth	and	activation	and	two	additional	mAbs,	reslizumab	(Cinqair®)	and	
benralizumab	 are	 already	 in	 the	 pipeline.	 While	 Nucala	 and	 Cinqair	 both	 bind	 IL-5	
directly	to	hinder	it	from	tacking	to	its	receptors	on	eosinophils,	benralizumab	targets	
the	 receptor	 α	 subunit	 in	 order	 to	 mediate	 the	 death	 of	 eosinophils	 by	 enhanced	
antibody-dependent	 cell-mediated	 cytotoxicity.	 As	 IL-5	 is	 not	 the	 only	 cytokine	




Besides	 that,	 several	 different	 biological	 targets	 are	 currently	 explored	 in	 asthma	
research.	 In	 addition	 to	 the	 IL-5	 mAbs,	 atopic	 patients	 with	 TH2-driven	 eosinophilic	
asthma	could	also	benefit	from	inhibition	of	IL-4	and	IL13.	A	blockade	of	IL-17	that	also	
contributes	to	steroid	resistance,	instead,	would	most	likely	be	useful	for	patients	with	
severe	 neutrophilic	 asthma.	 Combinations	 of	 biologics	 targeting	 different	 types	 of	
cytokines	could	be	applied	for	the	mixed	neutrophilic-eosinophilic	phenotypes,	a	group	
represented	 quite	 frequently	 among	 the	 exacerbation-prone	 form	 of	 severe	 asthma.	
Another	promising	approach	is	the	neutralization	of	the	effects	of	 innate	cytokines	IL-





The	 two	 major	 hurdles	 yet	 to	 overcome	 on	 the	 way	 to	 more	 efficient	 and	 easily	
accessible	 biological	 therapies	 are	 the	 lack	 of	 reliable	 biomarkers	 to	 characterize	
specific	 phenotypes	 and	 predict	 medication	 responsiveness	 and	 the	 need	 to	 design	
reasonable	clinical	 trials	 to	evaluate	 the	 long-term	safety	of	 these	 immunomodulatory	
agents.	Furthermore,	the	cost	factor	is	not	to	be	underestimated.	As	Nucala,	for	example,	
















































































large	 global	 market	 for	 asthma	 drugs	 [264]	 fuels	 research	 and	 development	 by	
pharmaceutical	 companies	 to	 develop	 new	 therapies	 to	 treat	 asthma.	 A	 stepwise	
approach	for	controlling	asthma	symptoms	is	recommended	by	the	Global	Initiative	for	
Asthma	 (GINA).	 For	 this	 stepwise	 approach	 inhaled	 rescue	 medications	 (e.g.	 short	
acting	β2-adrenoceptor	agonist	(SABA))	are	prescribed	and	taken	as	needed	to	relieve	
asthma	 symptoms	 in	 all	 asthmatic	 patients,	 and	 inhaled	 corticosteroids	 (ICS)	with	 or	
without	long	acting	β2-adrenoceptor	agonist	(LABA)	are	recommended	for	patients	with	
moderate	 persistent	 asthma.	 Additionally	 oral	 corticosteroids	 (OCS)	 and	 anti-IgE	
(omalizumab)	 may	 be	 applied	 in	 patients	 who	 have	 severe	 asthma	 [265].	 Although	
current	 treatment	 strategies	 can	 control	 asthma	 symptoms	 in	most	 patients,	 there	 is	
still	a	need	to	develop	alternative	therapies	for	asthma	primarily	because	of	concerns	of	
low	 patients	 compliance	 [266].	 Patient	 compliance	 remains	 low	 for	 asthma	 therapies	








Extensive	 research	 has	 been	 conducted	 to	 understand	 the	 detailed	 pathologic	
mechanisms	of	asthma	and	to	develop	new	therapies	for	asthma.	Numerous	drugs	have	
entered	 clinical	 trials	 but	 failed	 to	 demonstrate	 satisfactory	 therapeutic	 efficacy	 and	
safety.	 Nanomedicine	 may	 be	 a	 way	 to	 solve	 the	 poor	 safety	 and	 efficacy	 problems	
encountered	by	previously	tested	new	drug	candidates.	Nanomedicine	was	defined	by	
the	 Medical	 Standing	 Committee	 of	 the	 Europe	 Science	 Foundation	 on	 2004	 as	 “the	
science	 and	 technology	 of	 diagnosing,	 treating,	 and	 preventing	 disease	 and	 traumatic	
injury,	 of	 relieving	 pain,	 and	 of	 preserving	 and	 improving	 human	 health,	 using	
molecular	tools	and	molecular	knowledge	of	the	human	body”	[268].	The	advantages	of	
nanomedicine	 include	 increased	solubility,	 sustained	release,	and	enhanced	specificity	
of	 drug	 treatments.	 For	 example,	 a	 doxorubicin	 encapsulating	 liposome	 (Doxil®),	 the	
first	 nanodrug	 approved	 by	 FDA	 in	 1995	 to	 treat	 cancers,	 demonstrates	 increased	
circulation	 time,	consequently	enhanced	amounts	of	drug	 in	cancer	cells	and	 less	side	
effects	 compared	 with	 free	 doxorubicin	 [269].	 Nanomedicine	 is	 also	 suitable	 for	 the	





for	 asthma	 therapies.	 Then,	we	will	 elaborate	 on	how	 studies	 need	 to	 be	planned	 for	








Drugs	available	 for	 asthma	 therapy	 can	be	 categorized	 into	 small	molecule	drugs	and	




muscarinic	 antagonists	 (LAMA)	 are	 preferably	 formulated	 for	 pulmonary	 delivery.	
Currently,	there	are	only	two	biopharmaceutical	treatments	for	asthma	on	the	market,	
both	 of	 which	 are	 monoclonal	 antibodies,	 formulated	 for	 subcutaneous	 (s.c.)	
administration.	The	first	antibody,	omalizumab,	targets	a	high-affinity	receptor	binding	
site	on	IgE	and	is	approved	for	the	treatment	of	patients	with	severe	persistent	allergic	









oral	 or	 pulmonary	 delivery.	 New	 drugs	 for	 anti-leukotriene	 therapies	 have	
demonstrated	oral	activity,	such	as	a	dual	antagonist	of	cysteinyl-leukotriene	receptor	1	
(CysLT1)	 and	 CysLT2	 (Gemilukast)	 and	 a	 5-lipoxygenase-activating	 protein	 inhibitor	
(GSK2190915).	 Furthermore,	 chemokine	 receptor	 antagonists	 (e.g.	 GW766944),	
phosphodiesterase	 (PDE)	 inhibitors	 (e.g.	 Revamilast),	 and	 mast	 cell	 inhibitors	 (e.g.	
Masitinib)	are	also	administrated	orally	in	clinical	trials.	
Another	 typical	 example	 of	 orally	 administrated	 drugs	 is	 the	 group	 of	 antagonists	 of	
chemoattractant	 receptor-	 homologous	molecule	 expressed	 on	 T	 helper	 2	 (Th2)	 cells	
(CRTH2),	 also	 called	 D	 prostanoid	 receptor	 2	 (DP2)	 [271].	 Selective	 antagonists	 of	
CRTH2	 alleviate	 allergic	 inflammation	 by	 inhibiting	 the	 activation	 and	 recruitment	 of	
pro-inflammatory	cells	such	as	Th2	cells,	eosinophils,	and	basophils	 [272].	At	 least	13	
different	 CRTH2	 antagonists	 have	 been	 brought	 to	 clinical	 trials	 for	 the	 treatment	 of	




membrane	 of	 CHO	 cells	 and	 native	DP2	 expressed	 on	 Th2	 cells.	 Both	 of	 these	 studies	
demonstrated	the	high	potency	of	OC000459	for	DP2	(K(i)	=	0.013	μM	and	K(i)	=	0.004	
μM,	 respectively).	 OC000459	 had	 minimal	 inhibitory	 activity	 when	 assessed	 using	 a	
library	of	69	non-related	receptors	and	19	enzymes,	suggesting	OC000459	was	highly	
specific	 for	DP2.	OC000459	 treatment	 inhibited	PGD2	 induced	chemotaxis	of	Th2	cells	
(IC50	 =	 0.028	 μM)	 and	 IL-13	 production	 of	 Th2	 cells	 (IC50=	 0.019	 μM)	 as	 well	 as	
competitively	 antagonized	 eosinophil	 shape	 change	 in	 response	 to	 PGD2	 (pKB	 =	 7.9).	


















an	 allergic	 stimulus,	 another	 clinical	 trial	 was	 conducted	 in	 corticosteroid	 naïve	
asthmatic	patients.	 It	was	reported	that	treatment	with	200	mg	OC000459	twice	daily	
for	 16	 days	 reduced	 allergen	 induced	 later	 asthmatic	 response	 (LAR)	 determined	 by	
calculations	 of	 the	 area	 under	 the	 curve	 (AUC)	 of	 FEV1.	 Furthermore,	 this	 treatment	
regimen	 inhibited	 the	 induction	 of	 sputum	 eosinophils	 1	 day	 following	 allergen	
challenge	 when	 compared	 with	 placebo.	 Together,	 OC000459	 was	 shown	 to	 inhibit	
allergic	 asthma-related	 inflammation	 when	 administered	 orally	 to	 human	 patients	
[275].	To	determine	the	optimal	dose	of	OC000459	for	the	treatment	of	asthma,	patients	
with	mild	 to	moderate	persistent	asthma	were	 treated	with	 three	doses	of	OC000459	
(25	mg	or	200	mg	once	daily,	or	100	mg	twice	daily)	for	12	weeks.	Results	reflected	that	
the	 lung	 function,	as	determined	by	change	 in	FEV1,	was	 improved	 in	all	patients	who	
received	 OC000459	 when	 compared	 to	 placebo.	 Therefore,	 the	 lowest	 dose	 of	
0C000459	 tested	 (25	 mg	 daily)	 was	 sufficient	 to	 provide	 therapeutic	 efficacy.	 To	
investigate	 whether	 sub-populations	 would	 respond	 to	 treatment	 differently,	 lung	
function	 data	 from	 asthmatic	 patients	 with	 eosinophilia	 (blood	 eosinophils	 count	 ≥	
250/μl)	and	without	eosinophilia	 (blood	eosinophils	 count	<	250/μl)	were	compared.	
Patients	 with	 eosinophilia	 showed	 significant	 improvement	 of	 lung	 function	 with	
OC000459	 treatment	 when	 compared	 to	 placebo.	 Conversely,	 lung	 function	 was	 not	
improved	 in	 patients	without	 eosinophilia	 following	OC000459	 treatment,	 suggesting	





rhinitis.	 The	 safety	 of	 OC000459	 is	 also	 under	 investigation	 in	 healthy	 participants	
because	of	a	potential	interaction	between	OC000459	and	cytochrome	P450	3A4.	
Numerous	small	molecule	asthma	drugs	have	been	formulated	for	pulmonary	delivery	





RPL554,	 a	 dual	 inhibitor	 of	 PDE3&	PDE4,	 is	 administrated	 trough	 inhalation	 to	 avoid	
adverse	gastrointestinal	 side	effects	 reported	 for	oral	 formulations	of	PDE4	 inhibitors	
[277].	 In	 preclinical	 studies,	 RPL554	 was	 shown	 to	 potently	 inhibit	 the	 activity	 of	
isolated	 human	 PDE3	 and	 PDE4	 (IC50	 =	 0.4	 nM	 and	 IC50	 =	 1479	 nM,	 respectively).	
Inhibition	 of	 PDE3	was	 thought	 to	mediate	 human	 airway	 smooth	muscle	 relaxation,	
and	 both	 an	 in	 vitro	 model	 and	 an	 isolated	 guinea	 pig	 tracheal	 tissue	 were	 used	 to	
investigate	 the	 ability	 of	 RPL554	 inhibit	 the	 activity	 of	 PDE3.	 RPL554	 can	 relax	 the	
reproducible	 contractile	 of	 tracheal	 smooth	 muscle	 elicited	 by	 electrical	 field	
stimulation	 in	a	concentration	dependent	manner.	The	ability	 to	 inhibit	stimulation	of	
immune	 cells	 of	 RPL554	 was	 evaluated	 in	 human	 primary	 cells.	 It	 was	 shown	 that	
RPL554	 can	 inhibit	 the	 release	 of	 tumor	 necrosis	 factor	 alpha	 (TNFα)	 from	
lipopolysaccharide	 (LPS)	 activated	 human	 mononuclear	 cells	 (IC50	 =	 0.52	 μM)	 and	
inhibit	the	proliferation	of	mononuclear	cells	stimulated	by	phytohemagglutinin	(IC50	=	
0.46	 μM).	 In	 guinea	 pigs,	 inhalation	 of	 RPL554	 dry	 powder	 (3-5	 mg,	 blended	 with	
lactose)	 can	 reduce	 the	 bronchoconstriction	 and	 airway	 edema	 in	 response	 to	 i.v.	
administration	 of	 histamine	 as	 well	 as	 decrease	 the	 infiltration	 of	 eosinophils	 to	 the	
airway	of	 ovalbumin-sensitized	 asthmatic	 animals,	 indicating	 the	 feasibility	 to	 deliver	
RPL554	through	inhalation	for	anti-inflammatory	therapies	[278].		
Based	 on	 the	 efficient	 activity	 of	 bronchodilation	 and	 anti-inflammation,	 RPL554	was	






treatment	 can	 improve	 lung	 function	of	 asthmatic	patients,	 especially	at	high	dose,	 as	
determined	 by	 more	 than	 1.5	 fold	 of	 the	 concentration	 of	 methacholine	 needed	 to	
induce	a	20%	decrease	in	FEV1	compared	with	the	original	dose.	To	further	evaluate	the	
efficacy	 as	 a	 bronchodilator	 and	 the	 safety	 of	 RPL554,	 asthmatic	 patients	 received	
multiple	administrations	of	inhaled	RPL554	at	a	dose	of	0.018	mg/kg,	for	6	days.	FEV1	
was	 determined	 for	 6	 h	 post-inhalation	 of	 RPL554	 or	 placebo	 on	 days	 1,	 3,	 and	 6.	
Results	 showed	 that	 RPL554	 improved	 FEV1	 when	 compared	 to	 placebo.	 In	 another	
clinical	 trial,	 the	 anti-inflammatory	 effect	 of	 RPL554	 was	 investigated	 in	 healthy	
volunteers	challenged	by	 inhaled	LPS.	Participants	received	a	daily	dose	of	RPL554	of	
0.018mg/kg	for	6	days	before	LPS	challenge,	and	their	sputum	was	collected	6	h	and	24	
h	 post-	 challenge.	 Results	 showed	 significantly	 less	 macrophages,	 lymphocytes,	
neutrophils	and	eosinophils	in	the	sputum	from	participants	treated	with	RPL554	when	
compared	 with	 the	 placebo-treated	 group.	 Therefore,	 inhalation	 of	 RPL554	 was	
reported	to	inhibit	the	inflammatory	response.	[279].	Currently,	RPL554	is	investigated	






well	 tolerated	 in	 patients	 with	 mild-to-moderate	 or	 moderate-to-severe	 asthma,	
according	 to	 the	 reported	 adverse	 events,	 laboratory	 tests,	 vital	 signs,	 and	 ECG.	
Moreover,	lung	function	was	improved,	as	determined	by	FEV1	measurements,	in	a	dose	
dependent	manner	 in	 patients	 treated	with	MN-221	 [280].	 Another	 clinical	 trial	 was	
conducted	to	evaluate	the	efficacy	of	MN-221	in	patients	with	an	acute	exacerbation	of	
asthma.	 In	 this	 trial,	 patients	 admitted	 to	 the	 emergency	 room	 received	 the	 standard	
treatment	for	acute	asthma	exacerbation,	and	those	who	did	not	response	to	standard	
therapy	 (FEV1	 was	 less	 than	 50%	 of	 predicted)	 received	 an	 i.v.	 infusion	 of	 MN-221	
(1200	μg)	or	placebo,	followed	by	measurements	of	FEV1	for	3	h.	MN-221	treatment	in	
addition	 to	 standard	 therapy	 failed	 to	 significantly	 improve	 the	 lung	 function	
determined	by	AUC0-3h	of	%FEV1	when	compared	to	standard	treatment	[281].	Despite	
the	 apparent	 lack	 of	 improvement	 with	 MN-221	 treatment,	 it	 is	 possible	 that	 these	
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patients	were	 resistant	 to	 any	 asthma	 treatment,	 because	 these	 patients	 also	 did	 not	
respond	well	to	standard	treatment.	To	better	determine	the	efficacy	of	MN-221,	future	
clinical	 trials	 should	 include	 a	 more	 heterogeneous	 population,	 to	 avoid	 a	
disproportionate	number	of	treatment	resistant	patients.	




Asthma	 is	 a	 complicated	 disease	 involving	 numerous	 inflammatory	 cells	 and	 cellular	
mediators.	 Biopharmaceutical	 drugs	 can	 be	 used	 to	 intervene	 specific	 events,	 for	
example,	 blockage	 of	 interaction	 between	 cells	 or	 between	 receptors	 and	
cytokines/chemokines	 and	 inhibition	 of	 expression	 of	 key	 pathological	 factors	 (e.g.	
cytokines,	 receptors,	 transcription	 factors).	 Numerous	 biopharmaceutical	 drugs	 are	
currently	in	preclinical	and	clinical	development	for	the	treatment	of	asthma.	There	are	
two	major	kinds	of	biopharmaceutical	drugs	which	have	been	 in	 clinical	 trials	 for	 the	
treatment	 of	 asthma:	 1)	 protein	 based	 drugs,	 such	 as	 monoclonal	 antibodies	 and	
cytokines,	 and	 2)	 nucleic	 acid	 based	 drugs	 including	 DNAzymes,	 anti-sense	
oligonucleotides	and	small	interference	RNA	(siRNA).		
Protein	 based	 drugs,	 specifically	 monoclonal	 antibodies,	 are	 particularly	 promising	
treatments	 for	 asthma.	 	 Monoclonal	 antibodies	 have	 been	 successfully	 brought	 to	
market	 for	 the	 treatment	 of	 various	 diseases.	 Monoclonal	 antibodies	 can	 be	 raised	
against	specific	antigens	(i.e.	drug	targets)	and	administered	through	i.v.	or	s.c.	injection.	
Monoclonal	 antibodies	 have	 the	 benefit	 of	 being	 highly	 specific	 for	 a	 particular	 drug	
target,	and	with	little	off-target	binding.	Currently,	there	is	large	number	of	monoclonal	
antibodies	under	clinical	investigation.	Their	targets	include	1)	cytokines	such	as	IL-4	(	
e.g.	pascolizumab),	 IL-5	 (e.g.	mepolizumab),	 IL-9	 (e.g.,	MEDI-528),	 IL-13	 (e.g.	QAX576,	
CAT-354),	and	 IL-17A	(e.g.	 secukinumab);	2)	 receptors	such	as	 IL-13	receptor	α1	and	
α2	(e.g.	GSK679586	),	 IL-4	receptor	α	 (e.g.	AMG	317),	and	 IL-5	receptor	α	 (e.g.	MEDI-




Mepolizumab	 is	 a	 humanized	monoclonal	 antibody	 raised	 against	 IL-5.	 Mepolizumab	
can	bind	to	IL-5	inhibiting	the	interaction	between	IL-5	and	its	receptor	[282].	Because	
IL-5	 regulates	 the	 activation	 and	 survival	 of	 eosinophils,	 a	 proinflammatory	 cell	 type	




human	 TF-1.28	 cells,	 a	 human	 erythroleukemia	 cell	 line,	mepolizumab	 treatment	 can	
inhibit	 IL-5	 dependent	 cellular	 proliferation	 with	 an	 IC50	 value	 of	 <	 150	 pM.	
Mepolizumab	binding	is	highly	specific	for	the	human	IL-5	protein	and	does	not	bind	to	
IL-5	derived	from	mouse,	rat,	guinea	pig	or	dog	[283].	Therefore,	pharmacokinetic	and	
pharmacodynamic	 studies	 of	 mepolizumab	 were	 conducted	 in	 healthy	 cynomolgus	
monkeys.	 The	mean	 terminal	 half-life	 of	mepolizumab	 after	 i.v.	 administration	 (13.0±	
2.2	 days)	 and	 s.c.	 administration	 (14.5±	 3.8	 days)	 were	 similar	 and	 relatively	 long,	
indicating	mepolizumab	was	bioavailable	 following	s.c.	route.	A	single	dose	(1	mg/kg)	




long-term	 safety	 profile,	 mepolizumab	 was	 evaluated	 in	 a	 monkey	 allergy	 model	 or	
healthy	monkeys.	 In	monkeys	 naturally	 sensitized	 to	Ascaris	 suum	 (A.	 suum),	 a	 single	
dose	 of	 mepolizumab	 (i.v.,	 10mg/kg)	 inhibited	 the	 infiltration	 of	 eosinophils	 to	 the	
airways	and	blood	eosinophilia	 induced	by	 inhaled	A.	 suum	 antigen.	Healthy	monkeys	
were	treated	(i.v.)	twice	with	mepolizumab	at	different	doses	(0.05,	0.5	or	50	mg/kg)	on	
days	1	and	29.	Mepolizumab	mediated	a	dose-dependent	reduction	of	peripheral	blood	
eosinophils	 and	 inhibition	 of	 blood	 eosinophilia	 induced	by	 s.c.	 injection	 of	 rhIL-2	 on	
day	 30.	 Repeated	 i.v.	 administration	 (10	 or	 100	 mg/kg)	 or	 s.c.	 (10	 mg/kg)	 of	
mepolizumab	to	monkeys	monthly	for	6	months	was	conducted	to	investigate	long	term	
toxicity	 and	 pharmacodynamics.	 All	 doses	 were	 well	 tolerated	 and	 no	 adverse	 side	
effects	 were	 observed.	 More	 importantly,	 all	 doses	 effectively	 decreased	 circulating	
eosinophils	 but	 not	 significantly	 affected	 immature	 or	 mature	 eosinophils	 in	 bone	





single	 i.v.	 administration	 of	 mepolizumab	 (2.5	 mg/kg	 and	 10	mg/kg)	 were	 tested	 in	
patients	 with	mild	 allergic	 asthma.	Mepolizumab	 treatment	 can	 inhibit	 the	 increased	
blood	eosinophils	and	sputum	eosinophils	count	induced	by	inhaled	allergen.	However,	
mepolizumab	 did	 not	 significantly	 change	 airway	 response	 to	 inhaled	 histamine	 as	
determined	 by	 histamine	PC20	 (mg/ml)	 nor	 did	 it	 attenuate	 early	 asthmatic	 response	
(EAR)	and	LAR.	These	results	indicated	that	eosinophils	may	not	play	a	significant	role	
for	 airway	 hyper-responsiveness	 (AHR)	 and	 LAR	 but	 be	 more	 relevant	 to	 the	
pathogenesis	of	asthma.	[286].	Larger	scale	clinical	studies	on	the	safety	and	efficacy	of	
mepolizumab	 were	 conducted	 and	 provide	 more	 information	 about	 the	 role	 of	
eosinophils	 in	 asthma	 pathogenesis.	 In	 a	 placebo	 controlled	 clinical	 trial,	 asthma	
patients	 with	 persistent	 symptoms	 despite	 inhaled	 corticosteroid	 therapy	 received	
three	 i.v.	 infusions	 of	 mepolizumab	 (250	 and	 750	 mg)	 at	 4	 weeks	 interval.	 Results	
showed	 that	 mepolizumab	 treatment	 was	 well	 tolerated	 and	 significantly	 reduced	
eosinophils	 count	 in	 sputum	 and	 blood.	 Similar	 to	 the	 previous	 clinical	 study,	
mepolizumab	did	not	 improve	 lung	 function	as	determined	by	changed	morning	peak	
expiratory	 flow	 (PEF)	 and	 FEV1	 when	 compared	 to	 placebo,	 indicating	 that	
mepolizumab	treatment	may	not	be	effective	 to	alleviate	asthma	symptoms	and	other	
clinical	 outcome	 measures.	 However,	 patients	 that	 received	 high	 dose	 mepolizumab	
treatment	 (750	 mg)	 had	 a	 50%	 lower	 exacerbation	 rate	 (although	 not	 statistically	
significant)	when	compared	to	placebo,	suggesting	a	potential	benefit	of	mepolizumab	
treatment	 in	 preventing	 exacerbation	 [287].	 Because	 mepolizumab	 may	 be	 most	
effective	 in	 reducing	 the	 exacerbation	 rate	 of	 asthmatics,	 two	 clinical	 trials	 were	
conducted	 with	 patients	 displaying	 eosinophilia	 to	 determine	 the	 efficacy	 of	
mepolizumab	 to	 control	 exacerbation.	 In	 one	 of	 the	 clinical	 trial,	 patients,	 who	 had	
refractory	eosinophilic	asthma	and	a	history	of	recurrent	severe	exacerbation,	received	
i.v.	infusions	of	750	mg	mepolizumab	every	month	for	12	consecutive	months	[288].	In	
the	 other	 clinical	 trial,	 patients	 that	 had	 persistent	 sputum	 eosinophilia	 despite	
prednisone	treatment	received	i.v.	infusions	of	750	mg	mepolizumab	every	four	weeks	
for	24	weeks	 [289].	Both	 studies	 confirmed	 that	mepolizumab	 treatment	 significantly	
reduced	the	exacerbation	rate	 in	asthmatic	patients	with	eosinophilia	when	compared	
to	 placebo,	 without	 significantly	 improving	 lung	 function.	 To	 optimize	 the	




with	 severe	 asthma	 was	 conducted.	 The	 efficacy	 of	 s.c.	 administration	 of	 100	 mg	
mepolizumab	 was	 compared	 with	 i.v.	 administration	 of	 75	 mg	 mepolizumab	 for	 32	
weeks	at	 a	4-week	 interval.	Results	 showed	 that	mepolizumab	 treatment	 reduced	 the	
annualized	frequency	of	clinically	significant	exacerbations	when	compared	to	placebo.	
More	 importantly,	 s.c.	 administration	 achieved	 slightly	 better	 efficacy	 compared	with	
i.v.	administration.	The	mepolizumab	treatment	group	showed	a	trend	of	increased	lung	
function,	as	determined	by	FEV1	(although	not	statistically	significant)	and	an	increased	
quality	 of	 life	 according	 to	 the	 score	 of	 Asthma	 Control	 Questionnaire	 (ACQ)	 and	 St.	
George’s	 Respiratory	 Questionnaire	 (SGRQ)	 [290].	 Based	 on	 the	 outcome	 from	 these	
clinical	trials,	in	2015,	the	s.c.	administration	of	100	mg	mepolizumab	was	approved	by	
the	FDA	for	the	treatment	of	severe	asthma.	
Another	 class	 of	 biopharmaceutical	 drugs	 in	 clinical	 development	 are	 nucleic	 acids	
[291].	 Specific	 nucleic	 acid	 based	 therapies	 include	 DNA	 vaccines	 to	 induce	 immune	
tolerance	 [292],	antisense	oligonucleotides	[293],	 small	 interfering	RNA	(siRNA)	[293,	
294]	 and	 deoxyribozymes	 (DNAzyme)	 for	 the	 selective	 silencing	 of	 asthma	 related	
genes.	 For	 example,	 SB010	 is	 a	 10-23	 DNAzyme	 that	 targets	 (i.e.	 cleaves)	 GATA-3,	
possessing	a	catalytic	domain	and	two	GATA-3	mRNA	specific	binding	sites.	GATA-3	is	a	
key	factor	 in	asthma	pathogenesis	and	it	 is	 important	 for	Th2	cells	differentiation,	 the	
secretion	 of	 Th2	 cytokines,	 and	 the	 production	 of	 IgE	 and	 airway	 recruitment	 of	
eosinophils.	 In	 preclinical	 evaluation,	 in	 a	mouse	model	 of	 acute	 asthma,	 intranasally	
(i.n.)	 applied	 200	 μg	 SB010	 (hgd40),	 which	 is	 more	 active	 in	 humans,	 significantly	
reduced	 infiltration	 of	 leukocytes	while	 the	 scrambled	DNAzyme	was	 inactive.	 In	 the	
same	 study,	 administration	 (i.n.)	 of	 another	 GATA-3	 DNAzyme	 Gd21,	 which	 is	 more	
active	 in	 mice,	 to	 asthmatic	 mice	 inhibited	 the	 secretion	 of	 IL-5	 and	 infiltration	 of	
leukocytes	 and	 alleviated	 AHR	 and	 airway	 remodeling	 (e.g.	 goblet	 cells	 hyperplasia).	
These	results	indicate	the	therapeutic	potential	of	GATA-3	DNAzymes	in	asthma	[295].	
Potential	 off-target	 effects	 of	 SB010	 in	 immune	 cells	 were	 investigated	 in	 TLR-9-







dogs	 because	 both	 rats	 and	 dogs	 share	 the	 same	mRNA	 sequence	 to	 human	 GATA-3	
which	 SB010	 binds	 to.	 Results	 showed	 that	 prolonged	 exposure	 (28	 days)	 to	 inhaled	
SB010	 in	 dogs	 (14.6,	 40.8	 and	 115.5	mg/m3	 and	 the	 corresponding	 theoretical	 doses	
were	 103.3,	 250.4	 and	 739	 µg	 SB010/kg	 body	 weight	 (BW)	 )	 and	 in	 wistar	 rats	 at	
different	doses	 (14,	38	and	113	mg/m3	and	 the	corresponding	 theoretical	doses	were	
112	and	302	µg	SB010/kg	BW)	did	not	produce	signs	of	systemic	toxicity	as	measured	
by	clinical	chemistry,	urinalysis,	as	well	as	gross	pathology	and	histological	analysis	of	
the	 lung.	Although	minimal	histopathological	changes,	 including	 interstitial	 leukocytes	
infiltration,	 bronchus-associated	 lymphoid	 tissue	 hyperplasia,	 and	 compound	 related	
lesions	 in	 the	 lung,	were	observed	at	high	dose	of	 SB010	 (888.8	µg	SB010/kg	BW)	 in	
rats,	 these	 changes	only	occurred	at	 the	highest	dose	 and	were	 completely	 recovered	
after	 withdrawing	 SB10.	 Furthermore,	 long	 term	 exposure	 in	 rats	 didn’t	 change	 the	
splenic	cell	population	(e.g.	T	helper	cells,	NK	cells)	or	serum	levels	of	IgG,	IgA	and	IgE	
antibodies	 and	 there	was	 no	 abnormal	 expression	 of	 cytokines	 in	 the	 BALF	 except	 a	
small	 increase	of	IL-10	and	IFN-.	Dogs	received	i.v.	 infusion	of	SB10	(10	µg/kg)	for	10	
min	 and	 ECG	 and	 blood	 pressure	 were	 monitor.	 The	 results	 suggested	 that	 SB10	
treatment	didn’t	cause	cardiac	abnormalities.	Together,	these	toxicity	results	suggested	
that	SB10	 treatment	was	well	 tolerated	 in	dogs	and	rats	and	did	not	cause	significant	
histopathological	 changes	 (e.g.	 respiratory,	 cardiac)	 [297].	 Biodistribution	 studies	 of	
inhaled	SB010	were	conducted	in	mice	with	OVA	induced	airway	inflammation,	healthy	
rats	 and	 dogs.	 Fluorescently	 labeled	 200	 µg	 SB010	 was	 retained	 in	 the	 lungs	 of	
asthmatic	 mice	 up	 to	 24	 h	 after	 administration	 (i.n.)	 as	 observed	 by	 confocal	
microscopy.	Long	term	pharmacokinetics	of	 intratracheal	(i.t.)	 instillation	of	111Indium	
labeled	SB010	was	monitored	by	a	 single-photon	emission	 computerized	 tomography	
(SPECT)	 in	asthmatic	and	healthy	mice.	Results	 showed	 that	 111Indium	 labeled	SB010	
rapidly	 accumulated	 in	 the	 lung	 and	 bladder	 and	 was	 detectable	 in	 the	 lungs	 of	
asthmatic	 mice	 for	 up	 to	 150	 h.	 In	 comparison,	 less	 111Indium	 labeled	 SB010	
accumulation	was	observed	 in	 the	 lungs	of	healthy	mice.	Pharmacokinetics	of	 inhaled	
different	 doses	 of	 SB010	 were	 evaluated	 in	 rats	 (38.3	 and	 113.2	 mg/m3	 and	 the	
corresponding	theoretical	doses	were	303	and	889	µg	SB010/kg	BW)	and	dogs	(40	and	




post-exposure	 time	 points,	 and	 the	 concentration	 of	 SB10	 was	 measured	 by	 ELISA	
assay.	 SB010	was	 detectable	 shortly	 after	 application	 in	 both	 species	 indicating	 high	
systemic	 availability,	 while	 no	 plasma	 accumulation	 observed	 after	 multiple	
administration.	 These	 favorable	 pharmacokinetics	 characteristics	 support	 that	
inhalation	of	SB10	could	be	a	safe	and	efficient	administration	route	and	also	provides	
guidance	for	future	administration	dose	and	regimen	[298].	In	human	clinical	trials,	the	





plasma	 after	 inhalation	 of	 20	 and	 40	mg	 SB10	 and	 reach	 the	maximal	 concentration	
(Cmax)	 at	 0.5-2	h	 after	 administration.	Next,	 the	 safety	 and	pharmacokinetics	 of	 single	
dose	of	inhalation	of	SB10	(5,	10	and	20	mg)	was	investigated	in	asthmatic	patients.	The	
asthmatic	 patients	 overall	 had	 higher	 AUC	 and	 Cmax	 at	 given	 doses	 compared	 with	
healthy	participants	since	 their	airway	epithelium	may	be	damaged	[299].	Since	SB10	
treatment	was	safe	and	well	tolerated,	its	pharmacologic	activity	was	further	evaluated	
in	 asthmatic	 patients.	 Patients	with	mild	 asthma	 received	10	mg	SB10	or	placebo	 via	
inhalation	 for	 28	 days	 and	 an	 allergen	 challenge	 after	 the	 28	 days	 treatment.	 Results	
showed	 that	 SB010	 treatment	 improved	 the	 lung	 function	 and	 attenuated	 allergen	
induced	EAR	and	LAR	as	measured	by	FEV1.	SB010	treatment	also	resulted	in	reduced	
eosinophils	 in	 the	 sputum	 and	 lower	 IL-5	 plasma	 levels	 when	 compared	 to	 controls,	
indicating	 that	 SB010	 alleviated	 Th2-driven	 inflammatory	 responses	 and	 may	
consequently	 improve	 lung	 function	 [300].	 Despite	 promising	 results,	 clinical	 trials	
assessing	 the	 long-term	 safety	 and	 efficacy	 of	 SB010	 still	 need	 to	 be	 conducted	 in	 a	











on	 refining	 the	 formulation	of	potential	 small	molecules	and	biopharmaceutical	drugs	
for	oral	administration,	inhalation,	and	subcutaneous	injection.	
Oral	delivery	of	a	drug	 is	most	desirable	as	 it	can	greatly	 increase	patient	compliance,	
especially	 in	 chronic	diseases	which	 require	 frequent	 administration,	 such	 as	 asthma.	
Nanomedicine	 allows	 for	 small	 molecule	 drugs	 to	 be	 encapsulated	 in	 a	 polymer	
enhancing	 the	 drugs	 solubility	 and	 stability	 in	 the	 GI	 tract,	 ultimately	 increasing	
bioavailability	[301].	Only	a	few	orally	administered	anti-inflammatory	drugs	are	being	
developed	 using	 nanomedicine.	 For	 example,	 a	 nanoemulsion	 of	 vitamin	 D	
demonstrated	increased	bioavailability	and	attenuated	inflammatory	response	in	OVA-
induced	asthmatic	mice	when	administered	orally	[302].	A	nanoemulsion	of	curcurmin	
was	 evaluated	 in	 transgenic	 mice	 which	 a	 firefly	 luciferase	 reporter	 gene	 driven	 by	
NFκB	 responsive	 elements,	 and	 may	 serve	 as	 a	 potential	 therapy	 for	 inflammatory	
diseases	 through	 suppression	 of	 NFκB	 signaling	 pathway	 and	macrophage	migration	
[303].	However,	results	reported	in	these	two	studies	such	as	decreased	production	of	
IL-1β	 and	 TNF-α	 [302]	 and	 the	 reduction	 of	 peripheral	 macrophages	 [303]	 are	
insufficient	 to	 prove	 their	 clinical	 potential	 for	 asthma	 therapy.	 Additional	
investigations	are	needed	to	assess	therapeutic	effects	in	asthmatic	animal	models	such	
as	 the	 inhibition	 of	 the	 production	 of	 asthma	 related	 cytokines	 (e.g.	 IL-13,	 IL-5)	 in	
plasma	or	BALF,	improved	lung	function,	and	reduced	infiltration	of	leukocytes	in	BALF.	
Furthermore,	 the	 stability	 of	 the	 loaded	 drug	 and	 nanocarrier	 in	 the	 GI	 tract	 and	
potential	 systemic	 toxicity	 induced	 by	 drugs	 (e.g.	 β2-adrenoceptor	 agonists	 and	
glucocorticoids)	 or	 nanocarriers	 also	 need	 to	 be	 considered.	 Regarding	 the	 peroral	
delivery	of	biologics	in	nanomedicines,	we	can	learn	from	other	examples	where	efforts	
have	been	made	to	develop	an	oral	formulation.	Polyester	(poly(-ε-caprolactone)	and	a	
polycationic	 non-biodegradable	 acrylic	 polymer	 were	 used	 to	 encapsulate	 insulin	 for	
oral	 administrated	 to	 diabetic	 rats.	 Decreased	 glycemia	 was	 achieved	 by	 insulin	
nanoparticles	 indicating	the	potential	of	using	polymer	as	oral	administration	carriers	
for	proteins	[304].	Further	evaluation	need	to	be	performed	to	apply	biopharmaceutical	




be	 evaluated.	 In	 conclusion,	 oral	 formulation	 of	 nanomedicine	 still	 requires	 several	
steps	of	development	to	reach	the	clinic.	
Subcutaneous	 injections	 or	 intravenous	 infusions	 are	 the	 preferred	 means	 of	
administration	of	monoclonal	antibodies	in	asthma	therapy	because	they	are	degraded	
in	the	GI	and	generally	do	not	readily	cross	biological	barriers	such	as	cell	membranes.	
Compared	 with	 i.v.	 infusion,	 s.c.	 injection	 is	 a	 preferred	 route	 of	 administration	 for	





i.v.	 administration.	 To	 evaluate	 the	 potential	 of	 these	 formulations	 for	 applications	 in	
asthma	 therapy,	 more	 studies	 have	 to	 be	 undertaken	 including	 the	 assessment	 of	
efficacy	 in	 asthmatic	 animal	 model	 and	 pharmacokinetics	 compared	 with	 drug	 only.	
Since	 there	 is	 only	 a	 limited	 amount	 of	 s.c.	 formulations	 which	 are	 in	 development,	
nanomedicines	delivered	through	the	s.c.	route	will	most	probably	not	enter	the	clinic	
any	time	soon.	
The	 most	 common	 route	 of	 administration	 for	 nanomedicines	 in	 pre-clinical	
development	 for	 asthma	 therapy	 is	 inhalation.	 Inhalation	 is	 a	 non-invasive	 route	 and	
therefore	 is	 thought	 to	 have	 better	 patient	 compliance.	 Additionally,	 pulmonary	
inhalation	 has	 the	 advantage	 of	 delivering	 the	 drug	 directly	 to	 the	 diseased	 organ,	 of	
delivering	 the	drug	 to	a	 large	absorption	surface	area,	and	 the	advantage	of	generally	
lower	 dose	 requirements.	 So	 this	 route	 can	 consequently	 increase	 bioavailability	 and	
reduce	the	possibility	of	systemic	toxicity.	Small	molecule	drugs	can	be	encapsulated	in	
polymers	 [309-311]	 or	 liposomes	 [312]	 to	 achieve	 increased	 solubility	 and	 sustained	
release	 after	 pulmonary	 administration.	 For	 example,	 a	 commercially	 available	
corticosteroid,	budesonide	has	been	encapsulated	in	porous	poly(lactic-co-glycolic	acid)	
(PLGA),	a	biodegradable	polymer	approved	by	the	FDA	for	its	use	in	the	clinic,	and	was	
evaluated	 in	 a	 murine	 asthma	 model.	 Encapsulated	 budesonide	 provided	 sustained	
release	for	24	h	as	observed	in	vitro.	 In	the	murine	model,	an	aerosol	of	encapsulated	




free	 budesonide	 [309].	 To	 achieve	 a	 long	 lasting	 effect,	 a	 β2-	 adrenoceptor	 agonist,	
salbutamol	sulfate,	has	also	been	formulated	using	nanomedicine.	Specifically	the	drug	
was	 incorporated	 into	 artificial	 lipid	 vesicles,	 termed	 liposomes.	 When	 administered	
(i.t.)	 to	healthy	 rats,	 the	 aerosol	 of	 salbutamol	 sulfate	 loaded	 liposomes	 increased	 the	
half-life	 of	 salbutamol	 when	 compared	 to	 free	 drug.	 Additionally,	 larger	 AUC	 of	
salbutamol	 sulfate	 in	 the	 lung	 and	 plasma	 were	 observed	 compared	 with	 free	
salbutamol	sulfate,	indicating	that	liposome	encapsulation	achieved	sustained	release	of	
the	drug.	Salbutamol	sulfate	loaded	liposomes	increased	the	time	of	bronchodilation	in	
an	 asthmatic	 guinea	 pig	 model	 when	 compared	 to	 free	 drug,	 confirming	 that	 the	
liposome	suspension	could	provide	a	longer	lasting	therapeutic	effect	[312].		
Currently,	 a	 limited	 number	 of	 biopharmaceutical	 drugs	 have	 been	 formulated	 using	
nanomedicine	 for	 the	 treatment	of	 asthma.	One	example	 is	 IFN-γ-plasmid	DNA	which	
was	 encapsulated	 in	 chitosan	 and	 administered	 (i.n.)	 to	 asthmatic	 mice.	 Chitosan	
encapsulated	 IFN-γ-plasmid	 DNA	 attenuated	 AHR,	 and	 reduced	 the	 infiltration	 of	
eosinophils.	Additionally,	the	levels	of	IL-4	and	IL-5	in	BALF	as	well	as	the	infiltration	of	
leukocytes	 in	 the	 airway	 were	 decreased	 [313].	 However,	 pulmonary	 delivery	 of	
biopharmaceutical	drugs	such	as	siRNA	and	proteins	has	been	extensively	studied	 for	
diseases	 other	 than	 asthma.	 For	 example,	 inhalation	 of	 nebulized	 insulin	 loaded-
liposomes	 can	 continuously	 reduce	 blood	 glucose	 up	 to	 6	 h,	 while	 inhalation	 of	
nebulized	 insulin	 with	 empty	 liposomes	 decreased	 blood	 glucose	 temporarily	 which,	




A	 pMDI	 is	 a	widely	 used	 and	 inexpensive	 device,	 however,	many	 therapeutics	 do	 not	
readily	dissolve	in	the	hydrofluoroalkane	(HFA)	propellants	compatible	with	pMDIs.	To	
administer	nanomedicines	using	a	pMDI,	the	properties	of	the	nanomedicine	including	
physical	 stability	 in	 the	 pMDI	 formulation	 (e.g.	 aggregation)	 need	 to	 be	 carefully	
evaluated.	As	an	example,	Conti	et	al.	reported	in	2014	that	poly	amidoamine	dendrimer	
(PAMAM)/siRNA	 nanoparticles	 efficiently	 knocked	 down	 enhanced	 green	 fluorescent	






HFA,	 and	 no	 large/irreversible	 aggregation	 was	 observed	 within	 5	 h,	 suggesting	 the	
nanoparticles	 were	 stable	 in	 this	 pMDI	 formulation.	 The	 pMDI	 formulation	 was	
characterized	 by	 an	 eight-stage	 Andersen	 Cascade	 Impactor.	 Results	 showed	 that	 the	
aerosol	contained	a	respirable	fraction	and	fine	particle	fraction	of	approximately	77%	
and	 50%,	 respectively,	 similar	 to	 commercially	 available	 pMDI’s.	 Taken	 together,	 the	
authors	concluded	 that	 the	nanoparticles	demonstrated	high	potential	 to	be	used	 in	a	
clinical	setting	as	a	pMDI	[318].		
A	 nebulizer	 is	 an	 inhalation	 device	 that	 requires	 less	 coordination	 of	 the	 patient,	
compared	with	pMDIs	and	DPIs,	 and	 therefore	 it	 is	 suitable	 for	pediatric,	 elderly,	 and	
unconscious	patients.	Nebulization	is	suitable	for	nanomedicines	that	are	water	soluble.	





[319]	 or	 ultrasonic	 nebulizers	 [317].	 For	 example,	 plasmid	 DNA	 (15-20	 kb)	 is	 easily	
degraded	during	aerosol	production	because	of	the	shear	effects	[320].	The	degradation	
of	plasmid	DNA	can	be	prevented	by	both	PEI	[321-323]	and	liposomes	[324].	Another	
consideration	when	 formulating	 a	 nanomedicine	 for	 nebulizers	 is	 the	 large	 air-liquid	
interface	 created	 during	 nebulization,	 which	 may	 induce	 protein	 unfolding	 and	
aggregation	 [325].	 Many	 nanomedicine	 formulations	 tend	 to	 aggregate	 during	
nebulization	[326,	327]	due	to	the	concentration	of	nanoparticles	 in	 jet	and	ultrasonic	
nebulizers	 [327].	 For	 example,	 Ewe	 et	 al.	 reported	 in	 2014	 that	 lipopolyplexes	
formulated	 from	 liposome-PEI	 loaded	 with	 pDNA	 or	 siRNA	 can	 mediate	 efficient	
transfection	 in	 SKOV-3	 and	 in	 a	 luciferase	 expressing	 SKOV-3	 cell	 line	 (SKOV-3-LUC).	
The	size	of	pDNA	and	siRNA	lipopolyplexes	after	nebulization	was	generally	larger	than	
prior	 to	 nebulization,	 suggesting	 that	 aggregation	 occurred.	 However,	 the	 apparent	
aggregation	 did	 not	 decrease	 the	 transfection	 efficiency	 of	 lipopolyplexes.	 In	 fact,	 the	
transfection	efficiency	of	pDNA	lipopolyplexes	right	after	nebulization	or	when	stored	at	
4°C	 for	 1	 day	 after	 nebulization	 was	 enhanced	 compared	 with	 to	 the	 corresponding	
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pDNA	 lipopolyplexes	which	were	 not	 nebulized.	 This	 effect	 can	 be	 understood	 as	 the	
result	of	accelerated	sedimentation	of	 larger	particles	in	cell	culture.	In	vivo,	however,	




is	 used.	 The	 dry	 powder	 formulation	 demonstrates	 better	 chemical	 stability	 than	 the	
liquid	formulation	[317].	Several	key	considerations	should	be	made	when	formulating	
nanomedicines	 for	DPIs	 including	 the	stability	of	 the	drug	and	nanocarrier	during	 the	
production	 of	 the	 dry	 powder.	 Spray	 drying	 is	 a	 common	 method	 used	 to	 produce	
inhalable	 dry	 powders	 of	 drugs	 formulated	 with	 polymers	 (e.g.	 PLGA	 [329,	 330],	
chitosan	 [331,	 332],	 and	 polymer-lipid	 [333]).	 However,	 during	 the	 spray	 drying	
process,	droplets	of	the	formulation	are	rapidly	dried	by	a	hot	gas,	and	therefore	the	use	
of	 thermolabile	 drugs	 or	 thermo-sensitive	 polymers	 is	 limited.	 Spray	 freeze	 drying	
[334]	 or	 freeze	 drying	 followed	 by	 milling	 [334]	 may	 be	 a	 better	 choice	 for	 heat	
sensitive	 drugs,	 particularly	 proteins.	 Aqueous	 solubility,	 yield,	 and	 size	 change	 of	
reconstituted	 nanoparticles	must	 also	 be	 carefully	 assessed.	 Specifically	 for	 the	 lung,	
deposition	of	 inhaled	dry	powder	highly	depends	on	 its	 size	with	particles	 of	 1-5	µm	
needed	to	achieve	deep	lung	deposition.	It	is	also	important	to	assess	the	nanomedicine	
particle	size	once	it	is	reconstituted	in	an	aqueous	environment	(e.g.	lung	tissue).	Once	
delivered	 to	 the	 aqueous	 environment	 of	 the	 target	 tissue,	 the	 nanomedicine	 must	
maintain	 small	 size	 to	 penetrate	 through	 the	 mucus	 layer	 and	 be	 taken	 up	 by	 cells.	
Spray	dried	and	spray	freeze	dried	formulations	of	drugs	(e.g.	levofloxacin)	loaded	into	
polymer	 (e.g.	 PLGA)	 or	 lipid-polymer	 (lecithin-PLGA)	 have	 been	 characterized	 for	
pulmonary	 drug	 delivery.	 Spray	 freeze	 dried	 formulations	 of	 nanomedicines	 achieve	
better	aerosol	properties	including	approximately	26%	fine	particle	fraction	and	5.8	µm	
mass	 median	 aerodynamic	 diameters	 compared	 with	 spray	 dried	 formulations.	 To	
ensure	the	desired	particle	size	in	the	aerosol	requires	optimization	of	the	formulation	
methodology	 by	 carefully	 controlling	 the	 ratio	 of	 lipid,	 polymer,	 and	 excipients.	
However,	 following	optimization,	 the	production	yield	was	relatively	 low,	33%	(w/w)	
making	 further	 optimization	 necessary.	 In	 addition,	 reconstitution	 of	 nanoparticles	
 
 106	










discovery.	 Several	 animal	 models	 of	 asthma	 are	 currently	 used	 including	 mice,	 rats,	






Mouse	 models	 of	 asthma	 have	 several	 advantages	 including	 cost	 effectiveness,	
availability	of	several	transgenic	strains,	and	a	large	number	of	commercially	available	
mouse	 specific	 probes	 and	 tools.	 Because	 mice	 do	 not	 naturally	 develop	 asthma,	
allergens	 including	 ovalbumin	 (OVA)	 and	 house	 dust	 mite	 (HDM)	 extract	 have	 been	
used	to	artificially	induce	airway	inflammation.	In	both	models,	mice	are	first	sensitized	
by	 several	 injections	 (i.p.)	 of	 an	 allergen	 with	 or	 without	 adjuvant.	 Following	
sensitization	 (2-5	 weeks	 later),	 mice	 are	 exposed	 to	 the	 inhaled	 allergen	 which	
produces	 an	 inflammation	 response	 and	 AHR.	 For	 example,	 to	 test	 the	 therapeutic	
effects	of	GATA-3	specific	DNAzyme,	SB010,	of	which	phase	II	clinical	trials	have	been	
completed	 [300],	 Sel	 et	 al.	 established	 a	murine	 asthma	model	with	 the	 allergen	OVA	







36,	 animals	 received	 a	 4	 days	 i.n.	 treatment	 of	 GATA-3	 DNAzyme	 (Days	 35-38).	 The	
efficacy	 of	 DNAzyme	 was	 assessed	 on	 days	 39	 and	 40.	 Treatment	 with	 GATA-3	
DNAzyme	 relieved	 AHR,	 decreased	 mucus	 hypersecretion,	 and	 reduced	 the	 influx	 of	
eosinophils	[295].	This	short	term	(4-6	weeks)	mouse	model	has	been	widely	used	and	
demonstrates	 high	 reproducibility.	 However,	 asthma	 in	 humans	 is	 a	 chronic	 airway	
inflammatory	disease,	and	many	patients	show	airway	remodeling	such	as	goblet	cells	
hyperplasia,	 fibroblasts	of	smooth	muscles,	and	long	term	AHR	which	is	absent	 in	this	
acute	 allergic	 inflammation	 model.	 To	 address	 this,	 a	 model	 of	 chronic	 airway	
inflammation	 has	 been	 developed	 in	mice.	 This	 chronic	model	 is	 similar	 to	 the	 acute	
mouse	 asthma	model	with	 the	 exception	 that	 the	 challenge	 phase	 is	 extended.	 In	 the	
same	study,	Sel	et	al.	established	a	chronic	murine	asthma	model	to	further	investigate	
the	 efficacy	 of	 GATA-3	 DNAzyme.	 Mice	 were	 sensitized	 by	 three	 i.p	 injection	 of	
OVA/Al(OH)3	 on	 day	 0,	 day	 14	 and	 day	 21.	 Sensitized	 mice	 were	 challenged	 on	 2	
consecutive	days	each	week	 for	a	 total	14	weeks	(5th-	15th	week	and	19th-	21st	week).	
This	 chronic	 asthma	 model	 more	 closely	 approximated	 human	 asthma	 indicated	 by	
eosinophil	influx,	AHR,	goblet	cells	hyperplasia,	mucus	hypersecretion	and	subepithelial	
collagen	 deposition	 [295].	 However,	 there	 are	 still	 some	 limitations	 to	 this	 chronic	








Rat	 asthma	 models	 are	 also	 commonly	 used	 in	 asthma	 studies.	 The	 rat	 models	 of	
asthma,	 like	 the	 mouse	 models,	 are	 cheap	 and	 have	 many	 commercially	 available	
biological	probes.	In	the	rat	asthma	models,	AHR	and	LAR	can	be	induced	by	controlled	




[339-341]	 and	 HDM	 extracts	 [342].	 To	 establish	 the	 asthma	 models,	 rats	 are	 often	
sensitized	 by	 systemic	 injection	 of	 allergen	 with	 one	 (Al(OH)3)	 or	 two	 adjuvants	
(Al(OH)3	 &	 heat-killed	 Bordetella	 pertussis	 bacilli)	 followed	 by	 challenge	 of	 inhaled	
allergen	 aerosol	 or	 intratracheal	 (i.t)	 instillation	 of	 allergen.	 A	 rat	 asthma	model	was	
established	 for	 testing	 the	 preclinical	 profile	 of	 ciclesonide.	 To	 this	 extent,	 Brown	
Norway	(BN)	rats,	a	strain	of	rat	commonly	used	for	allergic	models,	were	sensitized	by	
i.p.	 injection	of	 suspension	of	100	μg	OVA/100	mg	Al(OH)3	 on	days	0,	 12	 and	21	and	
challenged	with	inhalation	of	1%	OVA	for	30	min	daily	for	4	consecutive	days	on	days	
27-30.	Meanwhile,	 ciclesonide	and	control	drug	 fluticasone	were	administrated	via	 i.t.	
instillation	 1	 h	 and	 24	 h	 before	 each	 challenge.	 Rats	 were	 sacrificed	 24	 h	 after	 final	











pig	 asthma	models	 demonstrated	well	 defined	 EAR	 and	 LAR	 after	 allergen	 challenge	
[344].	The	pharmacology	and	anatomy	 in	 the	guinea	pig	model	 is	more	similar	 to	 the	
conditions	 in	 humans	 as	 compared	 to	 rats	 and	mice	 and	 can	 be	 used	 as	 a	model	 for	
certain	subtypes	of	asthma	such	as	the	cough	variant	asthma	[345].	An	acute	guinea	pig	
model	of	asthma	has	been	reported	where	Dunkin-Hartley	guinea-pigs	were	sensitized	






0.1%	 OVA	 aerosol	 once	 every	 two	 days.	 To	 prevent	 fatal	 anaphylaxis,	 all	 additional	
challenges	but	 the	 last	one	was	under	mepyramine	cover	 (30	mg/kg,	 i.p).	Fluticasone	
propionate,	 roflumilast	 and	 GW274150,	 an	 inducible	 nitric	 oxide	 synthase	 (iNOS)	
inhibitor	have	been	tested	in	clinical	trials	for	patients	with	mild	asthma,	and	were	pre-
clinically	 tested	 in	 both	 aforementioned	 guinea	 pig	 models.	 The	 drugs	 were	
administrated	 three	 times	at	24	h	and	30	min	before	and	6	h	after	 the	 final	challenge	
either	by	aerosol	(Fluticasone,	0.51	mg/ml)	or	orally	(roflumilast,	1	mg/kg;	GW274150,	
5	 mg/kg	 as	 the	 phosphate).	 EAR,	 LAR,	 AHR,	 and	 influx	 of	 inflammatory	 cells	 were	
observed	in	both	models.	There	was	no	airway	remodeling	observed	in	the	acute	model	
compared	 with	 the	 saline	 challenged	 group,	 but	 in	 the	 chronic	 model	 such	 airway	
remodeling	 was	 observed	 including	 increased	 thickness	 of	 airway	 walls,	 bronchiolar	





Lager	animal	 asthma	models	have	been	developed	 in	dogs,	 sheep	and	monkeys.	They	
are	not	as	popular	as	rodent	models	because	the	costs	are	much	higher.	However,	it	is	




mechanism	 of	 asthma	 as	 well	 as	 the	 pharmacological	 response	 of	 new	 therapeutic	
reagents.	 There	 are	 three	 ways	 to	 establish	 dog	 asthma	 models:	 allergen	 challenge,	
hyperventilation-induced	 and	 ozone-induced	 asthma.	 Dogs	 naturally	 sensitized	 to	
Ascaris	 suum	 [348]	 can	 be	 challenged	 by	 inhalation	 of	 an	 A.	 suum	 extract	 aerosol.	
Asthmatic	response	can	be	induced	in	dogs	that	are	neonatally	sensitized	to	ragweed	by	
the	inhaled	antigen.	Becker	et	al.		described	a	ragweed	sensitized	dog	model	of	asthma	





inhalation	 of	 short	 ragweed	 (antigen	 E	 content	 120	 U/ml),	 all	 sensitized	 dogs	
demonstrated	EAR	and	some	individual	developed	LAR.	Furthermore,	AHR	in	sensitized	
dogs	was	 determined	 by	 non-allergic	 airway	 response	 to	 inhaled	 acetylcholine	 [349].	
The	 efficacy	 of	 GS-5759,	 a	 phosphodiesterase	 4	 (PDE4)	 inhibitor	with	 long-acting	 β2-




to	 decrease	 the	 allergen	 induced	 pulmonary	 resistance	 compared	 with	 indacaterol,	
which	is	in	line	with	the	results	in	different	animal	asthma	models	including	guinea	pig,	
monkey	 and	 rat	 [350].	 Ozone	 induced	 bronchoconstriction,	 airway	 inflammation	 and	
AHR	 in	dogs	was	used	 to	study	 the	 therapeutic	effect	of	MK-0591,	an	antagonist	of	5-
lipoxygenase-activating	 protein	 (FLAP),	 namely	 the	 inhibitor	 of	 biosynthesis	 of	
leukotrienes	 (LT).	 MK-0591	 (2mg/kg)	 was	 administrated	 intravenously	 to	 dogs	 and	
drug	 blood	 concentration	 was	 maintained	 by	 infusion	 of	 8	 μg/kg*min	 of	 MK-0591	
throughout	the	whole	experiment.	Ozone	was	delivered	through	the	endotracheal	tube	
at	 a	 concentration	 of	 3	 ppm	 for	 30	 min	 to	 establish	 airway	 inflammation.	 MK-0591	
treatment	 remarkably	 inhibited	 the	production	of	 LTB4	 in	 blood	 and	 in	BALF	 cells	 as	
well	as	the	production	of	LTE4	in	urine.	However,	there	was	no	effect	on	ozone	induced	
AHR,	bronchoconstriction	and	 influx	of	neutrophils	 in	 the	airway	 [351].	This	 result	 in	
the	dog	asthma	model	in	fact	predicts	the	result	in	a	preclinical	evaluation	of	MK-0591	
in	 patients	 with	 mild	 asthma.	 Orally	 administration	 of	 MK-0591	 for	 three	 times	 in	
asthmatic	patients	before	allergen	challenge	can	inhibit	LTB4	biosynthesis	in	blood	and	
urinary	LTE4	excretion.	Furthermore,	EAR	and	LAR	determined	by	change	of	FEV1	were	
alleviated	 by	 MK-0591	 treatment	 but	 not	 AHR	 measured	 by	 inhalation	 of	 histamine	
[352].	 Reversible	 bronchoconstriction	 in	 patients	 with	 asthma	 can	 be	 induced	 by	
exercise	and	inhaled	cold	air,	and	this	process	can	be	mimicked	by	the	hyperventilation	
induced	 dog	 asthma	 model.	 Anesthetized	 dogs	 were	 intubated	 endotracheally	 and	






Sheep	 are	 cheaper	 to	 purchase,	 maintain	 and	 handle	 compared	 with	 dogs	 and	 non-
human	primates.	Furthermore,	 there	are	many	similarities	between	 the	 lung	of	 sheep	
and	 humans,	 and	 sheep	 can	 be	 naturally	 sensitized	 by	 Ascaris	 suum.	 These	
characteristics	make	 sheep	 asthma	models	 the	most	 popular	 large	 animal	models	 for	
asthma.	As	an	example,	Abraham	et	al.	selected	sheep	that	were	naturally	sensitized	to	
A.	 suum	 and	 can	 develop	 EAR	 and	 LAR	 upon	 inhalation	 of	 A.	 suum	 to	 establish	
experimental	asthma.	Sheep	were	challenged	by	inhaled	A.	suum	extract	aerosol	(82,000	
protein	 nitrogen	 unit/	 ml)	 at	 20	 breaths/	 min	 for	 20	 min.	 EAR	 and	 LAR	 were	
determined	 by	 specific	 lung	 resistance	 (SRL),	 AHR	 existed	 for	 9	 days	 after	 antigen-
challenge	 and	 an	 increased	 influx	 of	 inflammatory	 cells	 was	 observed	 in	 BALF	 and	
bronchial	 biopsies.	 The	 anti-inflammation	 effect	 of	 multiple	 doses,	 a	 single	 dose	 and	
different	 concentrations	 and	 formulations	 of	 BIO-1211,	 a	 small	 molecule	 inhibitor	 of	
integrin	 α4β1	 also	 known	 as	 very	 late	 antigen-4	 (VLA-4),	 were	 tested	 in	 this	 model	
[355].	 An	 experimental	 sheep	 asthma	model	 where	 the	 animals	 were	 sensitized	 and	
challenged	by	HDM,	a	relevant	human	allergen,	was	developed	by	Bischof	et	al.	 [356].	
Sheep	were	 immunized	 subcutaneously	with	 a	 1	ml	 suspension	 of	 50	 μg	HDM	mixed	
with	50	μg	Al(OH)3	on	days	0,	14	and	28.	On	day	42,	tracheal	instillation	of	5	ml	HDM	
solution	(0.2	mg/	ml)	was	guided	by	a	 flexible	 fiber-optic	bronchoscope	deep	 into	the	
left	caudal	 lung	 lobe.	For	comparison,	saline	was	 instilled	 into	right	caudal	 lung.	HDM	
specific	antibodies	IgE,	IgG1	and	IgG2	were	increased	on	7	days	post-third	immunization	
and	increased	eosinophil	cell	counts	were	observed	in	peripheral	blood	and	BALF	48	h	
after	 HDM	 challenge	 in	 allergic	 sheep.	 In	 addition,	 infiltration	 of	 lymphocytes	 and	
eosinophil	 into	 the	peribronchial	 region	was	shown	 in	haematoxylin	and	eosin	 (H&E)	
stained	lung	tissue	[356].	A	sheep	model	of	chronic	asthma	was	developed	based	on	this	
protocol	by	the	same	group	in	which	sheep	were	challenged	twice	a	week	for	the	first	3	
months	 and	 once	 weekly	 for	 another	 3	 months.	 Airway	 remodeling,	 including	
hyperplasia	of	goblet	 cells	and	 increased	collagen	deposition	and	 thickness	of	 smooth	
muscle,	 were	 observed,	 however,	 the	 total	 time	 frame	 of	 approximately	 7	 month	 to	
establish	 this	 model	 is	 very	 long	 and	 time	 consuming	 [357].	 Van	 der	 Velden	 et	 al.	
investigated	the	effect	of	senicapoc	(ICA-17073),	an	inhibitor	of	the	KCa3.1	ion-channel	




Two	weeks	 after	 the	 final	 immunization,	 sheep	were	 challenged	with	 nebulized	HDM	
solution	(1	mg/ml)	at	20	breaths/min	for	10	min	once	every	two	weeks	for	14	weeks.	
Allergic	 sheep	received	orally	30	mg/kg	senicapoc	 twice	daily	 from	7	days	before	 the	
first	challenge	and	throughout	the	14-weeks	challenge	phase.	The	lung	resistance	RL	in	
allergic	 sheep	 was	 increased,	 EAR	 was	 observed	 but	 not	 LAR.	 However,	 increased	
collagen	 production	 and	 airway	 smooth	muscles	 remodeling	 were	 not	 shown	 in	 this	
model,	 but	 hyperplasia	 of	 goblet	 cells	 and	 increased	 density	 of	 blood	 vessels	 in	 the	
airway	 wall	 were	 observed.	 Senicapoc	 treatment	 maintained	 normal	 RL,	 reduced	 the	





marker,	however,	 it	did	not	achieve	 improved	 lung	 function	 [359].	An	HDM	challenge	
protocol	to	establish	a	sheep	asthma	model	is	more	standardized	compared	with	the	A.	
suum	challenged	protocol.	The	HDM	challenge	sheep	model	of	chronic	asthma	could	be	






the	medication	on	 the	condition	of	 the	human	body.	Besides	possible	side	effects	 that	
nanomedicines	 can	 induce,	 it	 is	 also	 important	 to	 monitor	 any	 changes	 they	 can	
provoke,	 e.g.	 in	 pH	 or	 temperature,	 as	 those	might	 decrease	 the	 valuable	 therapeutic	
effects	by	altering	the	drug	characteristics.	As	the	success	of	nanotherapy	in	asthmatic	
lungs	hinges	on	several	factors,	such	as	administration	route	and	characteristics	of	the	
particles,	 but	 also	 physiological	 aspects	 of	 the	 diseased	 organ,	 it	 is	 crucial	 to	 have	 an	




target	 organ	 as	 well	 as	 other	 parts	 of	 the	 body,	 different	 imaging	 techniques	 can	 be	
applied.	Previous	investigations	focusing	on	nanoparticles	as	contrast	enhancers	[360],	
intracellular	trafficking	of	nanocarriers	[361],	real-time	monitoring	of	pharmacokinetics	




Although	 the	 utilization	 of	 nano-scaled	 medications	 entails	 numerous	 advantages,	
including	 new	 material	 properties,	 an	 increased	 surface	 capability	 due	 to	 enlarged	
surface-volume	ratio,	a	shorter	 transport	 time,	 the	potential	of	selective	 targeting	and	
the	 minimized	 exposure	 of	 healthy	 tissue	 to	 the	 incorporated	 drug	 [364],	 the	





the	 conditions	 of	 an	 actual	 patient,	 it	 is	 crucial	 to	 reduce	 the	 risk	 of	 toxic	 effects	 and	
possible	adverse	reaction	as	much	as	possible	beforehand.		
Several	 assays	 to	ascertain	 the	 toxicity	of	nano-based	drug	 formulations	have	already	
been	established	and	can	employ	different	cellular	targets,	like	mitochondria,	lysosomal	
activity,	 cell	 membrane	 integrity	 or	 DNA	 ladder	 assays	 to	 determine	 cell	 death	
mechanisms.	 The	 standard	 testing	 method	 for	 cell	 viability	 after	 treatment	 with	
nanomaterials	 in	 a	 great	 range	 of	 cell	 lines	 is	 the	 colorimetric	 MTT	 (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium	bromide)	assay.	Other	tests	resting	upon	
the	 principle	 of	 the	 metabolic	 activity	 of	 mitochondria	 involve	 tetrazolium	 salts	 or	
resazurin.	 To	 improve	 statistical	 validity	 and	 minimize	 the	 error	 chance,	 it	 is	
recommended	 to	 combine	 multiple	 experiments.	 For	 example,	 the	 simultaneous	
performance	of	MTT	and	resazurin	assay	can	be	rational,	as	they	both	utilize	a	similar	
principle	 of	 testing.	 [365]	 Studies	 revolving	 around	 the	 specific	 disease	 instances	 of	
asthmatic	 lungs	 should	 take	 into	 consideration	 the	 correspondent	 conditions,	 pre-
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eminently	 airway	 hyperresponsiveness,	 mucus	 hypersecretion	 and	 the	 influx	 of	
inflammatory	cells	as	well	as	their	cytokines.	[294]	In	order	to	detect	possible	immune-
related	 and	 inflammatory	 responses,	 variations	 in	 activation	 levels	 of	 cytokines,	 e.g.	
TNF-α,	interleukins	and	prostaglandin	should	be	monitored.		







their	 findings,	 nonbiodegradable	 substances	 such	 as	 carbon	 nanotubes,	 carbon	 black,	
fullerenes,	silica,	metals	and	metal	oxides	can	generate	inflammation	and/or	fibrosis	in	




Different	 studies	 in	 humans	 have	 been	 performed	 to	 investigate	 the	 deposition	 of	
inhaled	nanoparticles	in	healthy	and	diseased	lungs	[369,	370].	An	increased	pulmonary	
deposition	and	retention	in	constricted	airways	was	predicted	by	computational	models	
[371]	 and	demonstrated	 in	obstructive	 lung	disease	 [372]	 and	asthma	 [373]	patients.	





in	 either	 group,	 but	 an	 exposure	 of	 healthy	 individuals	 to	 a	 higher	 concentration	 of	
particles	 resulted	 in	 a	 decreased	 midexpiratory	 flow	 rate	 and	 carbon	 monoxide	
diffusing	capacity,	indicating	that	nanoparticles	may	influence	respiratory	function	and	






not	 detected	 outside	 the	 lungs	 in	 appreciable	 concentrations	 [370,	 375,	 376].	
Nevertheless,	 it	 remains	 uncertain	whether	 other	 nanoparticles	 behave	 similarly,	 and	
the	possibility	of	particles	influencing	the	vasculature	is	still	not	excluded.	Besides	that,	
all	 studies	used	 single	 inhalation	 exposure	protocols	 so	 that	 further	 investigations	on	
the	 repercussions	 of	 repeated	 exposure,	 stronger	 pulmonary	 accumulation	 and,	
therefore,	translocation	of	greater	particle	quantities	are	urgently	needed.	[367]	
In	a	recent	study,	it	was	examined	whether	intratracheal	instillation	studies	can	be	used	
for	 evaluating	 any	 harmful	 effects	 of	 inhaled	 nanoparticles.	 Therefore,	 rats	 were	
exposed	 to	 nanoparticles	 composed	 of	Nickel	 oxide	 and	 titanium	dioxide	 as	 high	 and	
low	toxicity	examples.	Among	others,	increases	in	neutrophils	in	BALF	(bronchoalveolar	
lavage	fluid)	and	concentration	of	cytokine-induced	neutrophil	chemoattractants	were	
compared	 after	 single	 intratracheal	 installations	 and	 inhalations	 over	 4	 weeks,	 and	




The	 lung	 and	 its	 large	 surface	 area	with	 a	 high	 vascularization	 as	well	 as	 a	 thin	 air-
blood-barrier,	on	the	one	hand,	displays	an	 ideal	 location	 for	 the	absorption	of	agents	
[31].	 On	 the	 other	 hand,	 several	 physicochemical	 and	 biological	 barriers	 await	 the	
nanotherapeutics	in	the	pulmonary	system,	making	it	essential	to	thoroughly	track	their	






Figure	 2.	 Lung-intrinsic	 barriers	 to	 efficient	 pulmonary	 siRNA	 delivery.	 Reprinted	 with	
permission	from	[20].		
	
The	most	 important	parameter	 influencing	 the	deposition	of	 particles	 in	 the	different	
areas	 of	 the	 lung	 is	 their	 size.	 Depending	 on	 that,	 three	 different	 mechanisms	 of	
allocation	are	possible:	impaction,	sedimentation	and	Brownian	diffusion.	Particles	with	
a	 mass	 median	 aerodynamic	 diameter	 (MMAD)	 greater	 than	 5	 µm	 pass	 through	 the	
oropharynx	 and	 upper	 respiratory	 passage	 with	 a	 higher	 pace,	 collide	 with	 the	
respiratory	 wall	 due	 to	 the	 centrifugal	 force,	 and	 are	 deposited	 in	 the	 mouth	 and	










motion	 is	 the	 prevalent	 mechanism	 in	 the	 lower	 alveolar	 sections.	 The	 molecules	
surrounding	 the	 aqueous	 lung	 surfactant	 underlie	 the	 Brownian	 motion	 itself	 and	
induce	a	 random	moving	of	 the	particles.	The	dissolution	of	 the	 therapeutic	agents	 in	
the	lung	surfactant,	depending	on	the	concentration	gradient,	influences	this	process	as	
well.	 Particles	with	 a	 size	 smaller	 than	1	µm	deposit	 in	 the	 alveolar	 region	or	 can	be	
exhaled.	 Therefore,	 sedimentation	 is	 the	 preferably	 achieved	 process	 for	 therapeutic	
nanosystems	 in	order	 for	 them	 to	 stay	 in	 the	bronchiolar	 area	 for	 a	 long	 time	and	 to	
result	 in	the	desired	effects.	In	addition	to	these	particle	and	target	surface	depending	
characteristics,		breathing	patterns,	the	holding	of	breaths	and	tidal	volume,	but	also	air	
velocity	 and	 humidity	 are	 factors	 influencing	 the	 deposition	 and	 hence	 need	 to	 be	
considered.	[378]	
The	inside	of	the	upper	airways	is	covered	with	a	film	of	mucus	that	is	responsible	for	
trapping	and	purging	 invading	particles.	Before	 those	 can	 reach	 lower	 sections	of	 the	
lung	through	coughing	or	swallowing,	they	are	often	cleared	by	mucociliary	movements.	
Consequentially,	nano-sized	drugs	should	be	able	to	cross	the	mucus	layer	and	reach	the	
sol	 that	 covers	 the	 stratum	 below	 the	 gel	 coat.	 [379]	 As	 PEG	 nanoparticles	 were	
repeatedly	shown	to	be	capable	of	permeating	across	mucus	[380-382],	PEGylation	is	a	
possible	 approach	 to	 avoid	 bronchial	 clearance	 of	 nanomedicines.	 In	 the	 alveolar	
regions,	 the	 alveolar	 lining	 consisting	 of	 various	 proteins	 and	 lipids.	 Additionally,	 the	
existing	tight	junctions	hamper	the	transport	of	molecules.	According	to	the	structure	of	
the	 nanomedicine,	 active	 transport	 or	 passive	 diffusion	 through	 those	 transporter	
proteins	 are	 possible.	 Larger	 particles	 are,	 furthermore,	 prone	 to	 be	 cleared	 through	
phagocytosis	by	alveolar	macrophages.	[383]		
Once	 arrived	 inside	 the	 peripheral	 lung,	 the	 particles	 have	 to	 dissolve,	 and	 the	
incorporated	 drug	 has	 to	 diffuse	 through	 the	 epithelial	 barrier	 in	 order	 to	 reach	 the	
blood.	There	are	still	some	deficiencies	in	the	exact	understanding	of	the	process	of	cell-
uptake	 and	 how	 the	 particles	 are	 transported	 and	 reach	 the	 systemic	 circulation.	
Despite	 the	 existence	 of	 in	 vitro	models	 for	 studying	 the	 uptake	 and	 permeation,	 the	





Since	 asthma	 is	 a	 disease	 presenting	 itself	 in	 a	 very	 heterogeneous	 range	 of	
manifestations,	it	is	of	particular	importance	to	define	criteria	both	for	categorizing	the	
severity	of	the	existing	condition	as	well	as	for	evaluating	the	success	of	any	treatments.	
According	to	 the	current	GINA	(Global	 Initiative	 for	Asthma)	Report,	 ‘asthma	severity’	
should	 be	 “assessed	 retrospectively	 from	 the	 level	 of	 treatment	 required	 to	 control	
symptoms	and	exacerbations”	[265].	This	severity	is	not	necessarily	a	constant	feature,	
but	 can	 change	over	 time,	 so	 that	 it	 can	only	be	evaluated	after	 a	patient	has	 already	
been	 experiencing	 a	 controlling	 treatment	 for	 several	 months.	 Subsequently,	 the	
patient’s	status	can	be	rated	as	mild,	moderate	or	severe	asthma.	The	latter	is	thereby	




of	 asthma	 have	 been	 reduced	 or	 removed	 by	 treatment”	 [265].	 Among	 the	 current	
clinical	situation	of	the	patient,	and	therefore	factors	such	as	symptoms,	lung	function,	
the	 use	 of	 reliever	 medication	 and	 night	 awakenings,	 this	 concept	 additionally	
comprises	the	patient’s	future	risk	of	exacerbations	and	decline	in	lung	function	as	well	
as	 treatment	 related	 side	 effects.	 According	 to	 the	 GINA	 Guidelines,	 asthma	 can	 be	
regarded	as	controlled	when	daytime	symptoms	occur	only	twice	per	week	or	less,	daily	
activities	 are	 not	 limited,	 the	 lung	 function	 is	 normal	 or	 near	 normal,	 there	 are	 no	
exacerbations	and	no	symptoms	at	night-time	and	the	reliever	medications	only	needs	
to	 be	 used	 twice	 per	 week	 or	 less.	 The	 obtained	 control	 level	 through	 therapy	
determines	 the	 necessity	 to	 go	 up	 or	 down	 to	 the	 adjacent	 treatment	 level	 in	 the	
stepped	 management	 approach	 for	 asthma	 therapy	 that	 both	 the	 respective	 US	 and	
European	 guidelines	 recommend.	 Patients	 whose	 disease	 symptoms	 can	 not	 be	
controlled	in	an	adequate	way	by	the	highest	stage	of	treatment,	which	means	a	reliever	







When	 choosing	 patients	 for	 clinical	 studies,	 it	 is	 important	 to	 use	 uniform	 clinical	
guidelines	to	diagnose	and	pre-define	the	disease	status	based	on	clinical	symptoms	and	
disease	history	of	the	patient	as	well	as	on	assessment	of	airflow	limitation.	To	examine	
this	 factor,	 the	 preferred	 approach	 is	 to	 perform	 spirometry	 under	 standardized	
conditions.	In	this	way,	both	the	FEV1	(forced	expiratory	volume	in	one	second)	and	the	
FCV	(forced	vital	capacity)	can	be	measured	to	conclude	on	the	patient’s	existing	airflow	
limitation	 and	 its	 variability.	 In	 case	 this	 data	 is	 difficult	 to	 generate,	 e.g.	 because	 the	
patient	is	treated	with	a	controller	medication,	the	PEF	(Peak	expiratory	flow)	can	also	
be	 ascertained.	 A	 determination	 of	 airway	 hyperresponsiveness	 can	 be	 of	 use	 for	
patients	who	show	clinical	symptoms,	but	possess	a	normal	lung	function.	[384]	
For	patients	who	already	receive	a	treatment	against	asthma,	it	is	especially	important	
to	assess	and	establish	 the	minimum	level	of	 treatment	necessary	 to	maintain	control	
over	 their	 symptoms	 and	 standardize	 this	 treatment	 as	much	 as	 possible	 in	 order	 to	
ensure	 an	 appropriate	 baseline	 to	 interpret	 subsequent	 results.	 An	 accurate	 and	
detailed	 profile	 of	 every	 patient	 has	 to	 be	 compiled,	 including	 characterization	 of	
attributes	such	as	lung	function,	day-	or	night-time	symptoms,	and	previous	history	of	
exacerbations,	 as	 well	 as	 a	 documentation	 of	 all	 co-morbidities	 and	 concomitant	
treatments.	 Concerning	 the	 treatment	 of	 asthma	 in	 co-morbid	 patients,	 particular	
attention	has	 to	be	drawn	to	Chronic	obstructive	pulmonary	disease	 (COPD),	as	 these	
two	conditions	indeed	have	different	pathways	of	causation,	but	can	still	coexist	in	one	
patient.	 Therefore,	 patients	who	 suffer	 from	 COPD	 can	 distort	 respective	 results	 and	
should	not	be	included	in	asthma	studies.	As	opposed	to	this,	smokers	are	able	to	take	
part	 in	 these,	 although	 their	 smoking	 history	 has	 to	 be	 accurately	 recorded	 and	 it	 is	
advisable	 to	conduct	a	subgroup	analysis	 to	discover	any	 influence	 the	smoking	could	
have	on	study	results.	Other	possible	classifications	for	relevant	sub-populations	would	
be	 frequency	 of	 exacerbations,	 sensitivity	 to	 NSAID,	 eosinophilia	 or	 co-sensitivity	 to	
other	 allergens.	 When	 investigating	 a	 specific	 immunotherapy,	 a	 documentation	 and	






lung	 function	 testing	 and,	 where	 applicable,	 diary	 cards	 or	 other	 relevant	 evaluation	
tools.	[384]	
The	high	incidence	of	asthma	in	children	leads	to	them	being	a	target	group	of	special	
interest	 in	 the	 respective	 research.	 For	 them,	 as	 well	 as	 for	 the	 older	 generation,	
particular	 attention	has	 to	be	drawn	 to	 the	 adequate	utilization	of	 inhalation	devices.	
Studies	 in	 children	 should	 be	 conducted	 in	 the	 early	 development	 process,	when	 the	
therapy	 holds	 promise	 to	 be	 a	major	 advance	 for	 the	 pediatric	 population,	 of	 course	
implying	 that	 appropriate	 safety	 data	 are	 available.	 More	 detailed	 advice	 regarding	
studies	 for	 these	 special	 patient	 groups	 can	 be	 found	 in	 the	 respective	 ICH	
(International	 Council	 for	 Harmonization	 of	 Technical	 Requirements	 for	






For	 characterizing	 the	 effect	 of	 therapies	 on	 the	 lung	 function,	 the	 previously	
mentioned	FEV1	 and	PEF	 are	 suitable	 to	 detect	 and	 evaluate	 any	 airway	obstruction.	
The	 most	 accurate	 factor	 represents	 the	 pre-bronchodilator	 FEV1,	 being	 influenced	
even	 by	 short-term	 fluctuations.	 Nevertheless,	 it	 rather	 poorly	 correlates	 with	 the	
symptoms	the	patient	experiences.	To	achieve	a	more	relevant	portraiture	of	the	actual	




In	achieving	asthma	control,	 the	avoidance	of	exacerbations	 is	a	crucial	 factor,	which	
makes	it	a	relevant	endpoint	to	evaluate	controller	treatments	in	patients.	According	to	





of	 corticosteroids	 for	 at	 least	 three	 days	 and/or	 a	 need	 for	 an	 emergency	 visit,	 or	
hospitalization	 due	 to	 asthma”	 [384].	 Moderate	 exacerbations,	 however,	 arouse	 the	
need	for	a	change	in	treatment	in	order	to	prevent	a	deterioration	of	asthma	symptoms	
and,	 therefore,	 the	occurrence	of	 severe	 exacerbations.	 In	 order	 to	 really	 capture	 any	
changes	 in	 the	 number	 of	 exacerbation	 events	 in	 an	 appropriate	 way,	 the	 EMA	




that	 has	 hardly	 any	 influence	 on	 healthy	 persons.	 Therefore,	 direct	 factors	 such	 as	
histamine	 or	 indirect	 ones	 such	 as	 mannitol	 or	 hypertonic	 saline	 can	 be	 applied.	




number	 of	 night-awakening	 should	 be	 utilized.	 Besides	 that,	 there	 are	 special	
composite	 scores	 with	 categorical	 or	 numerical	 variables	 available	 for	 the	




reliever	use	as	 this	correlates	with	 the	 frequency	and	 intensity	of	 the	symptoms	and	
their	 tolerance,	 when	 being	 separated	 from	 the	 prophylactic	 use.	 Likewise,	 the	
reduction	 of	 controller	 medication	 can	 provide	 information	 about	 the	 therapy’s	
influence	on	the	patient.	
The	 underlying	 airway	 inflammation	 can	 be	 determined	 by	 measuring	 certain	
biomarkers,	 such	 as	 eosinophil	 counts	 and	 fractional	 concentration	 of	 exhaled	 nitric	
oxide	(FENO).	








Before	 starting	 the	 clinical	 study,	 answers	 for	 the	 following	questions	need	be	 found:	
How	 does	 the	 new	 therapy	 relate	 to	 current	 treatments?	 Is	 it	 a	 primary	 or	 add	 on	
therapy?	 Is	 it	 a	 reliever	 or	 controller	 treatment?	What	 is	 the	 intended	mechanism	 of	
action?	 Specific	 immunotherapies	 don’t	 belong	 to	 neither	 reliever	 nor	 controller	
medications	and	therefore	have	to	be	evaluated	in	an	individual	way.	
The	 guideline	 ICH	 E-4	 Dose	 Response	 Information	 to	 Support	 Drug	 Registration	
recommends	 to	 examine	 the	 dose	 related	 benefit	 and	 adverse	 effects	 of	 new	
pharmaceutical	products	in	randomized,	double	blind,	placebo	controlled	studies	[339].	
While	 cumulative	 dose	 response	 studies	 with	 FEV1	 or	 PEF	 as	 pharmacodynamic	
endpoints	 are	 applicable	 for	 β2	 adrenergic	 agonists,	 anti-inflammatory	 therapies	 are	
advised	to	be	tested	in	group	comparative	studies	parallel	to	a	control	group.	Both	types	
of	 treatment	can	also	be	 investigated	with	 the	bronchoprotection/bronchial	 reactivity	
model.	More	detailed	information	on	this	matter	can	be	found	in	the	CHMP	(Committee	
for	Medicinal	Products	for	Human	Use)	guideline	for	orally	inhaled	products	[388].	
The	duration	 of	 the	 trial	 is	 contingent	 on	both	 the	mechanism	of	 action	 of	 the	 tested	
drug	and	a	defined	efficacy	measurement.	6-12	week	studies	are	recommended	by	the	
EMA	for	long-acting	bronchodilators.	Short-acting	ones	can,	on	the	other	hand,	also	be	
acceptably	 examined	 in	 smaller	 periods	 of	 time.	 The	 exploration	 of	 an	 effect	 on	











Regarding	 comparator	 products,	 the	 preferential	 approach	 for	 reliever	 medication	
would	be	 a	 three-arm	study	 in	which	 the	new	product	 is	 compared	 to	 effects	of	 both	
placebo	and	a	short-acting	β2	agonist.	Medications	that	are	expected	to	be	utilized	as	a	
first-line	 controller	 therapy	 should	 be	 investigated	 in	 an	 active	 comparator	 trial	
comparing	 it	 with	 a	 standard	 treatment	 for	 a	 specific	 step	 in	 the	 treatment	 scheme.	
Typically,	 an	 inhalable	 corticosteroid	 is	 included	 in	 all	 steps,	which	 is	 supposed	 to	be	
administered	 in	 appropriate	doses	 and	durations.	 To	 guarantee	 assay	 sensitivity,	 it	 is	
generally	advisable	to	perform	a	three-arm	study	in	patients	with	milder	asthma	with	a	
placebo	 adjustment	 in	 at	 least	 one	 fundamental	 clinical	 trial.	 When	 inhaled	
corticosteroids	are	not	planned	to	substitute	the	new	medication,	add-on	study	designs	
are	 necessary,	 in	 which	 the	 drug	 being	 tested	 is	 compared	 to	 placebo	 and	 as	 the	
circumstances	require	also	a	standard	comparator	of	the	next	higher	treatment	scheme	
step.	
Since	 asthma	 is	 a	 disease	 that	 can	 lead	 to	 severe	 medical	 conditions,	 it	 is	 crucial	 to	
secure	 the	patients’	 safety	and	well-being	 in	each	 instance,	meaning	 that	 they	 receive	
appropriate	 treatment	 according	 to	 their	 severity	 level	 and	 that	 concomitant	 rescue	
therapy	always	has	to	be	available.	However,	this	proceeding	ought	to	be	standardized	
and	facilitated	as	much	as	possible	to	ensure	that	the	interpretation	of	generated	results	
is	 not	 distorted.	 Every	 concomitant	 treatment	 with	 bronchodilators,	 corticosteroids,	
antibiotics	 or	 mucolytic	 antioxidants	 has	 to	 be	 thoroughly	 documented	 and	 also	
balanced	between	different	trial	groups	in	order	to	establish	a	common	base.	[384]	
If	 applicable,	 it	 is	 advised	 to	 always	 carry	 out	 clinical	 trials	 for	 asthma	 in	 a	 double-
blinded	way.	When	this	can	not	be	achieved,	e.g.	 for	some	inhalable	products,	a	three-
arm	study	with	a	blinded	comparison	with	placebo	and	an	unblinded	comparison	with	
an	 active	 comparator	 is	 possible.	 Here,	 the	 respective	 personnel	 measuring	 and	
documenting	data	should	leastwise	be	left	unaware	of	the	received	treatment	option.	It	
is,	 anyhow,	 always	 preferable	 that	 the	most	 important	 results	 concerning	 safety	 and	
efficacy	are	collected	by	an	independent	adjusting	committee.		
When	 selecting	 suitable	 endpoints	 for	 asthma	 studies,	 it	 is	 essential	 to	 consider	 the	
diversity	 of	 this	 disease.	 Since	 it	 shows	 multiple	 manifestations	 that	 might	 not	 all	




new	medication	 (reliever	 or	 controller),	 its	 particular	 way	 of	 action	 and	 the	 asthma	
severity	 level.	 Whereas	 the	 examination	 should	 be	 concentrated	 on	 the	 airway	
construction	 and	 therefore	 FEV1	 assessments	 are	 suitable	 for	 reliever	 treatments,	
controller	 therapies	 are	 expected	 to	 control	 the	 asthma	 and	 diminish	 exacerbations.	
Hence,	studying	the	latter	has	to	include	both	lung	function	and	symptom	improvement	
as	 primary	 endpoints.	 For	 anti-inflammatory	 drugs,	 the	 focus	 particularly	 lies	 on	 the	
occurrence	of	exacerbations,	however,	in	patients	with	milder	asthma	this	might	not	be	
adequate	 enough	 and	 other	 symptom-based	 endpoints	 can	 be	 more	 suitable.	 Since	




the	 reduction	 in	 need	 for	 controller	 medication.	 Irrespective	 of	 the	 chosen	 primary	











studies	 of	 at	 least	 one	 year	 should	 be	 carried	 out,	 whereat	 the	 asthma	 severity	
determines	the	exact	 time	span	and	 intensity	of	 treatment.	Special	attention	has	to	be	
paid	 when	 investigating	 immunosuppressive	 therapies	 to	 detect	 any	 malignancy	
evoking	 effects.	 Concerning	 inhalable	 products,	 specific	 security	 issues	 such	 as	 oral	
infections,	 vocal	 cord	myopathy	or	 cataract	 formation	might	 be	necessary	 to	 address.	










be	 safe	 and	 effective	 before	 it	 can	 be	 approved	by	 the	 appropriate	 regulatory	 agency	
governing	 the	 respective	market.	 Apart	 from	 Japan,	 the	United	 States	 of	America	 and	
Europe	are	home	to	the	two	main	regulatory	agencies	 in	the	world.	The	United	States	
Food	and	Drug	Administration	(USFDA)	and	the	European	Medicines	Agency	(EMA)	set	
the	most	 demanding	 and	 stringent	 standards	 for	 approving	 new	medicinal	 products,	
bringing	 out	 legislations	 and	 guidelines	 for	 developing,	 testing,	 trialing	 and	
manufacturing	drugs	 [389].	Overall,	both	departments	base	 their	work	on	similar	key	
principles	 to	warrant	 public	 safety	 and	 health,	 however,	 the	 exact	 courses	 of	 actions	
display	some	minor	differences.	
The	USFDA	 (or	 in	 short,	 FDA)	drug	 approval	process	 generally	 consists	 of	 submitting	
two	essential	applications,	an	Investigational	New	Drug	Application	(IND)	followed	by	a	





for	 Drug	 Evaluation	 and	 Research	 (CDER)	 evaluates	 medicinal,	 chemical,	
pharmacological,	 toxicological,	 statistical	 and	 safety	 aspects	 in	 a	 review.	 When	 the	
product	is	confirmed	to	be	effective	and	not	causing	unreasonable	risks	in	clinical	trials,	
the	 manufacturer	 can	 next	 request	 to	 manufacture	 and	 sell	 the	 drug	 in	 the	 US	 by	
submitting	the	NDA.	[389]	In	the	following	process,	the	FDA	reviewers	decide	whether	
the	 new	 drug	 is	 safe	 and	 effective	 in	 its	 proposed	 use	 and	 the	 benefits	 outweigh	 the	
risks,	 whether	 its	 labeling	 is	 appropriate	 and	 whether	 manufacturing	 and	 control	




Comparably,	 the	 approval	 procedure	 in	 the	 EU	 likewise	 involves	 two	main	 steps,	 the	
clinical	trial	application	and	the	marketing	authorization	application.	While	the	former	
is	 approved	 at	 the	 level	 of	 one	 of	 the	 currently	 28	 member	 states,	 marketing	
authorizations	 can	 be	 administered	 at	 both	 member	 state	 or	 centralized	 levels.	
Altogether	 it	 can	 be	 distinguished	 between	 four	 different	 processes,	 namely	 the	
Centralized,	 Mutual	 Recognition,	 Nationalized	 and	 Decentralized	 Procedures.	 The	
Centralized	 Procedure,	 which	 is	 compulsory	 for	 certain	medicines,	 e.g.	 deriving	 from	
biotechnological	 processes,	 intended	 for	 cancer,	 HIV/Aids	 or	 diabetes	 and	 so-called	
orphan	drugs	is	mandatory	in	order	to	be	allowed	to	obtain	a	marketing	authorization	
valid	 throughout	 the	 EU.	 The	 respective	 application	 gets	 reviewed	 by	 an	 assigned	
rapporteur	and	submitted	to	the	European	Commission	for	final	approval.	To	receive	a	
marketing	authorization	 in	a	member	state	 (Concerned	Member	State)	other	 than	 the	
one	 where	 the	 drug	 was	 originally	 approved	 (Reference	 Member	 State),	 the	 Mutual	
Recognition	 Procedure	 is	 appropriate.	 The	 applicant	 submits	 dossiers	 to	 all	 desired	
states,	from	which	one	decides	to	take	command	and	evaluates	the	drug	and	afterwards	
reports	 its	 findings	to	the	other	states.	As	opposed	to	this,	 the	Nationalized	Procedure	
only	 accomplishes	 an	 authorization	 for	 one	 member	 state	 and	 involves	 just	 the	
respective	 authority.	 Medicinal	 products	 that	 have	 not	 yet	 been	 approved	 in	 any	 EU	
country	 and	 do	 not	 come	 within	 the	 Centralized	 Process,	 can	 undertake	 the	
Decentralized	Procedure	 and	be	 authorized	 simultaneously	 in	 several	member	 states.	
[389]	
Focusing	on	nanoscience	in	particular,	the	FDA	implemented	the	2013	Nanotechnology	
Regulatory	 Science	 Research	 Plan	 with	 the	 aim	 to	 lay	 out	 a	 framework	 and	
implementation	plan	to	provide	coordinated	leadership	and	foster	the	addressing	of	key	
scientific	gaps	in	knowledge,	methods,	or	tools	needed	to	make	regulatory	assessments	
of	 FDA-regulated	 products	 that	 either	 contain	 nanomaterial	 or	 otherwise	 involve	 the	
application	of	nanotechnology.	Led	by	 the	FDA	Nanotechnology	Task	Force	 formed	 in	
2006,	 issues	 such	 as	 the	 development	 of	 measurement	 tools	 for	 determination	 of	
physico-chemical	 properties	 of	 engineered	 nanomaterials	 and	 the	 development	 of	
appropriate	 in	 vitro	 and	 in	 vivo	 assays	 and	 models	 to	 predict	 human	 responses	 are	





clinic	 and	 the	 European	 Commission	 has	 developed	 several	 initiatives	 to	 stimulate	











In	 recent	 studies,	 the	 potential	 of	 nanomedicines	 to	 treat	 asthma	 could	 clearly	 be	
demonstrated.	It	was	shown	that	the	effects	of	steroids	against	airway	inflammation	are	
prolonged	 and	 enhanced	 when	 compacting	 them	 with	 nanoparticles	 [393]	 and	 that	
particles	 with	 smaller	 sizes	 induce	 bronchodilation	 more	 effectively	 [394].	 The	
advantages	of	nano-sizing	respective	substances	were	revealed	by	incorporating	several	
drugs	 routinely	used	 in	asthma	 treatment	 in	nanosystems.	 	 Salbutamol	 	nanoparticles	
were	proven	 to	 interact	more	 intensively	with	 the	 lung	membrane	due	 to	 augmented	
peripheral	 deposition	 and	 mucociliary	 movement	 to	 the	 tracheo-bronchial	 region,	
resulting	 in	 a	 higher	 and	 sustained	 drug	 concentration	 in	 the	 desired	 region	 [366],	
[363].	 Budesonide	 showed	 preferable	 properties	 in	 nanocluster	 formulations	 for	
efficient	drug	delivery	[395]	and	was	successfully	manufactured	in	nanosuspensions	by	
microfluidizer	 method	 [396]	 as	 well	 as	 in	 freeze-dried	 soy	 phophatidylcholine-
cholesterol	 liposome	 vehicles	 in	 combination	 with	 salbutamol	 [397],	 all	 approaches	
aiming	 for	 pulmonary	 delivery.	 Solid	 lipid	 nanoparticles	 and	 nanostructured	 lipid	
carriers	containing	Beclomethasone	were	produced	by	high-shear	homogenization	and	
efficiently	 nebulized	 to	 aerosols	 with	 a	 suitable	 particle	 size	 for	 deep	 lung	 delivery	
[398].	 Furthermore,	 Indomethacin	was	 incorporated	 in	 	 nanostructured	 lipid	 carriers	
showing	 a	 controlled	 drug	 release	 [399].	 Curcumin,	 an	 anti-inflammatory	 substance	
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with	 favorable	 pharmacological	 effects	 but	 poor	 bioavailability	 and	 rapid	
metabolization,	was	formulated	in	solid	lipid	nanoparticles	and	tested	in	an	ovalbumin-
induced	 allergic	 asthma	model	 in	 rats.	 The	 obtained	 release	 profile	 showed	 an	 initial	
burst	 followed	 by	 sustained	 release	 which	 resulted	 in	 significantly	 higher	 plasma	
concentrations	 than	 those	 after	 applying	 curcumin	 alone.	 Besides	 that,	 the	 particles	
were	 able	 to	 effectively	 diminish	 airway	 hyperresponsiveness	 and	 inflammatory	 cell	
influx	as	well	as	the	expression	of	T-helper-2-type	cytokines	in	BALF	[307].	
A	 different	 approach	 was	 developed	 by	 the	 2006	 founded	 biotechnology	 company	
Revalesio.	 Their	 lead	 product	 RNS60	 is	 based	 on	 charge-stabilized	 nanostructure	
technology,	 created	 by	 a	 patented	 device	 that	 produces	 stable	 nanostructures	 in	 an	
aqueous	 suspension	 by	 generating	 rotational	 forces,	 cavitation,	 and	 high-energy	 fluid	
dynamics.	 The	 obtained	 particles	 are	 smaller	 than	 100	 nanometers	 and	 consist	 of	 a	
stabilized	oxygen	bubble	core.	Other	than	traditional	therapies,	RNS60	does	not	target	
single	 cellular	 proteins,	 but	 aims	 to	 alter	 cellular	 inflammatory	 signaling	 in	 order	 to	
prevent	 cell	 and	 tissue	 damage	 by	 modulating	 the	 PI3K-Akt	 pathway,	 among	 others	
responsible	 for	 cellular	 protection	 from	 apoptosis	 and	 reduction	 of	 inflammation.	 	 In	
cell-based	 in	 vitro	 assays	 it	 was	 shown	 to	 change	 the	 responsiveness	 of	 epithelial,	
smooth	 muscle	 and	 immune	 cells	 to	 inflammatory	 stimuli	 that	 can	 trigger	 asthma	
attacks.	 Moreover,	 in	 vivo	 in	 an	 ovalbumin	 challenge	 model	 in	 rats	 it	 achieved	 a	
significant	 improvement	 in	 tidal	 volume	as	well	 as	 a	downregulation	of	 inflammatory	
cytokines	 and	 chemokines	 in	 blood	 and	 BALF.	 Two	 clinical	 safety	 studies	 of	 RNS60	
administered	 via	 nebulizer	 have	 already	 been	 completed,	 showing	 no	 concerns	
regarding	 safety	or	 tolerability	 in	neither	healthy	volunteers	nor	asthma	patients,	but	
significant	 improvements	 in	 PEF	 and	 QoL	 in	 diseased	 individuals.	 A	 clinical	 trial	
studying	the	effects	of	RNS60	on	the	late	phase	asthmatic	response	to	allergen	challenge	
was	 just	 completed	 and	 final	 data	 collection	 is	 being	 conducted.	 A	 further	 study	




the	challenge	 that	asthma	 is	a	very	patient-specific	disease,	 a	 crucial	 factor	 leading	 to	
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this	 discrepancy	 is	 the	 absence	 of	 relevant	 models	 that	 are	 really	 able	 to	 accurately	
mimic	the	actual	conditions	in	human	asthmatic	airway	tissue.		
One	auspicious	progression	that	could	help	reduce	this	lack	is	the	recent	development	
of	 a	 novel	 human	 airway	 musculature	 on	 a	 chip	 which	 is	 able	 to	 simulate	 the	
contraction	 of	 smooth	 muscles	 and	 hence	 imitate	 bronchoconstriction	 and	
bronchodilation	 in	 vitro	under	 asthmatic	 as	well	 as	healthy	 conditions.	 In	 this	model,	
asthmatic	 inflammation	 was	 imitated	 by	 exposition	 of	 the	 muscle	 tissue	 on	 a	 thin	
elastomeric	film	to	interleukin-13	(IL-13),	a	native	protein	that	often	is	hypersecreted	in	
asthmatic	airways.	When	consecutively	subjecting	it	to	acetylcholine,	the	airway	muscle	
responds	with	hypercontractility,	 just	as	 it	 is	observed	 in	both	asthmatic	patients	and	
animal	 tissue	 studies.	 The	 reverse	 reaction,	 a	 relaxation,	 can	 be	 achieved	 by	 using	 a	
muscarinic	antagonist	and	a	β-agonist	that	are	both	utilized	against	constricted	airways	
in	 the	 clinic.	 On	 the	 cellular	 level,	 the	 chip’s	 reaction	 coincides	 with	 the	 in	 vivo	
conditions,	 too:	 the	 known	 phenomena	 of	 atrophing	 smooth	 muscle	 cells	 in	 the	
presence	of	IL-13	as	well	as	the	increased	alignment	of	actin	fibers	in	asthmatic	airways	
were	also	observed	in	vitro.	As	a	first	example,	HA1077,	a	RhoA	targeting	inhibitor,	was	
tested.	 It	 resulted	 in	 decreased	 basal	 tone	 which	 prevented	 hypercontraction	 and	
improved	relaxation	and,	therefore,	made	the	muscle	tissue	less	sensitive	to	the	asthma	
triggering	IL-13.	Consequently,	 this	 tool	potentially	enables	an	 innovative	approach	to	
evaluate	the	efficacy	and	safety	of	novel	asthma	treatments.	[401]		
Another	 hurdle	 to	 overcome	 on	 the	 way	 to	 clinical	 translation	 is	 to	 find	 the	 ideal	
biocompatible	 nanocarrier	 with	 respective	 characteristics.	 Although	 several	 studies	
have	 been	 conducted	 on	 the	 safety	 of	 nano-based	 systems	 and	 materials,	 extensive	
biocompatibility	 investigations	 are	 rather	 scarce,	 yet	 it	 is	 essential	 to	 scrutinize	 all	
possible	 levels	of	toxicity	 in	a	responsible	way.	Equally	 important	 is	the	securing	of	 in	
vivo	stability	concerning	both	the	nanovector	and	the	active	compound.	Biodegradable	
nanoparticles	 indeed	 can	 be	 applied	 for	 sustained	 release	 effects,	 however,	 the	 exact	
drug	release	mechanisms	still	have	to	be	clarified.	Degradation	rates	of	the	polymer	as	
well	as	release	profiles	and	bioavailability	of	the	incorporated	drug	demand	comprising	
investigations.	 To	 successfully	 commercialize	 inhalable	 nanoparticles	 for	 asthma	
treatment,	 moreover,	 the	 development	 of	 suitable	 inhalation	 devices	 is	 of	 great	
importance.	 Apart	 from	 the	 appropriate	 device	 type,	 and,	 if	 applicable,	 respective	
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excipients	 and	 attached	 equipment,	 inhaler	 performance	 factors	 such	 as	 flow	 rate,	
administered	volume	and	dose	reproducibility	need	to	be	addressed.		
Concerning	the	 lung	as	a	 target	organ,	 the	 largest	gap	of	knowledge	 is	 the	uptake	and	
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the	 discovery	 of	 RNA	 interference	 (RNAi),	 providing	 a	 tool	 to	 potentially	 silence	 any	
chosen	gene.	Nevertheless,	efficient	delivery	still	presents	a	major	hurdle	to	translating	
this	 promising	 technology	 into	medical	 practice.	 Here,	we	 describe	 a	 straightforward	
method	 to	 prepare	 and	 characterize	 an	 effective	 delivery	 system	 consisting	 of	 low	
molecular	weight	polyethylenimine	(PEI)	and	transferrin	(Tf).	Tf-PEI	polyplexes	are	not	
only	able	to	successfully	transport	and	protect	the	sensitive	nucleic	acid	payload	from	
degradation,	 but	 also	 to	 selectively	 deliver	 the	 siRNA	 to	 transferrin	 receptor	 (TfR)	







RNA	 interference	 (RNAi)	 offers	 the	 potential	 to	 selectively	 target	 and	 functionally	
inhibit	 disease-related	 genes	 [14],	 paving	 the	 way	 for	 developing	 novel	 treatment	
options	 to	 solve	 unmet	 medical	 needs.	 Small	 interfering	 RNA	 (siRNA),	 as	 the	 most	
intensively	 studied	 RNAi	 mediator	 for	 therapeutic	 application	 in	 recent	 studies,	 [61]	
arouses	 significant	 interest	 in	modern	 research.	 Despite	 numerous	 studies	 aiming	 to	
translate	 this	 revolutionary	 technology	 into	 an	 applicable	 medication,	 its	 way	 into	
clinical	 routine	 is	 still	 hampered,	 and	 so	 far	 only	 one	 siRNA	 drug	 product	 has	 been	
clinically	approved.	[19]	Naked	siRNA	displays	several	unfavorable	characteristics	such	
as	its	strong	charge	and	susceptibility	to	nuclease	degradation.	[402]	In	order	to	avoid	
rapid	 clearance	 and	 facilitate	 transport	 across	 extra-	 and	 intracellular	 barriers	 it	 is	
therefore	 imperative	 to	 employ	 a	 suitable	 delivery	 system	 for	 the	 delicate	 payload.	
Although	 viral	 vectors	may	 offer	 high	 transfection	 efficiencies,	 due	 to	 their	 debatable	
safety	 profiles	 regarding	 immunogenicity	 and	 tumorigenicity,	 non-viral	 vectors	 are	
usually	the	preferred	option.	[403]	
Cancerous	 and	 inflammatory	 tissue	 share	 several	 common	 features,	 both	 exhibiting	
enhanced	 vascular	 permeability	 orchestrated	 by	mediators	 such	 as	 nitric	 oxide	 (NO),	
bradykinin,	 and	 prostaglandins.	 [404]	 The	 vascular	 anatomy	 of	 tumors	 is,	 moreover,	
characterized	by	reduced	lymphatic	drainage.	Nanosized	siRNA	systems	are,	therefore,	
not	 only	 preferentially	 taken	 up	 into	 tumor	 tissue	 via	 the	 leaky	 vasculature,	 but	
subsequently	 also	 captured	 due	 to	 poor	 clearance	 effects.	 [405]	 Although	 this	
phenomenon,	 known	 as	 the	 enhanced	 permeability	 and	 retention	 (EPR)	 effect,	 is	
expected	to	improve	delivery	of	nanoparticles	 into	tumors,	 it	actually	only	results	 in	a	
rather	modest	2-fold	increase	compared	to	critical	normal	organs	in	most	tumor	models	
but	 often	 is	 not	 reflected	 in	 the	 clinical	 picture.	 [406]	 The	 main	 difference	 between	
tumor	 and	 inflammatory	 tissue	 is	 the	 latter	 having	 a	 functional	 lymphatic	 system	 in	
place.	 It	 does,	 however,	 release	 various	 mediators	 inducing	 the	 EPR	 effect	 and	













promising	 example.	 Transferrin	 is	 a	 native	 circulating	 glycoprotein,	 responsible	 for	
controlling	 iron	 levels	 in	 biological	 fluids.	 Transferrin	 receptors	 (TfR)	 are	
transmembrane	proteins	which	bind	plasma	iron	complexes	with	transferrin,	enabling	
iron	 internalization	 into	cells	via	 receptor-mediated	endocytosis.	 [409]	While	TfR	1	 is	
ubiquitously	expressed	on	almost	all	generic	cell	surfaces	at	low	levels,	its	expression	is	
upregulated	 in	 highly	 proliferating	 cells	 such	 as	 in	 various	 cancer	 types	 and	
inflammatory	 tissues.	 [38]	 Enhanced	 TfR	 1	 expression	 has	 been	 reported	 in	 a	 wide	













transferrin	 (Tf)	 suitable	 for	 targeting	of	disease-related	cells	 in	 cancer	 [42]	as	well	 as	














































































and	mix	 the	 remaining	 solution	well.	 Add	B2	 up	 to	 a	 column	 volume	 of	 6	ml	 and	



















DMSO	to	aid	 formation	of	 the	disulfide	bonds.	Wrap	with	parafilm	and	stir	at	4	 °C	
overnight.		
10. Filter	 the	Tf-PEI	conjugate	with	a	13	mm,	0.22	µm	syringe	 filter	and	purify	with	2	
connected	HiTrap	SP	HP	1	ml	columns	using	an	FPLC	system,	such	as	the	ÄKTA	pure	
protein	purification	system.	(see	Note	7)	After	removing	the	storage	solutions	from	
the	 columns	 with	 buffer	 A,	 slowly	 (1	 ml/min)	 let	 the	 conjugate	 run	 through	 and	
collect	0.5	ml	fractions.	Wash	the	vial	used	for	the	conjugate	with	3	ml	buffer	A,	then	
switch	to	buffer	B	and	rinse	with	∼	9	ml,	collecting	0.5	ml	fractions.	(see	Note	8)	
11. To	 check	 which	 buffer	 B	 fractions	 contain	 the	 purified	 conjugate,	 measure	
absorbance	at	280	nm	with	buffer	B	as	blank.	



























Figure	 1.	 Schematic	 representation	 of	 the	 conjugation	 process	 of	 transferrin	 (Tf)	 and	
polyethylenimine	 (PEI),	 resulting	 in	 the	Tf-PEI	 conjugate.	Both	components	are	 first	activated	
with	 succinimidyl	 3-(2-pyridyldithio)	 propionate	 (SPDP).	 PEI-SPDP	 is	 subsequently	 reduced	






1. Harvest	cells	 following	 trypsinization	(or	other	appropriate	methods).	Count	viable	
cells	 and	 resuspend	 in	 PBS	 at	 10	 x	 106	 cells/ml	 and	 distribute	 100	 µl/tube	 of	 cell	







control.	Leave	3	samples	unstained.	Vortex	and	 incubate	30	min	 in	 the	refrigerator	
(2-8	°C).	
3. Centrifuge	 at	 350	 g	 for	 5	 min,	 discard	 supernatant	 and	 add	 500	 µl	 of	 PBS/2	 mM	





6.	 	Determine	the	%	of	positive	cells	 in	 the	PE	channel	 for	each	sample	as	depicted	 in	
Figure	2.		
	
Figure	 2.	 Levels	 of	 transferrin	 receptor	 1	 (TfR1,	 also	 known	 as	 CD71)	 on	 Jurkat	 cells	 as	
quantified	 by	 CD71-PE	 antibody	 staining	 and	 determination	 of	median	 fluorescence	 intensity	
(MFI)	by	flow	cytometry.	Results	are	presented	as	means	of	triplicates	±	SD.	Blank	samples	were	
left	unstained,	while	 isotype	controls	were	stained	with	an	 IgG	antibody	 to	exclude	unspecific	











prepare	100	µl	 of	 Tf-PEI/siRNA	 formulations	with	different	N/P	 ratios	 in	HBS	 and	
add	 into	 disposable	 micro-cuvettes.	 Determine	 sizes	 with	 a	 Zetasizer	 Nano	 ZS	
(Malvern	Instruments,	Malvern,	UK)	at	173°	backscatter	angle	with	3	times	15	runs	
per	 sample.	 Use	 0.88	 mPa*s	 for	 viscosity	 and	 1.33	 for	 refractive	 index	 for	 data	
analysis	with	the	Zetasizer	software.	Subsequently,	dilute	all	samples	with	900	µl	of	
nanopure	water	and	transfer	 to	a	 folded	capillary	cell.	Perform	three	zeta	potential	




Figure	 3.	 Hydrodynamic	 diameters,	 PDI,	 and	 zeta	 potentials	 of	 PEI	 and	 Tf-PEI	 polyplexes	 at	
different	 N/P	 ratios	 as	 measured	 by	 dynamic	 light	 scattering	 (DLS)	 and	 laser	 Doppler	
anemometry	(LDA),	respectively.	Data	points	indicate	means	±	SD.	Due	to	the	shielding	effect	of	
the	negatively	charged	transferrin,	Tf-PEI	polyplexes	are	distinctly	smaller	than	those	made	of	






polyplexes	with	50	pmol	siRNA	at	 rising	N/P	ratios	 in	5	%	glucose,	distribute	 in	a	
FluoroNunc	 96-well	white	 plate	 and	 incubate	 for	 20	min.	 Use	 controls	 containing	
only	siRNA	(N/P=0)	to	account	for	100	%	free	siRNA.	
2. Subsequently,	 add	 30	 µl	 of	 4x	 SYBR	 gold	 nucleic	 acid	 gel	 stain	 and	 incubate	 for	
another	10	min	in	the	dark.	(see	Note	15)	




















2. Prepare	 polyplexes	 with	 50	 pmol	 of	 fluorescently	 labeled	 siRNA	 (here:	 AF	 488	















siRNA	 in	 Jurkat	 cells	with	 or	without	 the	 presence	 of	 free	 transferrin	 in	 the	 culture	medium.	
Results	 are	 depicted	 as	means	 of	 triplicates	 ±	 SD,	 blank	 samples	 represent	 non-treated	 cells.	
While	the	concentration	of	 free	transferrin	does	not	affect	uptake	of	PEI	polyplexes,	uptake	of	







2. The	SPDP	solution	should	always	be	prepared	 freshly.	Yellow	coloring	 is	a	 sign	 for	
oxidation,	indicating	the	solution	should	not	be	used	any	longer.	













8. Rinsing	with	 buffer	A,	 containing	 a	 low	 amount	 of	 salt,	 results	 in	 removing	 of	 free	






11. The	 TNBS	 assay	 measures	 the	 primary	 amine	 groups	 of	 PEI	 by	 reacting	 to	 a	
chromogenic	product.	
12. It	 is	 necessary	 to	 determine	 this	 concentration,	 as	 the	 transferrin	 in	 the	
conjugate	 might	 interfere	 with	 the	 PEI	 concentration	 measurement.	 Therefore,	 a	
transferrin	solution	with	a	respective	concentration	has	to	be	added	to	the	standard	





next	 step,	meaning	 the	400	µg/ml	will	 only	 account	 for	200	µg/ml	PEI	 in	 the	 final	
assay	analysis.		
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siRNA	 delivery,	 knockdown,	 lung,	 inflammation,	 GATA-3,	 OVA	 challenged	 mice,	 flow	
cytometry,	cytokines,	T	cell	isolation,	intracellular	staining	
Abstract	
RNA	 interference	 (RNAi)	 offers	 a	 promising	 base	 for	 therapeutic	 knockdown	 of	
clinically	 relevant	 genes.	 Local	 delivery	 routes	 as	well	 as	 targeted	delivery	 to	 specific	
cell	 populations	 have	 been	 shown	 to	 circumvent	 several	 hurdles	 of	 successful	 siRNA	
delivery	in	vivo.	To	evaluate	and	quantify	the	treatment	effect	in	a	precise	way,	next	to	
measuring	 the	 downregulation	 on	 gene	 and	 protein	 levels,	 it	 is	 equally	 essential	 to	
investigate	the	influence	on	down-stream	factors	such	as	generated	cytokines.	Here,	we	
describe	 an	 expressive	 method	 to	 specifically	 isolate	 the	 desired	 target	 cells	 and	
determine	their	levels	of	intracellular	cytokines	by	flow	cytometry	using	the	example	of	
murine	lungs	after	pulmonary	in	vivo	transfection	with	siRNA.		
Therefore,	 the	 lungs	 of	 treated	 mice	 are	 harvested	 and	 processed	 into	 single	 cell	
suspensions,	 in	which	CD4	positive	T	 cells	 are	marked	by	 antibody-coupled	magnetic	
beads	 and	 isolated	 via	magnetic	 separation.	 These	 purified	 target	 cells	 are	 then	 fixed	









mechanism	 of	 RNA	 interference	 (RNAi)	 has	 aroused	 great	 interest	 for	 therapeutic	
purposes	and	found	its	way	into	several	human	clinical	trials	[15].	Despite	all	progress,	
however,	 there	are	still	hurdles	that	 impede	translation	 into	the	clinical	routine.	Since	
siRNA,	 due	 to	 its	 poor	 pharmacokinetics,	 was	 recognized	 at	 an	 early	 stage	 to	 be	
extremely	 problematic	 for	 systemic	 administration,	 a	 majority	 of	 the	 recent	 studies	
focuses	 on	 local	 delivery	 routes	 [31].	 Pulmonary	 application,	 as	 such	 a	way,	 not	 only	
circumvents	 several	 of	 the	 barriers	 that	 need	 to	 be	 overcome	 by	 nucleic	 acids	 and	
protects	the	sensitive	payload	from	degradation,	e.g.	by	serum	nucleases,	but	obviously	
also	 enables	 reductions	 of	 doses,	 and	 therefore,	 side	 effects	 [365].	 Furthermore,	 the	
therapeutics	 are	 instantly	 available	 at	 the	 target	 region	 where	 they	 are	 supposed	 to	
bring	about	their	effect	[34].		
For	 immune-related	 diseases,	 this	 target	 is	 oftentimes	 displayed	 by	 the	 cellular	
contingent	 of	 the	 immune	 system.	 Activated	 T	 cells,	 as	 the	 most	 important	 cellular	
mediators	 in	 immune	responses,	 are	anticipated	 to	be	 targeted	and	 treated	 in	 several	
related	 studies	 [23].	One	of	 the	numerous	diseases,	 in	whose	pathophysiology	T	 cells	
play	 a	 crucial	 role,	 is	 asthma,	 a	 chronic	 inflammatory	 disease	 of	 the	 airways	
characterized	by	infiltration	of	immune	cells	including	T	helper	2	cells	(TH2	cells),	a	type	
of	activated	T	cells	(ATC),	 in	 the	 lung	[412].	These	CD4+	T	cells	orchestrate	various	of	
the	 cytokine-based	 inflammatory	 cascades	 by	 secretion	 of	 interleukins	 such	 as	 IL-13,	
which	 in	 turn	 are	 produced	 upon	 activation	 of	 the	 key	 transcription	 factor	 GATA-3	
[413].	There	are	attempts	to	capture	the	cells	and	their	receptors	directly	[414,	415]	as	
well	as	indirect	methods	that	aim	to	modulate	the	cytokine	environment	[416].	Beyond	
targeting	 these	 single	 cytokines	 in	 particular,	 for	 example	with	 respective	 antibodies	







A	 well-established	 and	 extensively	 studied	 method	 to	 examine	 inflammatory	 and	
immune	 responses	 is	 the	 Ovalbumin	 (OVA)-sensitization	mouse	model	 [28]	 which	 is	
well	 suited,	 but	 by	 far	 not	 limited,	 for	 the	 use	 in	 asthma	 research	 [40].	 In	 these	
experimentally	challenged	animals,	it	is	possible	to	check	the	distinct	influence	of	siRNA	
treatment	 on	 enhanced	 cytokine	 levels	 in	 specific	 T	 cell	 subsets.	 To	 achieve	 this,	 an	
essential	step	is	to	isolate	the	desired	cell	type,	which	can	be	accomplished	by	antibody-
based	magnetic	cell	separation	as	a	straightforward	technique	[417].	In	order	to	access	
intracellular	 cytokines,	 the	 membrane	 of	 the	 obtained	 cells	 then	 has	 to	 be	
permeabilized,	 which	 is	 commonly	 approached	 with	 organic	 solvents	 or	 detergents	
such	 as	 saponin	 [418].	 The	 respective	 cytokines	 are	 now	attainable	 for	 fluorescently-





























Rat	 anti-mouse	 IL-13-PE,	 clone	 eBio13A	 (eBioscience,	 Frankfurt,	 Germany),	 1:10	
diluted	in	0.3%	saponin	buffer.	








For	 in	 vivo	 transfection,	 harvesting	 of	 the	 lungs	 and	 preparation	 of	 single	 cell	
suspensions,	 please	 refer	 to	 Chapter	 18	 of	 Methods	 in	 Molecular	 Biology	 –	























9. For	 cell	 separation,	 place	 the	 LS	 column	 in	 the	 magnetic	 field	 of	 a	 MidiMACS	
Separator.	
10. Rinse	the	column	with	3	ml	of	isolation	buffer	(see	Note	4).	




13. Optional:	 To	 obtain	 the	 labeled	 non-CD4+	 cells,	 remove	 the	 column	 from	 the	
separator,	place	it	on	a	collection	tube	and	add	5	ml	of	isolation	buffer.	Immediately	


















9. Adjust	 the	 laser	 power	 at	 the	 flow	 cytometer	 using	 the	 isotype	 controls	 and	
unstained	samples.		
10. Gate	the	cells	to	exclude	debris	and	cell	clumps.	Count	at	least	30.000	events.	































10. Discard	 the	 supernatant,	 add	 100	 µl	 0.3%	 saponin	 buffer	 per	 sample	 for	
permeabilzation,	mix	and	incubate	for	15	min	at	4	°C.	
11. Centrifuge	FACS	tubes	for	5	min	at	350	g.	
12. Discard	 the	 supernatant,	 add	10	µl	 diluted	Fc-block,	 add	10	µl	 of	 the	 appropriate	
dilutions	 of	 the	 antibodies	 against	 IL-13	 and	 IL-17A	 (or	 isotype	 controls),	 vortex	
and	incubate	for	25	min	at	4	°C	in	the	dark.		
13. Centrifuge	the	stained	cells	for	5	min	at	350	g.	
14. Discard	 the	 supernatant,	 wash	 with	 100	 µl	 0.3%	 saponin	 buffer	 twice,	 and	
centrifuge	the	cells	a	third	time	for	5	min	at	350	g.	
15. Discard	 the	 supernatant,	wash	with	 100	 µl	wash	 buffer	 once,	 centrifuge	 the	 cells	
again	for	5	min	at	350	g,	and	resuspend	them	in	200	µl	wash	buffer.	














Figure	3.	Mean	 fluorescence	values	 from	the	respective	channels	can	be	depicted	 in	bar	graphs.	
Here,	 the	cytokine	 levels	after	pulmonary	treatment	of	OVA	challenged	mice	with	GATA-3	siRNA	













5. A	 volume	 of	 not	 less	 than	 500	 µl	 is	 required	 for	 successful	 separation,	 smaller	
volumes	should	be	filled	up	with	buffer	at	this	point.	
6. If	some	of	the	T	cells	are	desired	to	be	kept	in	culture	for	further	experiments,	it	is	
strongly	 recommended	 to	 stimulate	 them,	 e.g.	 with	 antibodies	 against	 CD3e	
(Hamster	 anti-mouse	 CD3e,	 clone	 145-2C11	 (BD	 Biosciences,	 Heidelberg,	
Germany))	and	CD28	(Hamster	anti-mouse	CD28,	clone	37.51	RUO	(BD	Biosciences,	
Heidelberg,	 Germany)).	 Therefore,	 coat	 the	 appropriate	 number	 of	wells	 of	 a	 96-
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by	 the	 lack	 of	 efficient	 carrier	 systems	 for	 therapeutic	 siRNA,	 endosomal	 entrapment	
presenting	a	major	hurdle.	We	previously	developed	a	promising	siRNA	delivery	system	
on	 the	 base	 of	 polyethylenimine	 (PEI)	 and	 the	 targeting	 ligand	 transferrin	 (Tf)	 to	
specifically	 reach	 activated	 T	 cells	 in	 the	 lung.	 In	 the	 present	 work,	 we	 focused	 on	
optimizing	 Tf-PEI	 polyplexes	 for	 gene	 knockdown	 in	 primary	 activated	 T	 cells	 by	
improving	 their	 endosomal	 escape	 properties.	 Blending	 of	 the	 conjugate	 with	
membrane	 lytic	 melittin	 significantly	 enhanced	 endosomal	 release	 and	 thereby	
cytoplasmic	 delivery,	while	maintaining	 selective	 T	 cell	 targeting	 abilities	 and	 overall	
cell	tolerability.	The	gathered	data	furthermore	demonstrate	that	melittin	addition	also	
distinctly	 improved	 several	 other	 essential	 particle	 characteristics,	 such	 as	 siRNA	
encapsulation	efficiency	and	stability	in	lung	lining	fluids.	In	conclusion,	this	results	in	a	
novel	 upgraded	 siRNA	 delivery	 system	 that	 is	 not	 only	 able	 to	 specifically	 deliver	 its	






is	 not	 only	 of	 great	 interest	 for	 functional	 analysis,	 but	 can	 moreover	 be	 exploited	
therapeutically	 to	precisely	 influence	pathological	processes.	While	 siRNA	has	already	
emerged	 to	 be	 a	 standard	 research	 tool,	 its	 translation	 into	 therapeutic	 usage	 in	 the	
clinical	routine	has	been	slow,	with	overcoming	extra-	and	intracellular	barriers	being	a	
major	impediment.	Due	to	unfavorable	characteristics	such	as	relatively	high	molecular	
weight	 and	 strong	 charge,	 naked	 siRNA	 is	 hardly	 able	 to	 cross	 hydrophobic	 cell	
membranes	 and	 is	 furthermore	 very	 susceptible	 to	 degradation.[402]	 Therefore,	 it	 is	
necessary	 to	 employ	 a	 suitable	 delivery	 system	 that	 efficiently	 protects	 the	 siRNA,	
facilitates	 cellular	 delivery	 and	 aids	 cytoplasmic	 transport	 to	 achieve	 passage	 to	 the	




responses	 often	 occurring	 with	 viral	 vectors.[31]	 However,	 these	 carrier	 systems	
usually	 have	 two	 major	 drawbacks:	 high	 toxicity	 due	 to	 their	 positive	 charge	 and	
abundant	 endosomal	 entrapment	 of	 their	 payload.	 Endosomal	 escape	 is	 generally	
important	 to	 avoid	 degradation	 of	 sensitive	 material	 in	 the	 acidic	 and	 enzymatic	
conditions	 of	 the	 endolysosomal	 compartment.[419]	 For	 siRNA,	 it	 is	 yet	 particularly	
relevant,	 as	 it	 has	 to	 reach	 the	 RNA-induced	 silencing	 complex	 (RISC),	 the	 RNAi	
machinery	located	in	the	cytoplasm,	in	order	to	bring	about	its	effect.[79]	
A	 promising	 approach	 to	 facilitate	 efficient	 delivery	 of	 siRNA	 to	 the	 desired	 target	
region	 is	 to	 use	 local	 administration	 routes,	 circumventing	 systemic	 degradation	 and	





of	 Th2	 cytokines,	 activated	 T	 cells	 orchestrate	 several	 pathologic	 cascades	 underlying	
chronic	inflammatory	diseases,	such	as	asthma.[24]	Here,	blockage	of	these	cytokines	or	
preferably	 even	 their	 transcription	 factors	 can	 early-on	 undermine	 disease	 triggering	
processes	 and	 bears	 the	 potential	 to	 treat	 even	 severe	 forms	 in	 patients	 whose	
symptoms	are	currently	not	adequately	controlled.	Unfortunately,	T	cells	have	proven	
to	 be	 difficult	 to	 transfect	 as	 they	 are	 resistant	 to	 common	 non-viral	 vector	 based	
transfection	methods.	In	contrast	to	most	other	cell	types,	T	cells	are	devoid	of	caveolae	
as	 they	 do	 not	 express	 caveolin,[420]	 meaning	 that	 their	 active	 endocytosis	 of	
nanoparticles	 is	 limited.	 While	 other	 techniques	 such	 as	 viral	 delivery	 systems	 or	
electroporation	as	a	physical	method	may	be	effective	 in	vitro,	but	are	not	well	suited	
for	 therapeutic	 in	 vivo	application,[210]	 a	more	 sophisticated	way	has	 to	 be	 found	 to	
reach	the	T	cells.	
Previously,	 our	 group	 developed	 a	 conjugate	 consisting	 of	 transferrin	 (Tf)	 and	
polyethylenimine	(PEI),	namely	Tf-PEI,	that	can	efficiently	and	selectively	deliver	siRNA	
to	activated	T	cells	in	the	lung,[40]	exploiting	the	fact	that	Tf	receptor	(TfR)	expression	
is	 upregulated	 in	 activated	 T	 cells,	 while	 naïve	 T	 cells	 only	 show	 negligible	




naïve	 T	 cells	 unaffected,	 thereby	 avoiding	 influence	 on	 the	 general	 immune	 system.	
Besides	exhibiting	optimal	physicochemical	properties,	Tf-PEI	showed	significant	gene	
silencing	efficiencies	 in	vitro	and	preferentially	delivered	siRNA	 to	activated	T	cells	 in	
vivo.[40]	 However,	 despite	 promising	 results,	 one	 aspect	 that	 still	 left	 room	 for	
optimization	 and	 potentially	 prevented	 the	 conjugate	 from	 achieving	 therapeutically	
relevant	in	vivo	knockdown	rates	was	sufficient	endosomal	release	of	delivered	siRNA.	
Recent	 studies	 have	 identified	 escape	 of	 the	 endosomal	 pathway	 as	 the	 rate-
determining	 step	 in	 delivering	 therapeutic	 agents,	 being	 the	 only	 way	 to	 circumvent	
lysosomal	 entrapment	 and	 subsequent	 degradation.[51]	 We	 therefore	 hypothesized	
that	 the	 achieved	 gene	 silencing	 effect	 could	 possibly	 be	 enhanced	 by	 including	 an	
endosomolytic	component.	The	peptide	melittin	(Mel)	exhibits	an	inherent	capacity	for	
membrane	 disruption	 and	 was	 shown	 to	 be	 able	 to	 lyse	 red	 blood	 cells	 and	 model	
membranes.	 [421,	 422]	 As	 this	 effect	 is	 not	 impaired	 by	 acidic	 conditions,	 melittin	
exhibits	optimal	features	as	an	endosomolytic	agent	and	was	proven	to	be	a	useful	tool	
to	 release	 delivered	 therapeutics	 from	 the	 endosomal	 compartment.	 [423]	 Besides	
enhancing	transfection	efficiencies	of	both	polymeric	[54-56]and	lipid-based	[57]	gene	
delivery	 vectors,	 it	 can	 also	 be	 used	directly	 as	 an	 oligonucleotide	 transfection	 agent.	
[424]	The	evoked	pore-formation	in	membranes	can,	however,	cause	general	toxicity	if	
this	effect	is	not	limited	to	the	endosomes.[423]	For	this	reason,	a	pH-sensitive	shielding	
of	 melittin	 was	 applied,	 yielding	 a	 responsive	 conjugate	 with	 minimized	 membrane-
effects	at	extracellular	neutral	conditions,	but	precise	lytic	activity	upon	endolysosomal	
acidification.		
The	 aim	 of	 this	 study	 was	 therefore	 to	 refine	 and	 optimize	 our	 Tf-PEI	 conjugate	 by	
incorporating	a	bioresponsive	endosomolytic	domain	while	maintaining	 the	specific	T	
cell	 targeting	 ability	 in	 order	 to	develop	 a	 versatile	 siRNA	delivery	 system	combining	
the	 two	 essential	 features	 for	 successful	 directed	 delivery.	 The	 resulting	 Tf-Mel-PEI	
blend	was	 fully	characterized	and	compared	 to	 its	 single	components	Tf-PEI	and	Mel-
PEI	 as	 well	 as	 unmodified	 PEI	 polymer	 and	 demonstrated	 superior	 competences	 in	
terms	of	siRNA	encapsulation	and	protection,	Tf	related	cellular	uptake	and	transfection	











of	 Tf	 to	 PEI	 of	 approximately	 1.5:1.	 Low	 molecular	 weight	 (LMW,	 5k)	 PEI	 was	
successfully	 coupled	 to	 2,3-Dimethyl-maleic	 anhydride	 (DMMAn)	 modified	 melittin	
(Mel)	 to	 yield	 the	 Mel-PEI	 conjugate	 with	 pH-responsive	 lytic	 ability.	 The	 reversible	
masking	 of	 lysine	 residues	 and	 N-terminal	 amino	 groups	 with	 DMMAn	 resulted	 in	
bioresponsive	membrane-disruptive	properties	only	emerging	 in	acidic	environments,	
leading	 to	 a	 distinct	 reduction	of	 toxic	 side	 effects	 in	 the	 extracellular	 area.	As	 a	 first	
step,	PEI	was	coupled	to	the	SPDP-PEG4	linker	and	melittin	was	reacted	with	DMMAn	
after	activation	with	dithiothreitol	(DTT).	DMMAn-Mel	was	then	conjugated	with	PDP-
modified	 PEI	 via	 formation	 of	 a	 disulfide	 bond	 in	 the	 presence	 of	 1	 M	 guanidine	
hydrochloride	to	prevent	aggregation	of	positively	charged	modified	PEI	and	negatively	




Hydrodynamic	 diameter,	 polydispersity	 index	 (PDI)	 and	 zeta	 potential	 of	 prepared	
polyplexes	 were	 determined	 by	 dynamic	 light	 scattering	 and	 laser	 Doppler	
anemometry,	 respectively.	 As	 Figure	 1A	 shows,	 PEI/siRNA	 polyplexes	 demonstrated	









































Figure	 2.	 siRNA	 condensation	 efficiencies	 of	 polyplexes	 as	measured	 by	 SYBR	 gold	 assay.	 A)	













the	 interaction	 between	 the	 Tf-PEI	 and	 Tf-Mel-PEI	 conjugates,	 respectively,	 to	 the	











receptor,	 though	 the	overall	affinity	decreased	nearly	6-fold	 (KD=59	nM)	compared	 to	
free	transferrin,	which	was	due	to	a	lower	association	rate	of	Tf-PEI	(ka=5.3	x	10-3/M*s)	
(Figure	3B).	Binding	of	Tf-PEI	to	the	TfR	was	more	stable	compared	to	free	transferrin	
since	 no	 first	 high	 dissociation	 phase	 was	 observed.	 Assuming	 a	 1:1	 binding	
stoichiometry	the	overall	dissociation	rate	of	Tf-PEI	to	the	Tf-receptor	was	comparable	
to	that	of	free	transferrin	(kd=3.1	x	10-3/s).	Free	PEI	showed	no	interaction	with	the	chip	









spectroscopy.	 The	 transferrin	 receptor	 (TfR)	was	 captured	 via	 its	 His-tag	 onto	 a	 CM5	 sensor	
chip	coated	with	anti-His	antibody,	and	solutions	of	1	nM	(light	purple),	10	nM	(dark	blue),	25	
nM	 (blue),	 50	 nM	 (green),	 100	 nM	 (yellow),	 250	 nM	 (orange),	 500	 nM	 (red),	 1000	 nM	 (dark	
purple)	of	free	transferrin	(A),	TF-PEI	conjugate	(B),	Tf-Mel-PEI	(C)	conjugate,	and	unmodified	






cytometry.	 Figure	 4A	 shows	 the	Median	 Fluorescence	 Intensity	 (MFI)	 of	 Jurkat	 cells	
transfected	 with	 polyplexes	 composed	 of	 AF488-siRNA	 and	 different	 polymer	





Addition	of	melittin	 to	PEI,	however,	 tremendously	 increased	 the	obtained	MFI	 for	all	
tested	N/P	ratios.	Finally,	blending	of	Tf-PEI	and	Mel-PEI	in	a	1:1	ratio	(=”Tf-Mel-PEI”),	
resulted	 in	 the	most	 effective	 uptake	 for	N/P	 ratios	 10	 and	 15.	 Enhancing	 the	 Tf-PEI	
portion	 in	 the	 blend	 to	 75	 %	 did	 not	 further	 improve	 uptake,	 but	 rather	 lowered	
obtained	 MFI.	 Trypan	 blue	 quenching,	 to	 diminish	 extra-cellular	 fluorescent	 signals	






cells	 and	 thereby	 upregulation	 of	 their	 TfR	 expression,	 this	 enhancement	 was	 even	
more	 pronounced,	 implying	 Tf	 related	 uptake	mechanisms.	 Furthermore,	 blending	 of	
Tf-PEI	with	Mel-PEI	additionally	 increased	the	MFI	2.8	 fold	compared	to	Tf-PEI	alone.	
As	observed	for	Jurkat	cells,	trypan	blue	quenching	slightly	decreased	measured	signals,	
however,	 did	not	 affect	 the	 captured	 correlations	between	 the	 formulations	 (data	not	
shown).	
To	further	manifest	Tf	related	uptake	of	Tf	containing	polyplexes,	a	Tf	competition	assay	
was	 performed	 in	 Jurkat	 cells	 as	 depicted	 in	 Figure	 4C.	 MFI	 values,	 and	 therefore	
uptake,	of	both	Tf-PEI	and	Tf-Mel-PEI	polyplexes	were	distinctly	and	gradually	reduced	
by	 increasing	 concentrations	 of	 free	 Tf	 in	 the	 culture	 medium	 during	 transfection,	
indicating	 a	 Tf	 dependent	 uptake	 mechanism.	 Cellular	 uptake	 of	 non	 Tf-containing	
















Figure	 4.	 Cellular	 uptake	 of	 polyplexes	 as	 measured	 by	 flow	 cytometry	 and	 presented	 as	
median	fluorescence	intensity	(MFI).	A)	Uptake	in	Jurkat	cells	before	(left	panel)	and	after	(right	
panel)	 trypan	 blue	 quenching.	 B)	 Uptake	 in	 primary	 CD4+	 human	 T	 cells.	 “Blank”	 represents	
untreated	 control	 cells,	 “free	 siRNA”	 represents	 cells	 treated	 only	 with	 free	 siRNA,	 “LF”	
represents	cells	 treated	with	 lipofectamine	 lipoplexes.	 (Data	points	 indicate	mean	±	SD,	n	=	3;	










To	 evaluate	 transfection	 efficiencies,	 Jurkat	 cells	 were	 transfected	 with	 polyplexes	
containing	 a	 plasmid	 expressing	 green	 fluorescent	 protein	 (GFP)	 under	 an	 active	
constitutive	 promoter	 and	 resulting	 fluorescence	 levels	 were	 determined	 by	 flow	
cytometry.	As	seen	in	Figure	5A,	cells	treated	with	PEI/plasmid	polyplexes	showed	MFI	
values	similar	to	untreated	cells	or	cells	only	incubated	with	free	plasmid,	indicating	no	
sufficient	 transfection.	 Tf-PEI	 and	 Mel-PEI,	 however,	 demonstrated	 comparable	
transfection	efficiencies	as	LF,	while	 the	Tf-Mel-PEI	blend	even	surpassed	the	positive	
control	by	approximately	40	%.	
Next,	 GFP	 protein	 knockdown	 was	 tested	 in	 H1299	 cells	 stably	 expressing	 EGFP	
(H1299-mEGFP)	 using	 polyplexes	 encapsulating	 GFP	 targeting	 siRNA	 (GFP-siRNA)	
(either	 with	 or	 without	 simultaneous	 treatment	 with	 the	 lysosomotropic	 agent	
chloroquine)	compared	to	respective	particles	carrying	NC-siRNA	as	negative	controls.	
Figure	 5B	 depicts	 that	 neither	 PEI	 nor	 Tf-PEI	 polyplexes	 achieved	 a	 silencing	 effect,	
while	 Mel-PEI	 and	 Tf-Mel-PEI	 resulted	 in	 significant	 knockdown.	 Tf-Mel-PEI	 was	





Figure	 5.	 A)	 Transfection	 of	 Jurkat	 cells	 with	 a	 GFP	 expressing	 plasmid	 measured	 by	 flow	
cytometry	as	median	fluorescence	intensity	(MFI)	of	GFP.	B)	GFP	knockdown	in	H1299-mEGFP	
cells	depicted	as	MFI	of	GFP	after	treatment	with	GFP	siRNA	or	scrambled	control	siRNA	(NC)	





We	 then	 investigated	 whether	 the	 high	 cellular	 uptake	 also	 correlates	 with	
corresponding	 gene	 silencing.	Downregulation	was	 examined	using	 siRNA	 specifically	
targeting	the	house-keeping	gene	GAPDH	(GAPDH-siRNA)	followed	by	quantification	of	
respective	mRNA	levels	via	real	 time	PCR	(RT-PCR).	All	 tested	 formulations	were	also	
applied	 containing	 scrambled	 non-targeting	 siRNA	 (NC-siRNA)	 as	 a	 negative	 control.	
Figure	 6A	 shows	 GAPDH	 expression	 normalized	 to	 β-actin	 after	 treatment	 of	 Jurkat	
cells.	While	Tf-PEI	and	Tf-Mel-PEI/GAPDH-siRNA	polyplexes	were	able	to	significantly	
silence	 the	 gene	 expression	 compared	 to	 respective	 NC-siRNA	 and	 untreated	 control	




CD4+	 T	 cells	 (Figure	 6B).	 Again,	 unmodified	 PEI	 polyplexes	 did	 not	 result	 in	 efficient	




Figure	 6.	 GAPDH	 knockdown	 in	 A)	 Jurkat	 cells	 and	 B)	 primary	 CD4	 +	 human	 T	 cells	 after	










prior	 to	 imaging.	 Figure	 7A	 summarizes	 the	 degree	 of	 lysosomal	 disruption	 as	
visualized	by	 an	 increase	 in	 green	 fluorescence	 captured	by	 fluorescence	microscopy.	
Both	 melittin	 containing	 conjugates	 Mel-PEI	 (7A5)	 and	 Tf-Mel-PEI	 (7A6)	 induced	
acridine	orange	 release	 from	cytoplasmic	endosomal	vesicles	 similarly	 to	 chloroquine	
(7A2),	proving	efficient	endosomal	disruption	in	the	treated	cells.	Polyplexes	composed	
of	 unmodified	 PEI	 (7A3),	 however,	 did	 not	 visibly	 influence	 endosomal	 integrity,	
eventuating	 in	 red	 fluorescing	 cells	 comparable	 to	 the	 blank	 sample	 (7A1).	 Tf-PEI	
particles	 (7A4)	 only	 resulted	 in	 a	 vague	 green	 signal,	 suggesting	 insignificant	 dye	
release.		
To	portray	endosomal	release	of	polyplexes	taken	up	into	cells	in	a	more	accurate	way,	
Jurkat	 cells	 were	 transfected	 with	 AF488-siRNA	 and	 stained	 with	 LysoTracker	 Red	
DND-99,	a	fluorescent	probe	that	accumulates	in	acidic	vesicles,	as	well	as	DAPI	before	
analyzing	 them	 by	 confocal	 microscopy.	 Figure	 7B	 illustrates	 the	 different	 polyplex	
treatments	 and	 resulting	 effects	 on	 cellular	 uptake	 and	 endosomal	 release	 of	
fluorescently	 labeled	siRNA.	Blue	areas	depict	 the	cell	nuclei	colored	with	DAPI,	while	
red	 staining	 reflects	 lysosomes,	 and	 green	 staining	 is	 accounted	 to	 the	 incorporated	
siRNA.	As	Figure	7B2	shows,	no	green	signal	can	be	detected	in	the	free	siRNA	sample,	
meaning	 that	 no	 successful	 uptake	 can	 take	 place	 without	 an	 appropriate	 delivery	
system.	 Uptake	 with	 PEI	 (7B3)	 and	 Tf-PEI	 (7B4),	 however,	 results	 in	 a	 punctate	
distribution	 of	 fluorescent	 siRNA	 with	 an	 appearance	 similar	 to	 the	 red	 stained	
lysosomes,	suggesting	endosomal	entrapment	of	the	delivered	cargo.	In	contrast	to	this,	
Mel-PEI	 treated	 cells	 (7B5)	 show	 rather	 cloudy	 green	 signals	 evenly	 spread	 over	 the	
cells,	 implying	 that	 the	siRNA	was	not	only	 successfully	delivered	 inside	 the	cells,	but	
also	able	to	escape	the	endosomes	and	consistently	distribute	in	the	cytoplasm.	For	cells	
transfected	 with	 Tf-Mel-PEI	 polyplexes	 (7B6),	 both	 the	 point-shaped	 and	 the	
homogeneously	 spread	 signal	 can	 be	 observed,	 entailing	 that	 while	 parts	 of	 the	
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and	 treatment	 with	 chloroquine	 (A2),	 PEI	 polyplexes	 (A3),	 Tf-PEI	 polyplexes	 (A4),	 Mel-PEI	









MTS	 assay	 performed	 in	 A549	 cells	 that	 had	 been	 incubated	 with	 the	 different	
formulations	 at	 increasing	 N/P	 ratios.	 As	 exemplified	 in	 Figure	 8A,	 Mel-PEI	
demonstrated	the	greatest	negative	influence	on	cell	viability,	while	unmodified	PEI	was	
slightly	better	tolerated.	No	significant	differences	were	found	for	the	effects	of	Tf-PEI	
and	Tf-Mel-PEI	 for	any	 tested	 condition,	 indicating	 that	blending	with	Mel-PEI	has	no	
negative	 influence	on	 cell	 tolerability.	Notably,	 at	 treatment	 relevant	N/P	 ratios	of	10	
and	15,	both	Tf-PEI	and	Tf-Mel-PEI	showed	average	cell	viability	rates	of	around	90	%.		
For	 further	 examination	 of	 cell	 tolerability	 focusing	 on	 membrane	 integrity,	 an	 LDH	
Assay	was	 performed	 in	A549	 cells	 as	 presented	 in	 Figure	 8B.	 Analogous	 to	 the	MTS	
Assay,	 cells	were	 incubated	with	 polyplexes	 at	 different	 N/P	 ratios	 and	 the	 resulting	
LDH	 release	 was	 measured	 in	 comparison	 to	 untreated	 blank	 samples.	 Again,	 no	














being	 widely	 investigated	 for	 potential	 in	 vivo	 applications.[426]	 Its	 high	 density	 of	




these	 activated	 T	 cells	 exhibit	 a	 high	 metabolic	 activity	 and	 hence	 high	 iron	
consumption,	 Tf	 receptors	 are	 overexpressed	 in	 order	 to	 enhance	 the	 uptake	 of	 Tf-
coupled	 iron.[23]	 This	 can	 be	 exploited	 as	 an	 entry	 gate	 for	 Tf-targeted	 polyplexes	
reaching	 the,	 otherwise	 hard	 to	 transfect,	 primary	 T	 cells.	 Despite	 the	 critically-
discussed	 hypothesis	 that	 positively	 charged	 polymers	 such	 as	 PEI	 demonstrate	 the	
proton	 sponge	 effect	 upon	 acidification	 of	 endosomal	 compartments,[428]	 leading	 to	
disruption	 and	 release	 of	 delivered	 payload,	 PEI	 generally	 exhibits	 rather	 low	
endosomolytic	properties,	which	is	especially	true	for	LMW-PEI.	Since	it	is	crucial	that	
sufficient	 siRNA	molecules	 reach	 the	 cytoplasm	 to	 be	 therapeutically	 relevant,	 it	was	
aimed	 to	 apply	 an	 additional	 endosomal	 escape	 mechanism	 in	 this	 work	 by	
incorporating	 melittin	 into	 the	 Tf-PEI	 delivery	 system.	 Melittin	 is	 a	 26	 amino	 acid	
peptide	that	was	first	purified	from	the	venom	of	the	European	honeybee	in	1958	and	
shows	 a	 particularly	 strong	 lytic	 activity	 due	 to	 its	 high	 affinity	 to	 lipid	
membranes.[423]	Although	the	exact	mechanisms	of	this	properties	have	not	yet	been	
fully	 identified,	 it	 is	 currently	 assumed	 that	 the	 membrane	 destabilization	 is	 taking	
place	in	a	two-step	mechanism	that	is	comparable	to	the	effect	of	detergents:[422,	423]	
melittin	 first	 reacts	 with	 negatively	 charged	 lipid	 head	 groups	 via	 electrostatic	
interactions	and	binds	parallel	to	the	membrane.	When	a	critical	peptide	concentration	
is	 reached,	melittin	molecules	 rearrange	 perpendicular	 to	 the	membrane	 surface	 and	
form	 pores,	 thereby	 interrupting	 and	 destabilizing	 the	 membrane	 bilayer.	 It	 was	
successfully	 shown	 that	 despite	 of	 these	 lytic	 properties,	 in	 vivo	 toxicity	 of	 naked	
melittin	 can	 distinctly	 be	 attenuated	 by	 respective	 modifications,	 including	






are	 taken	 up	 into	 the	 endosome,	 the	 acidic	 environment	 triggers	 cleavage	 of	 these	
protecting	 groups	 and	 recovery	 of	 melittin’s	 membrane	 destabilizing	 effects.	 Initial	
studies	 showed	 diminished	 lytic	 activity	 by	 irreversibly	 masking	 lysines	 and	 the	
terminal	 amino	 function.[431]	 Rozema	 et	 al.	 then	 reversibly	 acylated	melittin	 with	 a	
dimethylmaleic	anhydride	[432],	following	the	role	model	of	viruses	such	as	adenovirus	
which	 presents	 its	 endosomolytic	 residues	 only	 upon	 endosomal	 acidification[433].	
Meyer	 et	 al.	 further	 developed	 this	 approach	 by	 covalently	 linking	 this	 reversibly	
masked	melittin	 to	 polycations	 delivering	DNA.[54]	 The	 reversible	 reaction	 of	maleic	
anhydrides	 with	 the	 amines	 of	 melittin	 is	 reverted	 at	 endosomal	 pH,	 restoring	 lytic	
activity[434]	 to	 aid	 subsequent	 cytoplasmic	 release	 of	 the	 delivered	 cargo.	 We	
ultimately	combined	 the	benefits	of	 coupling	both	 transferrin	and	melittin	 to	PEI	as	a	
gene	delivery	system	by	blending	 the	 two	conjugates	Tf-PEI	and	Mel-PEI	yielding	one	
bioresponsive	 siRNA	 carrier	 capable	 of	 both	 T	 cell	 targeted	 and	 efficient	 cytoplasmic	
delivery.	
DLS	measurements	 of	 resulting	 polyplexes	 confirmed	 our	 previous	 observations	 that	
modification	of	PEI	with	the	negatively	charged	hydrophilic	glycoprotein	Tf	eventuates	
in	a	considerable	reduction	of	particle	sizes.[40]	Coupling	of	PEI	with	melittin	likewise	
resulted	 in	 smaller	 polyplexes,	 while	 the	 blending	 of	 Tf-PEI	 with	 Mel-PEI	 yielded	
particles	with	even	smaller	and	more	homogenous	hydrodynamic	diameters	below	200	
nm,	 presenting	 optimal	 characteristics	 for	 efficient	 pulmonary	 transfection.	 The	
assumed	decoration	with	the	soluble	negatively	charged	Tf	on	the	outside	of	polyplexes	
is	supported	by	a	decrease	of	positive	surface	charges	for	TF-PEI	vs.	PEI	as	well	as	for	
Tf-Mel-PEI	 vs.	Mel-PEI.	While	 all	 tested	N/P	 ratios	 of	 Tf-PEI	 polyplexes	 held	 negative	




charged	 masked	 melittin	 seem	 to	 be	 present	 at	 the	 outer	 regions	 of	 the	 polyplexes	
resulting	in	an	overall	slightly	negative	zeta	potential.	At	higher	N/P	ratios	with	excess	
polymer,	 the	 particle	 composition	 changes	 to	more	 PEI	 being	 present	 at	 the	 surface,	
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raising	 the	 overall	 charge	 to	 positive	 values.	 Interestingly,	 viruses	 as	 well	 as	 virus-
mimicking	 particles	 coated	with	 both	 positively	 and	 negatively	 charged	 groups	were	
found	 to	 avoid	 electrostatic	 mucus	 adhesion,	 eventuating	 in	 minimized	 entrapment.	
[435]	 The	 modified	 surface	 properties	 may	 hence	 facilitate	 particle	 mobility	 in	 lung	
fluids	and	thereby	improve	respective	in	vivo	behavior	of	Tf-Mel-PEI	polyplexes.	
To	 investigate	the	 influence	of	melittin	unmasking	 in	acidic	environments	on	polyplex	
characteristics,	DLS	and	LDA	measurements	were	also	conducted	at	pH	5.	As	shown	in	
Figure	S1A,	zeta	potentials	of	Mel-PEI	as	well	as	Tf-Mel-PEI	polyplexes	overall	increase	
leading	 to	 invariably	 positively	 charged	 particles	 which	 can	 be	 explained	 by	 the	
unmasked	amine	groups	of	melittin.	Concerning	the	hydrodynamic	diameters,	Mel-PEI	





at	 all	 tested	 N/P	 ratios.	 As	 they	 do	 no	 longer	 display	 negative	 charges	 at	 any	 of	 the	
tested	 N/P	 ratios,	 it	 can	 be	 expected	 that	 the	 assumed	 exterior	 decoration	 with	
transferrin	 leading	 to	 shielding	 and	 tight	 condensation	 does	 not	 convey	 to	 the	 acidic	
environment.	 It	 is	 even	 conceivable	 that	 negative	 charges	 of	 transferrin	 and	 positive	















Since	 siRNA	 is	 easily	 degraded	 and	 rapidly	 excreted	 upon	 systemic	 injection,	 local	




liquid	 (surfactant).	 Cationic	 carrier	 systems,	 in	 particular,	 can	 nonspecifically	 interact	
with	 the	 negatively	 charged	 lung	 lining	 fluids,	 be	 entrapped,	 destabilized	 and	 their	
mobility	 is	decreased.[437]	 It	was	 shown	 that	modifying	positive	PEI	polyplexes	with	
the	negatively	charged	hydrophilic	glycoprotein	Tf	results	in	reduced	interactions	with	
polyanions	and	thus	enhanced	stability.[43]	This	was	also	demonstrated	in	our	previous	
work,	 wherein	 Tf-PEI	 polyplexes	 exhibited	 increased	 stability	 in	 artificial	 lung	 lining	
fluids[40].	Here,	we	examined	the	stability	of	all	conjugates	again,	including	the	Tf-Mel-











showed	 superior	 stability	 within	 the	 influence	 of	 surface	 active	 phospholipids	 and	




confirmed	 the	 specific	 binding	 of	 transferrin	 containing	 polyplexes,	 while	 no	 binding	
was	 observed	 for	 unmodified	 PEI	 particles.	 Comparison	 of	 binding	 affinities	 revealed	
that	 Tf-PEI	 particles	 bind	 even	more	 stable	 than	 free	 transferrin,	 showing	 an	 overall	




resulting	 in	 a	 reduced	 accessibility	 of	 Tf	 in	 the	 particles	 compared	 to	 the	 free	 ligand.	
Lack	 of	 the	 early	 high	 dissociation	 rate	 for	 Tf-PEI	 compared	 to	 free	 Tf,	 however,	
eventuates	 in	 an	 overall	 enhanced	 binding	 stability.	 Considering	 the	 fact	 that	 only	 an	
adequately	 stable	 and	 sustained	 receptor	binding	 can	 result	 in	 sufficient	downstream	
signaling	 and	 endocytosis,	 this	 parameter	 is	 extremely	 relevant	 for	 evaluating	 in	 vivo	
performance.	 Strikingly,	 Tf-Mel-PEI	 blend	 polyplexes	 presented	 an	 even	 increased	
binding	 affinity	 compared	 to	 the	 original	 conjugate.	 It	 was	 recently	 proposed	 that	
melittin	 itself	 also	 interacts	 with	 TfR[439],	 which	 taken	 together	 with	 evidently	
improved	 surface	 properties	 in	 the	 altered	 composition	 of	 the	 blend	 particles	 could	




charged	 cell	 membranes	 triggering	 adsorptive	 endocytosis.	 This	 non-targeted	 uptake	









distinctly	 enhanced	 uptake.	 As	 continuous	 cell	 lines	 significantly	 differentiate	 from	
primary	cells	 in	 their	membrane	composition	and	endocytosis	profiles,	we	decided	 to	
validate	these	data	in	primary	T	cells.	In	TfR	overexpressing	activated	CD4+	T	cells,	the	
distinctly	higher	uptake	of	Tf-targeted	polyplexes	compared	to	unmodified	PEI	and	Mel-
PEI	 suggests	 efficient	 Tf-mediated	 endocytosis	 of	 Tf-PEI	 and	 Tf-Mel-PEI.	 The	
preferential	uptake	of	Tf-PEI	 in	activated	as	opposed	to	naïve	T	cells	with	a	negligible	
receptor	 expression,	 was	 even	 more	 pronounced	 after	 the	 addition	 of	 melittin.	 The	
improved	 binding	 characteristics	 of	 the	 Tf-Mel-PEI	 blend	 demonstrated	 in	 the	 SPR	
experiments	 are	 also	 reflected	 in	 the	 uptake	 behavior	 of	 the	 polyplexes.	 Tf-Mel-PEI	
blends,	therefore,	seem	to	exhibit	ideal	characteristics	for	most	efficient	internalization	
without	losing	any	of	the	targeting	potential	of	Tf-PEI.	Increasing	the	Tf-PEI	fraction	to	
greater	 than	50%	did	not	 provide	 any	 additional	 targeting	benefit	 and	 increasing	 the	
melittin	containing	fraction	above	50%	would	presumably	decrease	the	specific	binding	
affinity	 too	much.	Therefore,	we	decided	 to	 further	pursue	 the	50:50	blend	of	Tf-Mel-
PEI	 as	 the	 most	 promising	 candidate	 for	 therapeutic	 application.	 Although	 N/P	 15	
showed	slightly	superior	uptake	efficiencies	than	N/P	10,	an	increased	polymer	excess	
usually	 correlates	 with	 a	 higher	 toxicity,	 so	 that	 N/P	 10	 was	 chosen	 for	 subsequent	
knockdown	studies.		
The	 specificity	 of	 uptake	 of	 the	 Tf-containing	 polyplexes	 was	 confirmed	 by	 a	 Tf	
competition	 assay.	While	 uptake	 of	 those	 polyplexes	 without	 the	 targeting	 ligand,	 as	
expected,	 was	 not	 influenced	 by	 the	 presence	 of	 free	 transferrin,	 the	 Tf-targeted	
polyplexes	exhibited	clearly	compromised	uptake	efficiencies,	although	the	uptake	was	
not	 blocked	 completely.	We	 recently	 described	 how	monovalent	 ligands	 cannot	 fully	
outcompete	 binding	 of	 multivalent	 ligands.[438]	 This	 concentration-dependent	
influence	 of	 additional	 free	 Tf	 molecules	 competing	 for	 the	 binding	 sites	 at	 the	 TfR	
supports	 the	 anticipated	 hypothesis	 that	 both	 Tf-PEI	 and	 Tf-Mel-PEI	 polyplexes	 are	




Thus,	 even	 the	 reduced	 Tf	 amount	 of	 50	 %	 in	 the	 blend	 is	 apparently	 sufficient	 for	
specific	receptor	binding,	and	it	can	be	expected	that	enough	Tf	is	still	located	towards	
the	surface	of	the	blend	polyplexes,	being	able	to	initiate	TfR	binding.		
Although	 uptake	 experiments	 confirmed	 efficient	 internalization	 of	 siRNA,	 its	
subsequent	 fate	and	 functionality	was	still	unknown.	We	therefore	evaluated	whether	
the	polyplexes	are	also	able	to	deliver	a	plasmid	that	would	subsequently	be	expressed	
by	 the	 cells.	 As	 expected,	 Tf-Mel-PEI	 showed	 the	 highest	 transfection	 efficiencies,	
mirroring	 the	 uptake	 results.	 This	 improved	 transfection	 did	 also	 result	 in	 enhanced	
knockdown	 effects	 on	 GFP	 protein	 levels,	 which	 could	 not	 be	 further	 amplified	 by	
chloroquine	treatment	for	Tf-Mel-PEI,	but	for	all	other	tested	polymers.	Thus,	the	blend	
polyplexes	seem	to	be	 the	only	delivery	system	being	able	 to	 induce	sufficient	uptake	
and	endosomal	release	of	 the	delivered	cargo	on	 its	own.	However,	 it	has	 to	be	noted	
that	the	used	cell	line	stably	expresses	GFP	which	has	a	reported	half-life	of	26	h	[440]	
and	 in	 unsynchronized	 cultures	 protein	 turnover	 rates	 are	 varied,	 which	 might	
potentially	mask	 the	 overall	 efficiency	 of	 the	 knockdown.	 Since	 siRNA	effects	 directly	
influence	mRNA	levels,	these	were	then	evaluated	by	qRT-PCR	after	treatment	with	the	
different	 polyplexes	 in	 the	 Jurkat	 cell	 line	 and	 in	 human	 primary	 CD4+	 T	 cells.	 The	
improved	uptake	and	endosomal	escape	properties	of	the	Tf-Mel-PEI	blend	did	indeed	




Based	 on	 these	 findings,	 it	 could	 already	 be	 postulated	 that	 adding	 melittin	 to	 the	
polyplexes	 does	 in	 fact	 improve	 endosomal	 escape	 of	 delivered	 siRNA.	 To	 verify	 that	
melittin-containing	 polyplexes	 are	 actually	 inducing	 endosomal	 disruption,	 acridine	
orange	 staining	 was	 performed	 in	 living	 cells.	 Acridine	 orange	 is	 a	 cell	 permeant,	
lysosomotropic,	 metachromatic	 dye	 with	 a	 luminescence	 wavelength	 strongly	











Endosomal	 release	 was	 further	 verified	 in	 Jurkat	 cells	 after	 transfection	 with	
fluorescently	 labeled	siRNA	via	 the	different	polyplexes.	Following	uptake	with	PEI	or	
Tf-PEI,	 siRNAs	 demonstrated	 a	 punctate	 distribution	 which	 correlated	 and	 partly	
colocalized	with	lysosomal	staining,	confirming	endosomal	entrapment.	Mel-PEI,	on	the	
other	hand,	showed	a	homogenous	distribution	of	the	siRNA	throughout	the	cytoplasm.	
Remarkably,	 Tf-Mel-PEI	 treated	 cells	 depicted	 both	 punctate	 and	 diffused	 siRNA	
distribution,	 indicating	 that	 while	 a	 fraction	 of	 the	 siRNA	 remains	 within	 the	
endosomes,	 a	 significant	 proportion	 was	 able	 to	 escape,	 marking	 a	 definite	
improvement	 to	 the	 original	 Tf-PEI.	 These	 results	 confirmed	 the	 favorable	 effect	 of	
melittin	on	endosomal	release	of	delivered	siRNA,	resulting	in	a	distinct	improvement	in	
cytosolic	 accumulation	 and	 eventual	 gene	 silencing.	 As	 most	 endocytic	 vesicles	 are	
rapidly	trafficked	to	the	early	endosome,	as	long	as	the	escape	does	not	happen	before	
this	 fusion,	 the	 influence	 of	 internalization	 mechanisms	 on	 endosomal	 escape	 is	 not	
clarified.[51]	It	 is	therefore	conceivable	that	besides	the	mere	lytic	activity	of	melittin,	
also	 the	 altered	 uptake	 of	 the	 Tf-Mel-PEI	 blends	 plays	 a	 role	 in	 this	 improvement.	









acute	 toxicity,	 it	 is	 crucial	 not	 to	 generate	 this	 effect	 until	 the	 delivery	 system	 is	
undergoing	the	endo/lysosomal	pathway.	In	the	Tf-Mel-PEI	blend	this	is	achieved	by	a	




protection,	 potential	 detrimental	 effects	 of	 melittin	 addition	 on	 cell	 tolerability	 were	
examined	 by	 MTS	 and	 LDH	 assay,	 investigating	 metabolic	 activity	 and	 membrane	
integrity	of	treated	cells,	respectively.	Cationic	polymers	and	peptides	such	as	PEI	and	






significant	LDH	release	 compared	 to	untreated	cells,	 indicating	 that	all	polyplexes	are	








of	 the	 delivered	 cargo.	 By	 adding	 an	 endosomolytic	 agent	 to	 our	 original	 Tf-PEI	
conjugate,	we	did	not	only	specifically	 improve	the	cytoplasmic	delivery	of	siRNA,	but	
furthermore	distinctly	advanced	several	other	important	properties.	The	pH-responsive	
shielding	 exploiting	 endosomal	 acidification	 triggers	 lytic	 activity	 only	 in	 lysosomes,	
avoiding	 general	 toxicity.	 Blending	 of	 Tf-PEI	 and	 Mel-PEI	 therefore	 yields	 a	 novel	












Tf-PEI	 conjugates	 were	 prepared	 as	 recently	 described[40]	 	 and	Mel-PEI	 conjugation	
was	 performed	 based	 on	 a	 previously	 described	 protocol	 with	 respective	
modifications.[54]	 In	 detail,	 5k	 PEI	 (Lupasol®	 G100,	 BASF,	 Ludwigshafen,	 Germany)	
was	dissolved	in	HEPES	buffered	saline	(HBS)	(20	mM	HEPES,	150	mM	NaCl,	pH	=	7.4)	
at	 a	 concentration	of	 5	mg/ml	 and	mixed	with	 an	 excess	of	 (4-polyethylene	 glycol-N-
succinimidyl	 3-(2-pyridyldithio)	 propionate	 (PEG4-SPDP,	 20	 mM)	 (Thermo	 Fisher	
Scientific,	Waltham,	USA)	in	dry	DMSO	and	stirred	overnight.	Cysteine	modified	melittin	
(Pepmic,	 Suzhou,	 China)	 was	 dissolved	 in	 HBS	 (3	 mg/mL),	 a	 150	 mM	 solution	 of	
dithiothreitol	(DTT)	was	added,	and	the	mixture	was	shaken	for	2	h.	Reduced	melittin	











term	 “Tf-Mel-PEI”	 is	 used	 for	 the	 50:50	mixture	 throughout	 this	 article	 if	 not	 stated	
otherwise)	were	diluted	 in	 either	HBS	or	 5	%	glucose	 and	defined	 amounts	 of	 siRNA	
were	 added	 in	 order	 to	 obtain	 specific	 amine	 to	phosphate	 (N/P)	 ratios.	 The	mass	 of	
polymer	 required	 for	 50	 pmol	 siRNA	 to	 yield	 a	 certain	 N/P	 ratio	 was	 calculated	
according	to	the	following	equation:	m	(PEI	in	pg)	=	50	pmol	x	43.1	g/mol	x	N/P	x	52	
(protonable	unit	of	PEI	=	43.1	g/mol,	number	of	nucleotides	of	25/27mer	siRNA	=	52).	
The	 formulations	 were	 mixed	 by	 pipetting	 and	 incubated	 for	 20	 min	 before	 further	







(Malvern	 Instruments,	Malvern,	 UK).	 As	 an	 example,	 for	N/P	 10,	 1.1	 µl	 of	 a	 1	mg/ml	




analysis	 with	 the	 Zetasizer	 software.	 Polyplexes	 were	 then	 diluted	 with	 900	 µl	 of	




To	 determine	 siRNA	 condensation	 efficiencies,	 polyplexes	 with	 50	 pmol	 siRNA	 were	
prepared	 at	 different	N/P	 ratios	 in	 5	%	 glucose,	 distributed	 in	 a	 FluoroNunc	 96-well	
white	plate	(Thermo	Fisher	Scientific)	and	incubated	for	20	min.	Subsequently,	30	µl	of	
4x	 SYBR®	 Gold	 Nucleic	 Acid	 Gel	 Stain	 (Thermo	 Fisher	 Scientific)	 was	 added	 and	
incubated	for	10	min	in	the	dark.	SYBR®	Gold	is	a	fluorescent	nucleic	acid	staining	dye	
that	fluoresces	only	when	intercalating	with	free	siRNA.	When	the	siRNA	is	protected	in	
a	 coherent	 polyplex	 and	 not	 accessible	 to	 the	 dye,	 no	 fluorescence	 signal	 is	 detected.	
Measurements	 were	 conducted	 on	 a	 FLUOstar	 Omega	 (BMG	 Labtech,	 Ortenberg,	




For	 evaluating	 polyplex	 stability	 in	 lung	 fluids,	 modified	 SYBR®	 Gold	 Assays	 were	
performed	[36]	in	the	presence	of	mucin	(Sigma-Aldrich)	or	lung	surfactant	Alveofact®	
(Lyomark	 Pharma,	 Oberhaching,	 Germany).	 Therefore,	 the	 described	 protocol	 was	
followed	with	polyplexes	at	N/P	ratio	10,	but	SYBR®	Gold	was	already	added	after	15	
min	 and	 incubated	 for	 10	 min.	 Subsequently,	 50	 µl	 of	 a	 serial	 dilution	 of	 mucin	 or	
Alveofact®	were	added	to	obtain	final	concentrations	of	0,	0.0005,	0.005,	0.05,	0.5,	and	
0.25	 mg/ml	 and	 incubated	 for	 another	 20	 min	 before	 fluorescence	 measurements.	
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investigated	by	 Surface	Plasmon	Resonance	 (SPR)	 spectroscopy.	To	 eliminate	 initially	
observed	 unspecific	 interactions	 of	 sticky	 PEI	 polymer	 with	 the	 sensor	 chip	 surface,	
gradient	addition	of	NaCl	to	the	sample	buffers	was	tested,	revealing	that	an	extra	625	





Tf	 and/or	 PEI,	 respectively.	 For	 comparison,	 free	 human	 holo-transferrin	 (Sigma	
Aldrich)	 was	 dissolved	 in	 the	 same	 buffer	 in	 which	 the	 polyplex	 samples	 were	
dispersed,	 and	 recombinant	 human	 transferrin	 receptor	 protein	 (Abcam,	 UK)	 was	
diluted	in	HBS-N	without	additional	NaCl.	
SPR	 assays	 were	 performed	 in	 a	 Biacore	 T200	 device	 using	 Biacore	 CM5	 Series	 S	




the	 four	 flow	cells	of	 the	 sensor	 chips	were	activated	by	 injecting	a	1:1	mixture	of	N-
ethyl-N-(3-dimethylaminopropyl)carbodiimide	 hydrochloride	 and	 N-
hydroxysuccinimide	using	 the	standard	amine-coupling	protocol.	Both	 flow	cells	were	
loaded	 with	 a	 final	 concentration	 of	 50	µg/ml	 of	 anti-histidine	 antibody	 in	 10	mM	
acetate	pH	4.5	using	a	contact	time	of	420	s,	so	that	the	surfaces	contained	densities	of	
approximately	 10,000	 resonance	 units	 (RU).	 Free	 binding	 sites	 of	 the	 flow	 cells	were	
saturated	by	injection	of	1	M	ethanolamine/HCl	pH	8.0.	Preparation	of	chip	surfaces	was	
carried	 out	 at	 a	 flow	 rate	 of	 10	µl/min.	 Interaction	 analyses	 between	 the	 prepared	
polyplexes	and	TfR-His	were	then	performed	in	HBS-N	buffer	+	625	mM	NaCl.	First,	TfR-
His	 (30	nM)	was	 captured	onto	 the	 second	 flow	cell	 using	a	 contact	 time	of	60	 s	 at	 a	
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constant	 flow	 rate	 of	 10	 µl/min,	 followed	 by	 a	 stabilization	 time	 of	 20	 s	 so	 that	
approximately	300-400	RU	of	TfR-His	were	captured.	Increasing	concentrations	(1	nM,	
10	nM,	25,	nM,	50	nM,	100	nM,	2	x	250	nM,	500	nM,	and	1000	nM)	of	 the	polyplexes	







obtain	 blank	 sensorgrams	 for	 subtraction	 of	 bulk	 refractive	 index	 background.	 The	








pyruvate,	 4500	 mg/l	 glucose,	 10	 %	 (v/v)	 heat	 inactivated	 fetal	 bovine	 serum	 (FBS,	
Sigma-Aldrich)	 and	 1	 x	 penicillin/streptomycin	 (Pen/Strep,	 Sigma-Aldrich).	 CD4+	
human	 primary	 T	 cells	were	 isolated	 from	 freshly	 obtained	 buffy	 coats	 (DRK,	 Berlin,	
Germany)	via	magnetic	bead	separation	with	a	CD4+		T	cell	isolation	kit	(Miltenyi	Biotec,	
Bergisch	 Gladbach,	 Germany)	 as	 described	 before.[443]	 Cells	 were	 subsequently	
cultured	in	the	same	media	as	Jurkat	cells	and,	where	described,	activated	with	anti-CD3	
and	 anti-CD28	monoclonal	 antibodies	 (BS	 Biosciences,	 Franklin	 Lake,	 USA)	 at	 a	 final	
concentration	 of	 5	 µg/ml	 or	 1	 µg/ml,	 respectively.	 A549	 cells,	 an	 adenocarcinomic	








For	 uptake	 experiments,	 amine	 modified	 siRNA	 (Integrated	 DNA	 Technologies,	
Coralville,	 USA)	 was	 labeled	 with	 succinimidyl	 ester	 (NHS)	 modified	 AF	 488	 (Life	
Technologies,	 Carlsbad,	 USA)	 according	 to	 the	 manufacturer’s	 protocol	 resulting	 in	
siRNA-AF488,	 and	 purified	 via	 ethanol	 precipitation	 and	 spin	 column	 binding	 as	
described	before.	[444]	Polyplexes	were	prepared	with	50	pmol	siRNA-488	at	different	
N/P	ratios	and	lipoplexes	were	prepared	with	LF	as	positive	control.	Per	well,	400.000	
Jurkat	 cells	 or	 human	 primary	 CD4+	 T	 cells	 were	 seeded	 in	 96-well	 plates	 (Thermo	
Fisher	Scientific)	at	a	concentration	of	2x106	cells/ml,	transfected	and	incubated	for	24	
h.	Primary	human	T	cells	were	transfected	directly	after	isolation	from	fresh	buffy	coats	
for	 non-activated	 cells	 or	 after	 48	 h	 of	 activation	 with	 CD3/CD28	 antibodies	 for	
activated	cells	as	described	above.	As	negative	controls,	blank	samples	were	seeded	and	
left	untreated	and	free	siRNA	samples	were	transfected	with	50	pmol	of	siRNA	diluted	
in	 5	%	glucose.	 Cells	were	 harvested	 and	washed	 three	 times	 before	 resuspension	 in	
400	µl	PBS/2	mM	EDTA	(Sigma-Aldrich).	Samples	were	analyzed	using	an	Attune®	NxT	
flow	cytometer	(Thermo	Fisher	Scientific)	with	488	nm	excitation	and	530/30	emission	
filter.	 All	 cells	 were	 gated	 according	 to	 morphology	 based	 on	 forward/sideward	
scattering,	 and	10.000	events	were	 evaluated	per	 sample.	 For	 trypan	blue	quenching,	
one	 half	 of	 each	 sample	 was	 washed	 with	 0.4	 %	 trypan	 blue	 to	 mask	 any	 signal	
originating	from	extracellular	fluorescence.		
For	Tf	competition	assays,	Jurkat	cells	were	seeded	in	medium	either	without	free	Tf	or	





seeded	 in	 a	 96-well	 plate	 or	 650.000	 CD4+	 T	 cells	 were	 seeded	 in	 a	 48-well	 plate	
(Thermo	 Fisher	 Scientific)	 and	 activated	 for	 48	 h	 as	 described	 above.	 Cells	 were	
transfected	with	polyplexes	containing	100	pmol	siRNA	either	directed	against	GAPDH	
(siGAPDH)	or	scrambled	negative	control	siRNA	(siNC),	respectively,	at	an	N/P	ratio	of	




digestion	 (Thermo	 Fisher	 Scientific).	 cDNA	was	 synthesized	 from	 RNA	 and	 amplified	
with	Brilliant	III	ultra-fast	SYBR®	green	QRT-PCR	master	mix	kit	(Agilent	Technologies,	
Santa	 Clara,	 USA)	 and	 QuantiTect®	 primer	 assays	 Hs_GAPDH_1_SG	 and	Hs_ACTB_2_SG	
(Qiagen,	Venlo,	Netherlands)	using	 a	qTOWER	real-time	PCR	 thermal	 cycler	 (Analytik	
Jena,	 Jena,	 Germany).	 Cycle	 threshold	 (Ct)	 values	 were	 obtained	 with	 the	 qPCRsoft	
software	 (Analytik	 Jena).	An	untreated	blank	sample	was	used	 to	prepare	a	1:5	 serial	
dilution	with	5	points	as	a	standard	curve	and	respective	Ct	values	were	plotted	against	





and	 transfected	 with	 polyplexes	 or	 LF	 lipoplexes	 containing	 0.75	 µg	 of	 pCMV-GFP	




nm	 excitation	 and	 530/30	 nm	 bandpass	 emission	 filter	 set.	 All	 samples	 were	 gated	
based	 on	 morphology	 with	 forward/sideward	 scattering,	 analyzing	 a	 minimum	 of	
10.000	viable	cells.		
For	GFP	protein	knockdown,	20.000	H1299-mEGFP	cells	were	seeded	in	a	24-well	plate	
(Thermo	 Fisher	 Scientific)	 24	 h	 prior	 to	 the	 experiment.	 Cells	 were	 then	 transfected	













For	 endosomal	 escape	 studies,	 15.000	 A549	 cells	 were	 seeded	 per	 well	 in	 8-well	
chamber	 slides	 (Ibidi,	 Martinsried,	 Germany)	 24	 h	 prior	 to	 the	 experiment.	 All	 wells	
were	then	stained	with	acridine	orange	(Sigma-Aldrich)	(0.1	µM	in	PBS)	for	15	min	and	
washed	 three	 times	with	PBS.	Cells	were	 resuspended	 in	culture	medium,	 transfected	
with	polyplexes	containing	siGAPDH	at	N/P	10	to	obtain	a	final	siRNA	concentration	of	
100	 nM	 and	 incubated	 for	 24	 h.	 Appropriate	 wells	 were	 treated	 with	 100	 µM	




with	polyplexes	 containing	AF488-siRNA	at	N/P	10.	After	 24	h	 incubation,	 cells	were	
harvested,	 washed	 with	 PBS	 and	 attached	 to	 shi-fix	 coverslips	 (Everest	 Biotech,	
Oxfordshire,	 UK)	 according	 to	 the	 manufacturer’s	 protocol	 in	 a	 24-well	 plate.	
Appropriate	wells	were	stained	with	100	µM	LysoTracker	Red	DND-99	(Invitrogen)	in	
pre-warmed	 cell	 culture	medium	 for	1	h	 at	37	 °C,	 5	%	CO2.	After	washing,	 cells	were	
fixed	with	4	%	paraformaldehyde	(PFA)	in	PBS	for	15	min	and	washed	again.	DAPI	was	
added	to	appropriate	wells	at	a	final	concentration	of	1	µg/ml	in	PBS	and	incubated	for	
20	 min.	 All	 cells	 were	 washed	 again	 and	 mounted	 using	 FluorSave	 reagent	 (Merck	


















and	 incubated	 for	 another	 24	 h.	 No	 cell	 controls	 were	 used	 to	 represent	 0	 %	 LDH	
release,	while	 cells	 treated	with	 lysis	 buffer	 represent	 100	%	LDH	 release.	Untreated	
cells	 were	 cultivated	 as	 blank	 controls.	 Afterwards,	 100	 µl	 of	 Cyto-Tox-ONE	 Reagent	
was	added	to	each	well	and	the	plate	was	shaken	for	30	sec	before	10	min	of	incubation.	
Subsequently,	50	µl	of	stop	solution	was	added	to	each	well,	the	plate	was	shaken	again	


























































































GATA3	 gene	 silencing	 in	 activated	 T	 cells	 displays	 a	 promising	 option	 to	 early-on	
prevent	 the	 activation	 of	 pathological	 pathways	 in	 the	 disease	 formation	 of	 allergic	
asthma.	The	central	transcription	factor	of	T	helper	2	(Th2)	cell	cytokines	IL-4,	IL-5,	and	
IL-13	plays	 a	major	 role	 in	 immune	 and	 inflammatory	 cascades	 underlying	 asthmatic	
processes	 in	 the	 airways.	 Pulmonary	 delivery	 of	 small	 interfering	 RNAs	 (siRNA)	 to	
induce	 GATA3	 knockdown	within	 disease	 related	 T	 cells	 in	 asthmatic	 lungs	 via	 RNA	
interference	(RNAi)	presents	an	auspicious	basis	to	realize	this	strategy,	however,	this	
approach	 still	 faces	 some	 important	 hurdles.	 Main	 obstacles	 for	 successful	 siRNA	
delivery	 in	 general	 comprise	 stability	 and	 targeting	 concerns,	 while	 in	 addition,	 the	
transfection	 of	 T	 cells	 presents	 a	 particularly	 challenging	 task	 by	 itself.	 In	 previous	
studies,	we	have	developed	and	advanced	an	eligible	siRNA	delivery	system	composed	
of	 polyethylenimine	 (PEI)	 as	 polycationic	 carrier,	 transferrin	 (Tf)	 as	 targeting	 ligand	
and	melittin	 (Mel)	 as	 endosomolytic	 agent.	 Resulting	 Tf-Mel-PEI	 polyplexes	 exhibited	
ideal	 characteristics	 for	 targeted	 siRNA	 delivery	 to	 activated	 T	 cells	 and	 achieved	
efficient	and	sequence-specific	gene	knockdown	of	surrogate	genes	in	primary	T	cells	ex	
vivo.	 In	 this	work,	 the	 therapeutic	 potential	 of	 this	 carrier	 system	was	 evaluated	 in	 a	
cellular	 model	 displaying	 the	 activated	 status	 of	 T	 cells	 as	 seen	 in	 asthmatic	 lungs.	
Therefore,	 a	 protocol	 was	 optimized	 for	 antibody-based	 activation	 of	 both	 primary	
human	T	cells	as	well	as	Jurkat	cells,	a	human	T	lymphocyte	cell	line.	Activation	status	
was	evaluated	via	determination	of	Tf	receptor	expression,	GATA3	gene	expression,	and	
respective	 cytokine	 levels	 and	 resulted	 in	 a	 distinct	 increase	 of	 all	 three	 parameters.	
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Moreover,	 a	 suitable	 siRNA	 sequence	 combination	 was	 found	 for	 effective	 and	
therapeutically	 relevant	GATA3	 gene	 silencing	 in	 human	 cells.	 The	 findings	 described	
here	 support	 the	 suitability	 of	Tf-Mel-PEI	 as	 siRNA	delivery	 system	 for	 targeted	 gene	






the	world	 and	accounting	 for	1000	deaths	per	day.	 [1]	The	disease	not	 only	 causes	 a	
high	 disability	 and	 death	 burden,	 but	 also	 raises	 tremendous	 socioeconomic	 issues.	
Although	currently	asthma	symptoms	can	be	controlled	in	the	majority	of	patients	using	
standard	 therapies	 mainly	 based	 on	 corticosteroids	 as	 controller	 and	 beta-2-
sympathomimetics	 as	 reliever	medications,	 in	 a	 distinct	 portion	 of	 patients	 (5-10	%)	
symptoms	can	still	not	be	adequately	commanded.	[8]	This	is	particularly	dangerous,	as	
these	 patients	 experience	 worse	 asthma	 symptoms,	 more	 concomitant	 comorbidities	
and,	 moreover,	 a	 specifically	 high	 risk	 of	 mortality.	 It	 is	 therefore	 inevitable	 to	 find	
novel,	more	precise	treatment	options	for	this	group	of	patients.	Asthma	is	a	reversible	
disease	of	the	airways	characterized	by	inflammation	resulting	in	bronchoconstriction,	
enhanced	 mucus	 production,	 hyperresponsiveness	 and	 ultimately	 remodeling	 of	 the	
airways.	 [3]	 The	 fact	 that	 current	 therapies	 only	 show	 limited	 benefits	 in	 certain	
subgroups	 of	 patients	 may	 be	 due	 to	 the	 heterogenicity	 of	 the	 disease	 resulting	 in	
several	different	phenotypes	with	distinct	clinical,	functional	and	pathological	patterns.	
[445]	 The	 underlying	 pathological	 base	 is	 distinguished	 by	 different	 patterns	 of	
cytokine-based	 airway	 inflammation	 involving	 immune	 and	 inflammatory	 cell	 types	
such	 as	 T	 and	B	 lymphocytes.	 These	 cytokines	 therefore	 display	 promising	 targets	 of	
novel	 therapies	 tailored	 for	 patients	 suffering	 from	 severe	 asthma	 who	 do	 not	 fully	
respond	to	conventional	treatments.	[24]		
Allergic	 asthma	 plays	 a	 major	 role	 in	 this	 context,	 comprising	 all	 levels	 of	 disease	




inflammatory	response	driven	by	 type	2	T	helper	 (Th2)	cells	orchestrating	a	 complex	
interplay	 between	 the	 innate	 and	 adaptive	 immune	 system.	 [205]	 Prevalently,	 these	
processes	already	start	in	the	childhood	via	sensitization	to	common	inhaled	allergens	
such	as	house	dust	mites	or	pollens.	These	allergens	are	taken	up	by	antigen-presenting	
cells	 (APCs),	 for	 example	 dendritic	 cells	 (DCs),	 processing	 and	 presenting	 antigenic	
molecules	to	naïve	T	helper	cells.	Consequently,	allergen-specific	Th2	cells	are	activated	
and	 produce	 and	 secrete	 the	major	 Th2	 cytokines	 interleukin	 (IL)-4,	 IL-5,	 and	 IL-13,	
playing	an	essential	role	 in	the	development	of	asthmatic	 inflammation.	 [446]	Besides	
individually	interfering	with	these	single	cytokines,	silencing	of	their	common	activating	
transcription	factor	GATA3	[27]	provides	the	option	of	interfering	with	the	production	
of	 all	 of	 them	 at	 once	 and	 therein	 early-on	 prevent	 the	 inflammatory	 cascade	 from	
commencing.	 However,	 transfection	 of	 T	 cells	 displays	 an	 especially	 challenging	
endeavor,	 since	 caveolae-mediated	 uptake,	 the	 commonly	 used	 strategy	 for	 non-viral	
vector-based	 transfection	methods,	 cannot	 be	 applied	 to	 the	 non-caveolin	 expressing	
cells.		[420]		
RNA	interference	(RNAi)	offers	a	promising	option	to	even	treat	diseases	that	have	so	
far	 thought	 to	 be	 “undruggable”,	 enabling	 the	 potential	 targeting	 of	 any	 chosen	 gene	
with	an	established	sequence.	[14]	Small	interfering	RNAs	(siRNA)	have	therefore	been	
subject	to	extensive	research	leading	to	the	recent	approval	of	the	first	siRNA-mediated	
therapy	 on	 the	 market.	 [19]	 The	 main	 drawbacks,	 however,	 still	 holding	 back	 the	
potential	 of	 these	 novel	 treatment	 forms,	 are	 the	 poor	 pharmacological	 properties	 of	
nucleic	 acids	 which	 are	 easily	 degraded	 by	 nucleases	 ubiquitously	 found	 in	 the	
bloodstream	 and	 rapidly	 excreted	 upon	 systemic	 injection.	 [20]	 In	 recent	 years,	
however,	 key	 improvements	 have	 been	 made	 in	 stable	 packaging	 of	 siRNA	 within	
nanoparticles	mostly	composed	of	polymers	and/or	lipid	formulations.	A	further	way	to	
improve	siRNA	delivery	and	circumvent	 i.v.	 stability	 concerns,	 thereby	also	bypassing	
first	 pass	 metabolism,	 is	 to	 use	 local	 administration	 routes.	 In	 case	 of	 asthma,	
pulmonary	 delivery	 obviously	 offers	 a	 suitable	 approach	 to	 effectively	 target	 disease	
related	cells	in	asthmatic	lungs.	[447]		
In	our	previous	work,	we	have	developed	and	optimized	an	siRNA	carrier	system	based	
on	 low	 molecular	 weight	 (LMW)	 polyethylenimine	 (PEI),	 [40]	 the	 most	 extensively	




is	 therefore	overexpressed	on	highly	proliferating	 cell	 types	 such	 as	 activated	T	 cells,	
[23]	providing	both	an	entry	gate	via	receptor	mediated	endocytosis	and	the	potential	
to	 specifically	 target	 such	 activated	T	 cells.	 Since	naïve	T	 cells	 only	 show	a	negligible	
expression	of	the	transferrin	receptor	(TfR),	they	are	not	considerably	transfected	and	a	
general	immune	suppression	by	the	treatment	can	be	avoided.	While	administering	Tf-
PEI	 polyplexes	 containing	 fluorescently	 labeled	 siRNA	 to	 the	 lungs	 of	 ovalbumin-
sensitized	mice	 showed	promising	 results	 in	 terms	of	 T	 cell	 targeting	 in	 the	diseased	
state,	 [40]	 administration	 of	 such	 polyplexes	 containing	 siRNA	 against	 GATA3	 to	 the	
same	 experimental	 asthma	model	 resulted	 only	 in	 non-significant	 gene	 silencing	 and	
intracellular	 cytokine	 levels.	 [448]	 In	 a	 follow-up	 study,	 [449]	 the	 Tf-PEI	 polyplexes	
were	 therefore	 further	 advanced	 by	 blending	 them	with	 an	 LMW-PEI	 conjugate	with	
pH-resonsively	 protected	 melittin,	 a	 cationic	 peptide	 with	 lysosomal	 properties.	 The	
resulting	Tf-Mel-PEI	blend	formed	polyplexes	which	were	able	to	efficiently	be	released	
from	 the	 endosomes	 after	 being	 taken	 up	 reflected	 in	 more	 efficient	 ex	 vivo	 gene	





For	 this	 purpose,	 primary	 as	 well	 as	 immortal	 T	 cells	 were	 used	 to	 generate	 and	
optimize	 an	 appropriate	 model	 for	 the	 activated	 T	 cell	 status	 in	 inflamed	 lungs.	 A	
suitable	 GATA3	 sequence	 combination	 was	 found	 for	 distinct	 gene	 silencing	 and	
downstream	effects	of	this	knockdown	were	investigated.	Overall,	the	results	gathered	












and	 the	 standard	protocol	of	using	 soluble	 antibodies	directed	against	CD3	and	CD28	
was	 compared	with	 so-called	Dynabeads®,	 beads	 covalently	 coupled	 to	 anti-CD3	 and	







Since	 Jurkat	 cells	 express	 TfR	 constitutively,	 the	 percentage	 of	 TfR	 expressing	 cells	
could	 not	 be	 enhanced	 any	 further,	 but	 was	 steadily	 maintained	 for	 3	 days.	 The	
corresponding	 median	 fluorescence	 intensity	 (MFI)	 of	 CD71-PE	 labeled	 cells	 was,	
however,	 increased	 via	 bead	 activation	 at	 day	 1,	 while	 treatment	 with	 soluble	
antibodies	resulted	in	a	consistent	decrease	of	receptor	expression.	In	contrast	to	this,	
naïve	primary	T	cells	only	show	a	negligible	TfR	expression	without	activation	stimuli	
and	 were	 therefore	 successfully	 activated,	 eventuating	 in	 a	 distinct	 increase	 in	 both	
CD71	 positive	 cells	 and	 MFI	 of	 CD71-PE.	 Dynabead	 activation	 outperformed	 soluble	
antibodies,	 resulting	 in	45	%	positive	cells	already	after	24	h	of	activation	which	was	













Figure	 1.	 Transferrin	 receptor	 (TfR,	 equivalent	 to	 CD71)	 expression	 as	 measured	 by	 flow	
cytometry	 and	presented	 as	median	 fluorescence	 intensity	 (MFI)	 or	%	of	 CD71	positive	 cells,	
respectively.	A)	TfR	expression	in	Jurkat	cells,	B)	TfR	expression	in	human	primary	CD4+	T	cells	
after	0,	1,	2,	or	3	days	of	activation	via	beads	(dark	green,	squares)	or	soluble	antibodies	(light	








In	 Figure	 2,	 GATA3	 expression	 of	 Jurkat	 cells	 (Figure	 2A)	 and	 primary	 CD4+	 T	 cells	
(Figure	2B)	normalized	to	β-Actin	is	depicted	after	the	different	activation	procedures	
as	 quantified	 by	 qRT-PCR.	 In	 both	 cell	 types,	 GATA3	 expression	 was	 distinctly	
upregulated	 via	 CD3/CD28	 based	 activation	 compared	 to	 untreated	 blank	 cells.	 In	
Jurkat	cells,	beads	and	soluble	antibodies	worked	comparably	well,	while	in	the	primary	
T	 cells,	 the	 bead	 activation	 was	 also	 more	 effective	 in	 regards	 to	 GATA3	 activation,	
resulting	 in	 a	 twice	 as	 high	 expression	 after	 three	 days	 of	 activation	 compared	 to	
soluble	antibodies	and	a	three	times	higher	expression	compared	to	non-activated	cells.		
	












antibodies	 (Figure	 3B)	 compared	 to	 non-stimulated	 naïve	 T	 cells.	 In	 general,	 all	 3	
interleukins	were	only	secreted	at	a	non-detectable	level	without	activation.	In	marked	
contrast	to	this,	secretion	of	all	tested	cytokines	was	considerably	upregulated	by	both	
activation	 processes,	 with	 IL-13	 showing	 the	 strongest	 increase	 in	 each	 case.	 Bead	
based	activation	enhanced	IL-13	concentration	approximately	10-fold,	 from	20	to	200	
pg/ml.	 In	general,	both	beads	and	soluble	antibodies	 show	a	 comparable	 trend	 in	 the	
activation	 of	 T	 cells.	 However,	 bead	 based	 activation	 showed	more	 reproducible	 and	
reliable	 results	 reflected	 in	 smaller	 deviations	 between	 replicates	 as	 compared	 to	














For	 optimization	 of	 siRNA	 sequences	 which	 downregulate	 human	 GATA3,	 several	
different	 sequences	were	 screened	 in	preliminary	experiments	using	 lipofectamine	as	
the	transfection	reagent	and	MCF-7	cells	as	an	easy-to-transfect	model	cell	line.	Figure	
4A	 depicts	 GATA3	 expression	 24	 h	 after	 transfection	 with	 the	 four	 most	 promising	
different	GATA3	sequences	 compared	 to	untreated	blank	 cells	 as	well	 as	 cells	 treated	
with	a	 scrambled	negative	 control	 sequence.	While	 sequences	GATA3_1	and	GATA3_7	
did	not	result	 in	any	considerable	knockdown	effect,	 the	 two	sequences	GATA3_8	and	
GATA3_9	 were	 found	 to	 induce	 significant	 gene	 silencing	 compared	 to	 the	 negative	
control	sequence	NC-siRNA.	Consequently,	these	two	sequences	were	combined	in	a	1:1	




significance	 compared	 to	both	 the	negative	 controls	 and	 the	untreated	blank	 samples	
(p<0.05,	Figure	4B).		
A)	 	 	 	 				 	 					B)	
	








GATA3	 gene	 silencing	 as	 achieved	 by	 using	 the	 two	 siRNA	 sequences	 GATA3_8	 and	
GATA3_9	but	formulated	as	Tf-Mel-PEI	polyplexes	rather	than	lipoplexes	was	confirmed	
in	Jurkat	cells.	Figure	5	 illustrates	GATA3	expression	normalized	to	β-Actin	24	h	after	
treatment	 with	 Tf-Mel-PEI	 polyplexes	 containing	 either	 only	 sequence	 GATA3_8	 or	
GATA3_9	or	a	1:1	mixture	of	both	sequences,	always	formulated	at	the	same	final	siRNA	
concentration	 and	 with	 N/P	 ratio	 of	 10.	 For	 comparison,	 again,	 an	 untreated	 blank	













The	 optimized	 GATA3	 sequences	 were	 then	 evaluated	 for	 gene	 knockdown	 in	 both	
Jurkat	cells	and	primary	CD4+	T	cells	within	polyplexes	prepared	with	unmodified	PEI,	
the	 previously	 described	 Tf-PEI	 conjugate,	 as	well	 as	 the	 Tf-Mel-PEI	 conjugate	 blend.	




not	 significant	 compared	 to	 treatment	 with	 scrambled	 negative	 control	 siRNA.	 In	
primary	T	cells,	on	 the	contrary,	Tf-PEI	 in	 fact	 induced	a	 significant	gene	knockdown.	




efficiency	 of	 approximately	 65	%	 in	 Jurkat	 cells	 and	 70	%	 in	 human	 CD4+	 primary	 T	
cells,	compared	to	negative	controls,	respectively.		
A)		 	 	 	 	 	 							B)	
	







Downstream	 effects	 of	 GATA3	 gene	 silencing	 on	 respective	 cytokine	 secretion	 by	
primary	T	cells	was	evaluated	using	ELISA.	Concentrations	of	the	three	interleukins	IL-
4,	IL-5,	and	IL-13	were	measured	in	the	supernatant	of	treated	cells	48	h	after	activation	
and	 subsequent	 transfection	 with	 Tf-Mel-PEI	 polyplexes	 containing	 either	 scrambled	
control	 NC-siRNA	 or	 siRNA	 directed	 against	 GATA3	 (GATA3_8	 and	 GATA3_9	 in	 a	 1:1	
mixture)	 at	 N/P	 ratio	 10.	 Figure	 7	 summarizes	 the	 results	 of	 respective	 sandwich	
ELISAs.	 Secretion	of	all	 three	 interleukins	was	 significantly	downregulated	via	GATA3	
targeted	 treatment	 compared	 to	 negative	 controls,	 indicating	 that	GATA3	knockdown	
can	indeed	affect	appropriate	downstream	signaling.	The	best	results	were	obtained	for	
IL-5	 and	 IL-13,	 wherein	 GATA3	 knockdown	 resulted	 in	 a	 consequent	 decrease	 of	
interleukin	production	of	50	%	and	35	%,	respectively,	compared	to	negative	controls.	
For	 IL-4,	 negative	 values	 were	 obtained	 based	 on	 data	 interpolation	 resulting	 in	 not	
 
 208	





primary	 CD4+	 T	 cells	 after	 48	 h	 of	 activation	 and	 subsequent	 transfection	 with	 Tf-Mel-PEI	
polyplexes	 containing	a	1:1	mixture	of	 siRNA	sequences	GATA3_8	and	GATA3_9.	Control	 cells	








Current	 asthma	 treatment	 focusses	 on	 palliating	 symptoms	 while	 the	 underlying	
inflammatory	 pathways	 involved	 in	 the	 disease	 remain	 largely	 uncontrolled.	
Consequently,	 GATA3,	 the	 central	 transcription	 factor	 in	 Th2	 mediated	 asthmatic	
airway	 inflammation	offers	a	promising	 target	 for	respective	medications,	however,	 is	
challenging	to	reach.	Transferrin	was	found	to	be	a	suitable	option	to	achieve	the	entry	
into	 otherwise	 hard-to-transfect	 T	 cells	 and	 targeted	 delivery	 to	 activated	 disease-
related	 T	 cells	 in	 particular.	 [40]	 As	 early	 as	 in	 1999,	 the	 group	 of	 Wagner	 et	 al.	
described	 how	 coupling	 of	 transferrin	 to	 polycationic	 vectors	 such	 as	 PEI	 results	 in	
stable	carriers	for	efficient	and	target-specific	gene	delivery	to	subcutaneously	growing	
tumors.	 [450]	 This	 strategy	was	 thenceforward	 constantly	 advanced	 and	 refined	 and	
applied	for	various	cancer	targeting	approaches	[41],	but	eventually	also	found	suitable	
for	 further	 applications	 other	 than	 tumor	 targeting.	 The	 transferrin	 receptor	 (TfR)	 as	
entry	port	 for	 iron	 transport	 is	not	only	overexpressed	on	different	 cancer	 cell	 types,	
but	 also	 on	 the	 membrane	 of	 cells	 involved	 in	 inflammatory	 cascades,	 to	 meet	 their	
elevated	iron	requirements	for	enhanced	cell	proliferation	and	differentiation.	[451]	It	
can	 therefore	 also	 be	 used	 to	 target	 disease-causing	 cell	 subsets	 in	 inflammatory	
diseases	 such	 as	 asthma.	 In	 our	 previous	work,	we	 developed	 a	 Tf-PEI	 based	 carrier	
system	 for	 specific	 delivery	 of	 siRNA	 to	 activated	 T	 cells	 as	 a	 potential	 novel	 asthma	
therapy.	Despite	showing	optimal	particle	characteristics	and	being	able	to	successfully	
and	preferentially	knock-down	particular	genes	 in	vitro,	 [40]	Tf-PEI	polyplexes	 lacked	
efficient	in	vivo	gene	silencing	capability.	[448]	In	a	follow-up	study,	the	original	Tf-PEI	
formulation	 was	 therefore	 modulated	 by	 blending	 with	 a	 PEI	 conjugate	 with	 the	
endosomolytic	peptide	melittin	in	order	to	increase	endosomal	escape	of	the	polyplexes	




Mel-PEI	 polyplexes,	 their	 endosomal	 escape	 abilities,	 and	 their	 binding	 specificity	
towards	the	TfR	as	measured	by	several	proof-of-concept	experiments	and	knockdown	
of	 surrogate	genes	due	 to	 lack	of	 available	validated	human	GATA3	siRNA	sequences,	
the	 focus	 of	 the	 work	 presented	 here	 was	 achieving	 therapeutically	 relevant	 gene	
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knockdown	 in	 activated	 T	 cells,	 specifically	 of	 GATA3	 and	 evaluation	 of	 respective	
downstream	treatment	effects.	
The	 first	 step	was	 to	gain	more	precise	 insights	 into	 the	T	cell	 activation	process	and	
optimize	respective	processes	to	develop	a	suitable	model	mirroring	the	characteristics	
of	 activated,	 disease-related	 T	 cells	 in	 asthmatic	 patients.	 Therefore,	 two	 different	
activation	 procedures	 were	 tested,	 namely	 the	 standard	 lab	 protocol	 using	 soluble	
antibodies	directed	against	CD3	and	CD28	and	the	application	of	so-called	Dynabeads®,	
which	 are	magnetic	 ferric	 oxide	 beads	 covalently	 coupled	 to	 anti-CD3	 and	 anti-CD28	
antibodies.	 These	 beads	 have	 a	 diameter	 of	 4.5	 µm	 resembling	 the	 size	 of	 antigen	
presenting	 cells	 and,	moreover,	 are	 chemically	 inert	 and	superparamagnetic,	meaning	
that	 they	can	easily	be	 removed	 from	activated	cell	 cultures	using	a	magnet.	CD3	and	
CD28	were	 chosen	 as	 the	 typically	 used	 primary	 and	 costimulatory	 signals	 for	 T	 cell	
activation	 partially	 mimicking	 in	 vivo	 stimulation	 via	 antigen-presenting	 cells	 (APC).	
[452]	 The	 activation	 process	 is	 generally	 initiated	 by	 recognition	 of	 peptide-loaded	
major	histocompatibility	complexes	(MHCs)	on	APCs	by	T	cell	receptors	(TCRs).	These	
APCs	 provide	 at	 the	minimum	 two	 signals	 required	 for	 T	 cell	 activation,	 one	 via	 the	
TCR/CD3	 complex	 and	 one	 additional	 signal	 through	 one	 or	more	 costimulatory	 cell	
interactions	 such	 as	 via	 CD28.	 [453]	 Exclusively	 in	 the	 presence	 of	 an	 appropriate	
costimulatory	 signal,	 the	 primed	 T	 cell	 is	 capable	 of	 starting	 a	 productive	 immune	
responsive	characterized	by	differentiation,	proliferation,	IL-2	production	and	following	














previous	 experiments,	 the	 targeting	 specificity	 of	 Tf-Mel-PEI	 towards	 TfR	 was	
confirmed	 by	 surface	 plasmon	 resonance	 spectroscopy	 (SPR)	measurements	 and	 the	
preferential	uptake	in	activated	vs.	naïve	T	cells	was	highlighted.	[449]	While	in	Jurkat	
cells	100	%	of	the	cells	express	the	receptor	constitutively,	primary	T	cells	only	show	a	
negligible	TfR	expression	at	naïve	 levels.	Here,	 the	 receptor	 expression	was	distinctly	
upregulated	via	both	activation	procedures:	with	soluble	antibodies	and	with	antibody	
coated	 beads.	 Dynabeads,	 in	 particular,	 increased	 TfR	 expression	 resulting	 in	 a	 CD71	
positive	 cell	 population	 accounting	 for	 45	%	 compared	 to	 almost	 no	 positive	 cells	 at	
naïve	 status.	 This	 upregulation	 could	 furthermore	 be	maintained	 for	 additional	 48	 h,	
indicating	that	the	activation	process	and	subsequent	receptor	expression	proceeds	in	a	
sustained	and	reproducible	way.	In	comparison,	T	cell	activation	with	soluble	CD3	and	
CD28	 antibodies	 resulted	 in	 a	 lower,	 but	 still	 distinct	 upregulation	 of	 TfR	 expression,	






activation	 procedures	 led	 to	 a	 distinct	 activation	 with	 a	 subsequent	 increase	 of	
respective	 expression.	While	 the	maximally	 reached	GATA3	 expression	 in	 Jurkat	 cells	
was	 comparable	 for	 the	 two	 activation	 methods,	 in	 primary	 CD4+	 T	 cells,	 the	 beads	
clearly	 surpassed	 the	 soluble	 antibodies,	 resulting	 in	 a	 steady	 and	 activation	 time	
dependent	increase	in	gene	expression.	A	significant	GATA3	expression	was	also	found	
in	mice	 by	 Yagi	 et	 al.	 after	 naïve	 T	 cell	 activation,	 eventuating	 in	 Th2	 differentiation.	
[455]	 Overall	 these	 results	 give	 reason	 to	 assume	 that	 the	 selected	 activation	
procedures	are	able	to	achieve	increased	GATA3	levels	and	thereby	simulate	respective	
inflammation	 processes	 orchestrated	 by	 activated	 T	 cells	 in	 the	 lungs	 of	 asthmatic	
patients.		






nucleus	 upon	 T	 cell	 receptor	 stimulation	 [456]	 and	 being	 involved	 in	 interleukin	
promoter	activation	and	Th2	cell	differentiation.	GATA3	protein	is	hypothesized	to	dock	
on	and	 interfere	with	promoter	 regions	of	 the	 interleukin	genes,	 in	 turn	upregulating	
their	expression.	However,	 this	mechanism	 is	not	yet	 fully	clarified.	 [457]	 IL-4	mainly	
drives	 polarization	 of	 the	 CD4+	 T	 cell	 response	 in	 the	 Th2	 phenotype	 in	 combination	
with	 suppression	 of	 interferon	 (IFN)-γ-producing	 Th1	 cells	 [458],	 substantially	
impacting	 the	 Th1/Th2	 imbalance	 in	 inflammatory	 cascades	 in	 asthma.	 Moreover,	 it	
directs	differentiation	of	T	cells	into	IL-4	producing	effector	T	cells,	as	even	naïve	T	cells	
are	able	to	produce	IL-4.	In	this	way,	a	significant	population	of	naïve	CD4+	is	stimulated	
to	 secrete	 IL-4	 after	 primary	 activation.	 [455]	 IL-4	 also	 controls	 the	 growth	 and	
differentiation	of	B	cells	 [459]	and	the	specificity	of	 the	 immunoglobulin	G	(IgG)	class	
switching,	 navigating	 further	 disease	 related	 processes.	 IL-5	 is	 known	 to	 be	 key	
maturation	 and	 differentiation	 factor	 for	 eosinophils,	 leading	 to	 increased	 eosinophil	
numbers	 and	 antibody	 levels	 upon	 over-expression.	 It	 regulates	 expression	 of	 genes	
involved	in	cell	survival,	proliferation,	and	maturation	of	eosinophils	as	well	as	B	cells	
and	therefore	plays	a	major	role	in	both	innate	and	acquired	immune	response	as	well	
as	 eosinophilia.	 [460]	 IL-13,	 on	 the	 other	 hand,	 intersects	 with	 several	 biological	
activities	 of	 IL-4,	 both	 sharing	 the	 IL-4	 receptor	 alpha-chain	 essential	 for	 signal	
transduction.	 Since	T	 cells,	 however,	do	not	 express	 functional	 IL-13	 receptors,	 IL-13,	
unlike	IL-4,	 is	not	able	to	 induce	Th2	cell	differentiation	in	a	 feedback	loop.	[461]	The	
effects	of	 the	 former	comprise	goblet	 cell	differentiation	 resulting	 in	enhanced	mucus	
production,	increase	of	bronchial	hyperresponsiveness,	activation	of	fibroblasts	as	well	
as	B	cell	antibody	switch	from	IgM	to	IgE.	[462]	In	this	work,	analogous	to	the	first	two	
tested	 factors,	 TfR	 and	 GATA3	 expression,	 a	 distinct	 increase	 was	 also	 observed	 for	
interleukin	secretion	upon	soluble	as	well	as	bead	based	activation.	As	experiments	in	
the	 Jurkat	cell	 line	unfortunately	yielded	 inconsistent	results,	only	data	obtained	 from	
human	 primary	 CD4+	 T	 cells	 are	 discussed	 here.	 The	 consistent	 enhancement	 of	
production	of	all	three	tested	cytokines	confirms	that	both	activation	procedures	do	not	
only	 influence	 the	 T	 cells	 themselves,	 but	 furthermore	 also	 their	 surrounding	
microenvironments	 and	 thereby	 presumably	 even	 further	 cell	 types	 and	 other	
downstream	processes	and	cascades.	As	all	 three	 tested	 interleukins	play	key	roles	 in	
the	 inflammation	 process	 underlying	 allergic	 asthma	 pathogenesis,	 it	 can	 hence	 be	
expected	 that	 this	 stage	 of	 the	 disease	 process	 can	 properly	 be	 illustrated	 in	 the	
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activated	 T	 cell	 model.	 IL-13	 was	 by	 far	 the	 strongest	 affected	 cytokine	 and	 will	 be	
discussed	in	more	detail	below.		
In	summary	it	can	be	stated	that	both	tested	activation	procedures,	beads	and	soluble	
antibodies,	 achieved	 a	 distinct	 activation	 of	 continuous	 as	 well	 as	 primary	 T	 cells	
resulting	in	an	upregulation	of	TfR,	GATA3	as	well	as	secretion	of	selected	interleukins.	
In	 comparison,	CD3	and	CD28	antibody	 coated	beads	were	 shown	 to	be	overall	more	
effective.	As	 the	 ferric	oxide	beads	 resemble	antigen	presenting	 cells	 in	 size,	 they	 can	
mimic	these	essential	helpers	in	the	activation	process,	thereby	leading	to	more	precise	
signaling.	 Increasing	 the	 activation	 time	 from	 two	 to	 three	 days	 did	 not	 considerably	
increase	 activation	 parameters	 further	 and	 rather	 resulted	 in	 reduced	 cell	 viability.	
Consequently,	 Dynabead	 activation	 for	 48	 h	 was	 chosen	 as	 the	 preferred	 T	 cell	
activation	method	to	achieve	a	proper	model	for	activated	T	cells	mirroring	the	status	in	
inflamed	airways	of	asthmatic	lungs.	
For	 the	 knockdown	 of	 GATA3,	 a	 potent	 murine	 siRNA	 sequence	 had	 already	 been	
optimized	 by	 the	 group	 of	 Garn	 et	 al.	 and	 was	 shown	 to	 decrease	 the	 number	 of	
eosinophils	and	level	of	airway	hyperresponsiveness	in	models	of	acute	allergic	airway	
inflammation	after	intranasal	administration.	[27]	For	humans,	however,	to	the	best	of	
our	 knowledge,	 no	 comparably	 suitable	 sequence	 had	 been	 detected	 to	 this	 point.	
Therefore,	 the	 first	 step	 towards	successful	GATA3	knockdown	 in	human	cells	was	 to	
discover	 an	 appropriate	 functional	 siRNA	 sequence	 resulting	 in	 significant	 gene	
silencing.	 After	 testing	 multiple	 sequences	 from	 different	 vendors	 in	 preliminary	
screening	 experiments	 with	 lipofectamine	 as	 transfection	 agent	 in	 easy-to-transfect	
MCF-7	 cells,	 two	 sequences	 were	 found	 to	 be	 particularly	 eligible	 for	 this	 purpose,	
namely	GATA3_8	 and	GATA3_9.	 It	was	 then	 hypothesized	 that	 these	 sequences	 taken	
together,	 at	 the	 same	 final	 siRNA	 concentration,	 could	 be	 even	 more	 effective	 as	
combining	 more	 than	 one	 siRNA	 sequence	 had	 been	 shown	 to	 have	 significant	
advantages	over	use	of	 the	 corresponding	 individual	 siRNAs	 [463]	 and	 can	 lower	off-
target	effects	of	single	sequences	due	to	smaller	applied	concentrations	[464].	In	fact,	a	
1:1	 mixture	 of	 both	 functional	 siRNA	 sequences	 resulted	 in	 approximately	 90	 %	





within	 the	 Tf-Mel-PEI	 blend	 polyplexes,	 confirming	 the	 capability	 of	 both	 sequences	
seperately,	 and	 all	 the	more	 in	 combination,	 resulting	 in	 a	 significant	 silencing	 of	 the	
target	 gene.	 The	 knockdown	 potential	 of	 Tf-Mel-PEI	 was	 furthermore	 highlighted	 in	
comparative	 experiments	 in	 Jurkat	 cells	 as	 well	 as	 primary	 human	 CD4+	 T	 cells	
involving	unmodified	PEI	and	the	previously	described	Tf-PEI	conjugate	as	controls.	In	
both	 cell	 types,	 the	 superior	 gene	 silencing	 efficiency	 of	 the	 blend	 polyplexes	 could	
clearly	 be	 pointed	 out,	 again	 emphasizing	 the	 essential	 role	 of	 endosomal	 escape	
particularly	 in	 T	 cells	 for	 effective	 siRNA	 therapy.	 Although	 Tf-PEI	 also	 resulted	 in	 a	
distinct	 knockdown	 effect	 compared	 to	 respective	 negative	 controls,	 only	 after	 the	
addition	of	melittin,	the	transport	of	the	siRNA	cargo	from	the	endosomes	to	the	cytosol	
was	 enhanced	 and	 this	 really	maximized	 the	 treatment	outcome.	These	 results	 are	 in	
line	with	 the	previous	 findings	of	Olden	et	al.	 showing	 that	endosomal	acidification	 in	
human	T	cells	 in	general	both	 takes	place	 slower	and	 is	 less	 robust	 than	 in	other	 cell	
types,		[50]	underlining	the	need	for	further	endosomal	escape	triggers.		
To	determine	whether	the	achieved	knockdown	of	GATA3	would	also	result	in	sufficient	
interference	with	 respective	parameters	 in	downstream	cascades	orchestrated	by	 the	
transcription	factor,	concentrations	of	the	three	most	relevant	cytokines	IL-4,	IL-5,	and	
IL-13	 were	 measured	 in	 cell	 supernatants	 by	 sandwich	 ELISA.	 Even	 if	 for	 IL-4,	 an	
average	mathematically	negative	value	was	obtained	by	extrapolation,	a	reduction	of	all	
three	cytokines	was	observed	after	treatment	with	GATA3	siRNA	formulated	in	Tf-Mel-
PEI	 polyplexes.	 The	 strongest	 decrease	 in	 secretion	 was	 achieved	 for	 IL-5,	 the	
predominant	cytokine	involved	in	eosinophilic	activation,	causing	airway	inflammation	
as	 a	 classic	 feature	 of	 severe	 allergic	 asthma.	 [465]	 IL-5	 displays	 the	 main	 growth,	
differentiation,	and	activation	factor	for	human	eosinophils,	highly	expressing	the	IL-5	
receptor	on	 their	 surface	membranes.	Therefore,	 the	downregulation	of	 IL-5	 amongst	
other	 cytokines	 can	 have	 particularly	 positive	 influences	 on	 patients	 with	 severe	
asthma,	especially	when	suffering	from	eosinophilic	inflammation.	[466]	In	fact,	several	
monoclonal	 antibodies	 targeting	 IL-5,	 namely	 mepolizumab,	 reslizumab,	 and	
benralizumab	 have	 been	 developed	 to	 specifically	 bind	 and	 interfere	 with	 the	 IL-5	
receptor	on	eosinophils	and	were	recently	approved	for	the	treatment	of	adult	patients	
with	 severe	 eosinophilic	 asthma.	 [466,	 467]	 Beyond	 IL-5,	 a	 significant	 reduction	was	
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also	 observed	 for	 IL-13	 concentration.	 IL-13	 is	 another	 central	 effector	 of	 asthmatic	
processes,	most	notably	inducing	goblet	cell	hyperplasia	and	mucus	hypersecretion	[8]	
and	 IL-13	 signaling	 was	 shown	 to	 directly	 result	 in	 mucin	 secretion,	 airway	
hyperresponsiveness	 and	 pulmonary	 fibrosis	 in	 animal	 models	 of	 asthma	 [468].	
Although	glucocorticoids	are	effective	and	widely	used	maintenance	therapies	in	acute	
and	chronic	asthma,	some	patients	are	non-responsive	to	steroids	maintaining	elevated	
IL-13	 levels.	 [469]	 For	 these	 severe	 cases,	 antibodies	 targeting	 IL-13	 are	 under	
investigation	 as	 novel	 targeted	 add-on	 treatments.	 Despite	 of	 the	 benefit	 of	 these	
specific	 therapies	 concentrating	 on	 single	 interleukins,	 the	 aim	 of	 this	 work	 is	 to	
interfere	with	 GATA3	 as	 the	 central	 transcription	 factor	 regulating	 the	 expression	 of	








cultures	 of	 normal	 as	 well	 as	 asthmatic	 primary	 human	 bronchial	 epithelial	 cells	
resembling	the	actual	status	in	asthmatic	patients.	Furthermore,	studies	in	precision	cut	
lung	slices	are	planned	to	investigate	the	influence	of	transfection	not	only	on	single	cell	
types,	 but	 also	 on	 surrounding	 lung	 tissue.	 As	 a	 last	 step,	 in	 vivo	 experiments	 in	 a	
murine	 asthma	 model	 are	 inevitable	 to	 gain	 further	 insights	 into	 distribution,	




status	 of	 activated	 T	 cells	 as	 a	model	 for	 asthmatic	 processes.	 A	 functional	 sequence	
combination	to	silence	GATA3	gene	expression	via	siRNA-mediated	RNAi	was	found	and	
applied	 for	 the	 first	 time	 for	 specific	 knockdown	 in	 activated	 T	 cells.	 Tf-Mel-PEI	
polyplexes	were	confirmed	to	be	an	eligible	carrier	system	for	targeted	GATA3	silencing	
in	 activated	 T	 cells,	 resulting	 in	 respective	 alleviation	 of	 downstream	 cytokine	
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production.	 Although	 it	 was	 already	 shown	 that	 asthmatic	 patients	 can	 benefit	 from	
GATA3	 downregulation	 via	 specific	 DNAzymes	 [28],	 in	 this	 approach,	 the	
pharmaceutically	active	cargo	was	delivered	without	any	delivery	system.	For	a	specific	





lower	 doses	 and	 reduced	 side	 effects.	 Finally,	 the	 carrier	 system	 can	 be	 specifically	
tailored	for	individual	needs	and	used	to	co-deliver	other	small	molecule	drugs	as	well	
as	be	equipped	with	ligands	enabling	specific	targeting	of	disease-related	cell	and	tissue	
types.	 The	 Tf-Mel-PEI	 delivery	 system	 is	 currently	 undergoing	 testing	 under	more	 in	
vivo	 like	 conditions	 to	ultimately	 support	 conclusions	on	 in	 vivo	 fate	 and	effect	 of	 the	
polyplexes.	 Overall,	 the	 described	 blend	 particles	 display	 a	 promising	way	 to	 deliver	






was	 coupled	 to	 5	 k	 PEI	 (Lupasol®	 G100,	 BASF,	 Ludwigshafen,	 Germany)	 via	
succinimidyl	3-(2-pyridyldithio)	propionate	(SPDP,	Thermo	Fisher	Scientific,	Waltham,	
USA)	 to	yield	 the	Tf-PEI	 conjugate	with	a	 reducible	disulfide	bond.	 Similarly,	 cysteine	
modified	melittin	(Mel,	Pepmic,	Suzhou,	China)	was	coupled	 to	PEI	via	4-polyethylene	
glycol-N-succinimidyl	 3-(2-pyridyldithio)	 propionate	 (PEG4-SPDP,	 Thermo	 Fisher	
Scientific,	 Waltham,	 USA)	 after	 masking	 of	 its	 lytic	 amine	 groups	 with	 2,3-Dimethyl-
maleic	 anhydride	 solution	 (DMMAn,	 Sigma-Aldrich,	 St.	 Louis,	 USA)	 to	 yield	 the	 pH-
responsive	Mel-PEI	conjugate.	












(Institute	 for	 Immunology,	 Biomedical	 Center	Munich).	 They	were	 cultured	 in	 RPMI-
1640	 cell	 culture	 medium	 (Sigma-Aldrich)	 supplemented	 with	 10	 mM	 HEPES,	 1	 mM	
sodium	pyruvate,	 4500	mg/l	 glucose,	 10	%	 (v/v)	 heat	 inactivated	 fetal	 bovine	 serum	
(FBS,	 Sigma-Aldrich)	 and	 1	 x	 penicillin/streptomycin	 (Pen/Strep,	 Sigma-Aldrich).	








48-well	 cell	 culture	 plates	 (Thermo	 Fisher	 Scientific)	 were	 coated	 with	 anti-CD3	
antibody	(BD	Biosciences,	Franklin	Lake,	USA)	at	a	concentration	of	5	µg/ml	in	PBS	and	
incubated	 for	3	h	 at	 37	 °C	or	 overnight	 at	 4	 °C.	After	washing	 the	wells	 3	 times	with	
rising	 amounts	of	PBS,	 100.000	 (for	 flow	 cytometry)	or	500.000	 (for	PCR	and	ELISA)	
Jurkat	cells	or	primary	T	cells,	respectively,	were	added	per	well	in	fresh	medium.	Anti-
CD28	 antibody	 (BD	 Biosciences)	 was	 added	 at	 a	 final	 concentration	 of	 1	 µg/ml.	 For	
activation	 via	beads,	Dynabeads™	Human	T-Activator	CD3/CD28	 for	T	Cell	 Expansion	
and	 Activation	 (Thermo	 Fisher	 Scientific)	 were	 washed	 and	 added	 to	 the	 cells	 in	 a	
bead:cell	ratio	of	1:1	according	to	the	manufacturer’s	protocol.	Cells	were	activated	for	










anti-CD71	 antibody	 (eBioscience)	 was	 added	 to	 appropriate	 samples,	 while	 isotype	
controls	 were	 stained	with	 IgG1	 antibody	 (eBioscience)	 and	 blank	 samples	were	 left	
unstained.	All	 samples	were	vortexed	and	 incubated	 for	another	30	min	at	4	 °C	while	
protected	from	light.	After	washing	with	PBS	3	times,	cells	were	resuspended	in	400	µl	
PBS	 with	 2	 mM	 EDTA	 and	 samples	 were	 analyzed	 using	 an	 Attune	 ®	 NxT	 flow	
cytometer	(Thermo	Fisher	Scientific)	with	488	nm	excitation	and	574/26	nm	emission	
filter.	 The	 cells	 of	 all	 samples	 were	 gated	 according	 to	 morphology	 based	 on	
forward/sideward	scattering,	and	10.000	events	were	evaluated	per	sample.		
GATA3	Expression:	Jurkat	cells	and	primary	CD4+	T	cells	from	the	activation	procedure	
were	 collected	 at	 different	 days	 post	 activation	 and	 total	 RNA	was	 isolated	 with	 the	
PureLink	RNA	mini	 kit	 (Thermo	Fisher	 Scientific)	 or	 the	RNeasy	micro	 kit	 (QIAGEN),	
respectively,	 according	 to	 the	 manufacturer’s	 protocol	 with	 additional	 DNAse	 I	
digestion.	 From	 the	 obtained	 RNA,	 cDNA	 was	 synthesized	 and	 amplified	 with	 the	
Brilliant	 III	 ultra-fast	 SYBR®	 green	 QRT-PCR	 master	 mix	 kit	 (Agilent	 Technologies,	




an	untreated	blank	 sample	was	prepared	as	 a	 standard	 curve.	 Ct	 values	were	plotted	
against	the	assigned	concentration	of	each	point	in	the	curve	(1,	0.2,	0.004,	0.0008,	and	





Primary	 CD4+	 T	 cells	 from	 the	 activation	 procedure	were	 harvested	 at	 different	 days	






To	 find	 a	 suitable	 human	 siRNA	 sequence	 for	 efficient	 GATA3	 knockdown,	 different	
siRNA	 sequences,	 namely	 Hs_GATA3_1,	 Hs_GATA3_7,	 Hs_GATA3_8,	 and	 Hs_GATA3_9	
(QIAGEN)	were	screened.	Therefore,	100.000	MCF-7	cells	per	sample	were	seeded	in	a	
24-well	 plate	 (Thermo	 Fisher	 Scientific),	 transfected	with	 LipofectamineTM	 lipoplexes	
containing	 25	 pmol	 siRNA	 either	 directed	 against	 GATA3	 (siGATA3_1,	 siGATA3_7,	


















































































develop	 a	 potential	 novel	 treatment	 for	 asthma	 patients	 suffering	 from	 uncontrolled	
symptoms	 despite	 standard	 mediation	 compliance.	 Via	 initiation	 of	 RNAi	 and	
subsequent	 silencing	 of	 specific	 genes,	 siRNA	 therapy	 offers	 an	 auspicious	 basis	 to	
target	disease-related	pathways	that	otherwise	would	be	difficult	or	even	impossible	to	
tackle.	Despite	numerous	positive	attributes	such	as	specificity,	potency	and	the	ability	
to	 achieve	 controlled	 transient	 gene	 knockdown,	 siRNA	 certainly	 also	 encounters	




two	 approaches	 to	 circumvent	 these	 hurdles,	 namely	 local	 delivery	 via	 pulmonary	




not	 impacted	 by	 the	 disease	 mostly	 unaffected.	 	 Tf-PEI	 polyplexes	 showed	 very	
favorable	 characteristics	 such	 as	 particles	 sizes	 below	 200	 nm,	 slightly	 negative	 zeta	





cascades,	 the	aim	of	 this	work	was	to	develop	a	therapy	that	would	early-on	 interfere	
with	 disease-causing	 cascades.	 Rather	 than	 downregulating	 single	 inflammatory	







downstream	 treatment	 effects	 in	 a	 more	 physiologic	 setup.	 A	 potent	 GATA3	 siRNA	
sequence	 combination	was	 found	 to	 specifically	 downregulate	 gene	 expression	 of	 the	
zinc	finger	transcription	factor	in	human	cells	and	previously	described	sequences	were	
successfully	applied	for	gene	knockdown	in	murine	cells,	respectively.		
In	 the	 further	 course,	 next	 to	 successful	 cellular	 delivery,	 endosomal	 escape	 was	
identified	 as	 a	 second	 essential	 hurdle	 on	 the	 way	 to	 transfer	 siRNA	mediated	 gene	
knockdown	 into	 significant	 in	 vivo	 effects.	Even	 if	 siRNA	polyplexes	were	 successfully	
taken	up	by	target	cell	populations,	another	hurdle	to	overcome	was	efficient	release	of	
the	 therapeutic	 nucleic	 acids	 into	 the	 cytosol	 for	 an	 efficient	 therapeutic	 impact.	




system.	 The	 Tf-Mel-PEI	 blend	 polyplexes	were	 designed	 to	 combine	 both	 the	 specific	
targeting	 of	 disease-related	 activated	 T	 cells	 and	 efficient	 extra-	 and	 intracellular	
delivery	to	the	site	of	action	in	one	versatile	siRNA	carrier	system.		





are	 planned	 in	 order	 to	 find	 out	 what	 percentage	 of	 each	 conjugate	 is	 bound	 in	 the	
particles	or	freely	diffusing,	respectively.		
To	more	specifically	investigate	the	therapeutic	effect	of	the	polyplex	treatment	not	only	
on	 cultures	 of	 immortalized	 or	 primary	 cells,	 an	 air-liquid-interface	 (ALI)	 culture	 of	
bronchial	tracheal	epithelial	cells	is	currently	developed.	In	this	model,	parameters	such	
as	 uptake,	 gene	 silencing	 effect	 and	 influence	 on	 cytokine	 levels	 can	 be	 tested	 under	
more	in	vivo	like	conditions	involving	the	presence	of	mucus,	for	example.	To	mimic	the	





Subsequently,	 more	 in	 vivo	 experiments	 have	 to	 be	 performed	 to	 evaluate	 the	
tolerability	of	Tf-Mel-PEI	polyplexes	beyond	the	in	vitro	state.	Further	studies	will	focus	
on	the	therapeutic	outcome	and	investigate	 influence	of	the	hopefully	achieved	 in	vivo	
knockdown	 of	 GATA3	 on	 downstream	 cascades	 such	 as	 levels	 of	 inflammatory	
cytokines	and	immune	cell	composition	within	the	lung	of	asthmatic	mice.		
In	 parallel,	 an	 inhalable	 dry	 powder	 formulation	 is	 currently	 developed	 to	 pack	 the	
optimized	 siRNA	 polyplexes	 into	 so-called	 nano-in-microparticles	 with	 suitable	
characteristics	as	a	convenient	treatment	form	for	asthma	patients.	This	step	is	crucial	
for	 transferring	 this	 promising	 gene	 silencing	 approach	 into	 a	 routinely	 applicable	
therapeutic	dosage	form.		
Although	the	Tf-Mel-PEI	blend	particles	were	very	well	tolerated	in	performed	in	vitro	
toxicity	 assays	 and	 the	 transferrin	 shielding	 was	 confirmed	 to	 distinctly	 reduce	 PEI	
related	inflammatory	effects	of	Tf-PEI	in	vivo,	the	general	toxicity	of	PEI	certainly	raises	
some	concerns.	Particularly	with	regards	to	the	fact	that	siRNA	therapy	usually	has	to	
be	applied	repeatedly,	a	biodegradable	polymer	would	be	preferable	 in	 the	 long	term.	
Therefore,	 suitable	 options	 are	 evaluated	 to	 replace	 the	 cationic	 polymer	 in	 the	
conjugates	with	more	biocompatible	materials	such	as	oligospermines.		
Taken	 together,	within	 this	work,	 efforts	were	made	 to	 realize	 siRNA	mediated	 gene	
silencing	 in	 diseased	 lungs	 of	 asthma	 patients	 as	 a	 potential	 new	 treatment	 form	 by	
tackling	 some	 major	 hurdles	 on	 the	 way.	 Tf-Mel-PEI	 blend	 polyplexes	 present	 a	
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